SMS 201-995 in the Management of Portal Hypertension by McKee, Ruth Fraser
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
SMS 201-995 IN THE 
M A N A G E M E N T  OF PORTAL H Y P E R T E N S I O N
© R U T H  FRASER McKEE, B.Sc., M.B., F.R.C.S.
A Th esi s submitted for the degree of 
Doctor of M e d icine  
to the 
Un i v ersity  of Glasgow.
Based on re search carried out at the 
Un i v e r s i t y  Dep ar tm ent of Surgery, 
Royal Infirmary, Glasgow. 
August 1988
ProQuest Number: 10999310
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10999310
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
A C K N O W L ED GE MENTS
I would p a r t i cu la rly like to thank Professor David C. 
Carter for the op po r t u n i t y  to carry out this work in the 
U n i v er si ty Depa rtmen t of Surgery and for his help and 
a d v i c e .
Numerous medical and nursing colleagues have helped in 
the man age me nt of the patients studied, and thanks are due 
to all of them. Mr. James Garden has contr ibute d a great 
deal in teaching end oscopic  techniques and advice about the 
clinical studies. Dr. Stuart D. Pringle performed the right 
heart c a t h e t e r i s a t i o n s  for the study descr ibed in Chapter 
3. Mr. Graham Ha ddoc k under to ok the analysis of the 
patients' ca senotes for the study descri bed in Chapter 2.
I am gra tef ul to Mr. James Geraght y and Mr. Wilson 
Angerson who gave much advice about the animal work. Mr. 
Douglas Bell, Miss. Sheelah Smith and the staff of the 
Animal Unit, Royal Infirmary, Glasgow, also made a large 
c o n t r ibut io n in the care of the animals. Thanks are due to 
Mr. Robert Wright and the technical staff in the Uni ve rs ity 
De pa rtment of Surgery for help with the ma in t e n a n c e  and 
a c q u is it ion of equipment.
The se cretaries of the U n i v e r s i t y  Departm ent of 
Surgery, Anne, Winnie, Jean, Sheena and Rayh an na have been 
very helpful in tracing case records, and other sec retarial 
duties.
Dr. Caro lyn Gree n w o o d - W i g a r t  and Dr. Stephen Rowntree, 
Sandoz U.K. Limited, have given advice and supplied SMS 201
995 for both patient and animal studies.
Pa rt icular thanks are due to my husband who has 
contributed a great deal in terms of encour ag ement as well 
as kno wl ed ge of computing.
This work was sup ported in part by an equipment grant 
from the Research  Support Group, Greater Gl asgow Health 
Board.
P r e s e n t a t i o n s  and P u b l i c a t i o n s
Parts of this work have been presented to learned societies. 
These p r e s e nt at ions are listed below.
1) The Effect of SMS 201-995 on portal and systemic 
h ae mo dynami cs  in cirrhosis.
Asso ci ation of Surgeons of Great Britain and Ireland 
April 1987.
2) SMS 201-995 in portal hyp ertension.
Gl as go w G a s t r o e n t e r o l o g y  Club, June 1987.
3) SMS 201-995 in the m ana ge ment of variceal bleeding. 
British Society of Gast ro en t e r o l o g y ,  Sept emb er 1987.
The following papers have been submitted for p ub li cation 
or accepted for publication.
1) The effect of SMS 201-995 on portal and systemic
h ae mo d y n a m i c s  in cirrhosis. McKee R F , Pringle SD, 
McKee R F , Pringle S D , Garden 0J , Lorimar AR and 
Carter D C .
Accepted for pub li ca tion by A l i m en ta ry P h a r maco lo gy 
and Therapeutics.
2) The use of oesopha geal tamponade in the mana gemen t 
of variceal bleeding.
Had dock G, McKee R F , Garden OJ , Anderson JR and 
Carter D C .
Submitted to Diges tive Diseases and Science.
These studies were performed between August 1986 and July 
1988 when I was a registrar in the U niv er sity Departm ent 
of Surgery, Royal Infirmary, Glasgow.
I declare that I am the sole author of this thesis. All 
the studies were planned and carried out by myself except 
as ackno wl ed ged above. Where assist ance has been obtained 
from others, such help has been freely acknowledged.
INDEX
LIST OF TABLES 6
LIST OF FIGURES 10
SUMMARY 13
CHAP TER  1 - HI S T O R I C A L  REVIEW  16
P AT H O P H Y S I O L O G Y  17
The cause of the chronic rise in portal pressure 18
The dist r i b u t i o n  of collateral flow 22
The cause of variceal bleeding 2 3
TH ERAPY  - THE ACUTE BLEED 27
Diagnosis and general measures 28
Control of bleeding 31
i )Oesophag eal tamponade 31
ii)Drugs 33
a ) V a s o p r e s s i n  33
b )Pro prano lo l 37
c)0thers 38
d )S o ma tostati n 39
i i i )Injection s c l e r ot herapy  43
iv) Oes op hageal  trans ection 45
v) P o r t asy st emic shunts 46
1
THERAPY - PR EV ENTION  OF REBLE ED ING 47
His tory 48
Po rta systemi c shunts 4 9
O eso phageal  transection 53
Injection s cl erothe ra py 56
T ransh ep at ic o b l i t erati on  of varices 62
The use of drugs in the pr ev entio n of rebleeding 63
PR OPH YLAXIS 67
AIMS OF THESIS 69
CHA PTE R 2 - O E S O PHAG EA L T A M PO NA DE IN THE MA NAGEMENT 
OF ACUTE VA R I C E A L  H A E M O R R H A G E  70
I N TROD UC TI ON 71
PATIENTS AND METH ODS 72
RESULTS 75
DISC USSIO N 85
CHAP TER  3 - THE ACUTE EFFECTS OF SMS 201-995 ON
PORTAL AND SYSTEMIC H A E M O D Y N A M I C S  IN STABLE
CIRR HOT IC PATIENTS 91
IN TRODU CT IO N 92
PATIENTS AND METHOD S 93
RESULTS 97
DISC USSIO N 106
2
CHAPTER 4 - RAT MODELS OF EXTR AHEPA TI C  
AND INTRAHEP AT IC PORTAL H Y P E R T E N S I O N  111
INTRODU CT IO N 112
ANIM ALS  AND M A I N TEN AN CE 112
RAT MODELS 114
Partial portal vein ligation 114
Carbon tetrac hloride  induced cirrhosis 118
CH APTER 5 - METH ODS  USED IN ANIMA L H A E M O D Y N A M I C  STUDIES 124 
IN TR ODUC TI ON  125
CONDUCT OF H A E M O D Y N A M I C  STUDIES 126
Fasting 12 7
Anaes thes ia 12 8
Blood gases 12 9
Body temperature 13 0
Systemic blood pressure 131
M E A S UREME NT  OF MEAN ARTERIA L PRESSURE AND PORTAL 
VENOUS PRESSURE 132
THE USE OF G A M M A - L A B E L L E D  M I C R O SPHER ES  FOR
H AE MO D Y N A M I C  E XPER IM ENTS 134
Coun t ing 13 6
Problems 13 7
i) Ag gr egatio n 137
ii)Leaching 138
i i i )St reaming 139
iv) Spi llover 140
DRUG LEVELS 142
3
CHAPTER 6 - THE EFFECTS OF SMS 201-995 IN NORMAL
RATS AND TWO RAT MODELS OF PORTAL HYPE R T E N S I O N  143
THE EFFECT OF SMS 201-995 ON CARDIAC OUTPUT
AND ORGAN BLOOD FLOWS IN NORMAL RATS 144
Intro duc tion 144
Materi als  and methods 14 5
Re s u 1 1 s 15 2
D i s cus s ion 160
THE EFFECT OF SMS 201-995 ON PORTAL PRESSURE 
IN NORMAL RATS 162
IntroductI on 162
Mater ial s and methods 163
Results 16 5
Di sc ussion 16 7
THE EFFECT OF SMS 201-995 ON PORTAL PRESSURE 
IN PORTAL H Y P E R T E N S I V E  RATS 168
Introduc tion 168
Materi als  and methods 16 9
Results 171
Dis cus sion 17 4
THE EFFECT OF REPEATE D INJECTION  OF M I C R O SPHERES  
ON P O RTASY ST EMIC SHU NTI NG M EASU RE MENTS 176
In troductio n 17 6
Mat erials and methods 17 7
Results 17 9
Di sc ussi on  182
4
THE EFFECT OF SMS 201-995 ON PORTAL PRESSURE 
AND P O RTAS YS TE MIC SHUNTING IN PORTAL
HY PER T E N S I V E  RATS 183
In troductio n 183
Mate ria ls and methods 184
Results 187
Dis cus sion 19 5
THE EFFECT OF SMS 201-995 ON PORTAL PRESSURE 
AND PO RTA S Y S T E M I C  SHUNTI NG IN CIRRH OTIC RATS 197
Intr odu ction 19 7
Materials and methods 198
Re sult s 2 00
Discussio n 2 04
DISCUSSIO N 205
CHAPTER 7 - A COM P A R I S O N  OF THE EFFICAC Y OF
SMS 201-995 AND O ESO PH AGEAL TA M P O N A D E  IN THE
CONTROL OF ACUTE V A R I C E A L  H A E M O R R H A G E  208
INTRODU CT ION 209
PATIENTS AND METHODS 211
RESULTS 216
DISCUSS IO N 225
CHAPTER 8 - CO NC LUSIONS 233
REFERENCES 239
5
LIST OF TABLES
Table 1. Results from four trials of the use of 
p rop ranolol  in the prev en tion of
variceal haemorrhage. 66
Table 2 . A e t i ol ogy of portal h y p e r tens io n in 138 
patients admitted with acute variceal 
haemorrha ge and its relat io nship
to modified Child's grading. 80
Table 3. Control of haemorr hage by tamponade in 
138 patients admitted with acute 
variceal hae mo rr hage and its re lat ion ship 
to mod if ie d Child's grading. 81
Table 4. C o mpli ca tions of tamponade in 138 patients 
admitted with acute variceal haemorrhage.
Figures in parent heses denote deaths related 
to tamponade. 82
Table 3. Deaths thought to be associated with tamponade 
in r el ation sh ip to sc le r o t h e r a p y  and 
pr ognostic index. 83
6
Table 6. Summary of results in some trials of
o eso phageal  tamponade in variceal bleeding. 90
Table 7 . The ch aract e r i s t i c s  of the stable cirrhotic
patients in the control and study groups. 99
Table 8. Portal and systemic h aemodyn am ic
results in control and study groups of stable 
cir rhotic patients. 100
Table 9. Liver function tests in previousl y
c ha ra cteris ed  rat model of cirrhosis. 122
Table 10.Weight and blood gases in four groups of
normal rats who had cardiac index and organ 
blood flows measur ed after saline, 1, 2 or 
4 jug/kg/hr SMS 201-995 . 1 54
Table 11. T he effect of saline, 1, 2 or 4/ig/kg/hr 
SMS 201- 995 on mean arterial pressure, 
cardiac index and portal venous inflow in 
four groups of normal rats. 155
Table 12 .The effect of saline, 1, 2 or 4jug/kg/hr 
SMS 201- 995 on organ blood flows in
four groups of normal rats. 156
7
Table 13.The results of Wilcoxon signed rank tests
on the dif fe re nces in mean arterial pressure 
after saline, 1, 2 or 4>ig/kg/hr SMS 201-995 
in four groups of normal rats.
Table 14.The effect of SMS 201-995 on portal pressure 
in normal rats .
Table 15.The effect of SMS 201-995 on portal pressure 
in portal hyp erte nsive rats.
Table 16.The effect of intra porta l in jection of 
m i c r o s p h e r e s  on % p o r t a syst em ic shunting 
m e a s u r e m e n t s .
Table 1 7. C omp ar ison of two successive  %po rtasyst em ic  
shunting mea su r e m e n t s  in five rats.
Table 18. The effect of 4/ig/kg/hr SMS 201-995 on portal 
pressure and %porta s y s t e m i c  shunting in three 
day post portal vein ligation rats.
Table 19.The effect of 4;ug/kg/hr SMS 201-995 on portal 
pressure and %porta s y s t e m i c  shunting in 
twent y-e ight day post portal vein ligation 
rats.
157
166
172
180
181
189
191
8
Table 2 0 . Liver function tests in 18 cirrhotic rats. 201
Table 21. The effect of 4>ig/kg/hr SMS 201-995 on portal 
pressure and % p o r t as ys temic shunting in 
cir rhotic rats.
Table 2 2. The reasons for exclu si on from the trial of 
56 other bleeds thought to be from 
oesoph age al varices.
Table 2 3 . Patient c h a r a c teristi cs  for the two groups 
treated with oe sophageal tamponade or 
SMS 201- 995 infusion for active 
varic eal  bleeding.
Table 2 4 . Cha r a c t e r i s t i c s  of the bleed for the two 
groups treated with oes op ha geal tamponade 
or SMS 201-995 infusion for active 
variceal bleeding.
Table 2 5 . Incidence of chest infection in c om pariso n  
with type of treatment and occurrenc e of 
rebleed i n g .
202
221
2 2 2
223
224
9
LIST OF FIGURES
Figure 1 . Outcome of 223 episodes of acute variceal
bleeding in 138 patients. 84
Figure 2. Change in wedged hepatic venous pressure
with time in control and study groups of
stable cir rhotic patients. 101
Figure 3. Change in tran she patic venous gradient
with time in control and study groups of
stable cir rhotic patients. 102
Figure 4. Change in cardiac index with time in
control and study groups of stable cirrhotic
patients. 103
Figure 3. Change in systemic v a s cu la r resistance
with time in control and study groups of
stable cir rhotic patients. 104
Figure 6« Mean plasma levels of SMS 201-995 for 
eight stable cirrhotic patients given 
SMS 201-995. 105
10
116
117
123
141
150
1 51
1 58
159
7. The anatomy of the portal venous system in
the rat.
8. Po rto gra m showing partial portal vein 
ligation in the rat.
9. Retic ul in stain of a section of liver in 
a rat treated with carbon tetrachloride.
10.The energy peaks of gamma radiation
from the commonly  used radioactive isotopes.
11.Tracing from Gould recorder showing 
arterial pressure during insertion of left 
ventric ul ar cannulas.
12.The expe rimen ta l lay-out for the 
measureme nt of cardiac output and organ 
blood flow in the rat.
1 3 . Cardiac index in normal rats following 
SMS 201-995 infusion.
14 . Portal venous inflow in normal rats 
foll owi ng SMS 201-995 infusion.
11
Figure 15 .Change in mean portal pressure in portal 
hype r tens ive
rats given increasing doses of SMS 201-995. 173
Figure 1 6 . % p o rt as ystemic  shunting in 3 day post
portal vein ligation rats before and after 
infusion of saline or SMS 201-995.
Figure 17.Change in portal pressure against initial
portal pressure in portal hyperte nsive rats 
given SMS 201-995.
Figure 1 8 . Change in portal pressure against
change in %por ta s y s t e m i c  shunting in portal 
hyp ert ensi ve  rats given SMS 201-995.
Figure 1 9 . Change in portal pressure against
change in mean arterial pressure in portal 
h yp er tensiv e rats given SMS 201-995 
or saline.
Figure 2 0 . % p o r t a systemi c shunting in cirrhotic rats
mea su red before and after infusion of saline 
or SMS 201-995.
190
192
193
194
203
12
SUMMARY OF THESI S
Blee din g from oesoph ageal varices is one of the most
serious emer ge ncies  seen in med ical practice. Control of the 
bleeding is the first prior it y but neither of the two
treatme nts  co mm on ly used today, oes oph ag eal tamponade or 
intravenous vaso pressin, is ideal. Oeso phageal tamponade can 
give co ntr ol of bleeding in more than 90% of cases (1) but
may cause as p i r a t i o n  pneum on ia or r e s p i r a t o r y  arrest and
ce r t a i n l y  causes cons id erable di scomfort to the patient. 
V as o p r e s s i n  is hardly less unple asant and carries the risk 
of m y o c ar dial i nfarct io n and cardiac arrest (2,3). Th erefore 
a new drug for the tempo ra ry cont rol  of bleed ing from 
oe sophag eal varices would be useful. There is evidence that 
na turally occ urring s o m a t o s t a t i n  is at least as effec tiv e as 
v a s o p r e s s i n  in this regard and has no major sid e-effects 
(4,5) but its short half-life and in st ability  in soluti on  
are d i s a d v antag eo us. SMS 201-995 is a new lo ng -acting 
analogue of s o m a t o s t a t i n  with a plasma half-life of 45 
mi nutes and which  is stable in solutio n (6). Little work has 
been done using this analogue and in particular it has not 
been assessed in a cli ni cal trial of trea tment  of bleeding 
varices. This thesis sets out to examine the effects of SMS 
201-995 in patients with portal h y pe rt ension and in two rat 
models of portal hyp ert ension. The literature on portal 
h y p e r tens io n is revi ewed with particular reference to the
13
m an age men t of bleeding oesop hageal varices.
Chapter 2 consists of a retr os pective  study of oesophageal 
tamponade in the ma na gemen t of variceal bleeding, assessing 
its efficacy in bleeding control as well as the
co m p l ic ations encountered.
In Chapters 3 to 7, three studies using SMS 201-995 are 
reported. The acute effects of SMS 201-995 on portal and 
systemic hae modynam ics were measured in stable cirrhotic 
patients and this is described in Chapter 3. Cardiac output 
and systemic vascular resistance were measured using the 
th e r m o d i l u t i o n  method and portal pressure was assessed by 
m e a su ring the wedged and free hepatic venous pressures. 
Th ereaf te r work pro ceeded in two areas simultaneously.
Chapters 4 to 6 describe studies of the effects of SMS 
201-995 in normal rats and in two rat models of portal 
hy per tension . A rat model of e x t r a -h ep atic portal 
hypertension, using partial portal vein ligation, and a rat 
model of cirrhosis, induced by carbo n tetrachloride , had 
been e stab li sh ed and char a c t e r i s e d  previo us ly in the 
Uni ver sity Departm ent  of Surgery, G l a s g o w  Royal Infirmary
(7). These models were used to study the effects of SMS
201-995 on systemic h a e m o d y n a m i c s , portal pressure and 
po rta sy st emic shunting. A radioactiv e micr osphere  method was 
used to measure blood flow and portasyst emic shunting.
Running c o n c u r r e n t l y  wit h this animal study a controlled 
cli ni cal trial was u n d e r t a k e n  to compare the e f f ic acy of SMS 
201-995 with that of oes ophageal tam ponade in active
14
variceal bleeding. This trial is described in Chapter 7. The 
efficac y of both treatments with regard to control of
bleeding was studied along with their com plicat io ns and
si de -effect s , in 40 episodes  of varicea l bleeding.
In Chapter 8 co nclusio ns are d r awn  from the results of
these studies and the work is placed in the context of other 
recent work in therapy for portal hypertension. A number of 
questions are raised by this work and several avenues for 
further inves t i g a t i o n  are suggested.
15
CH APT ER 1
H I S T O R I C A L  REVIEW
16
PA T HOP HY SI OLOGY
An u n d e r s t a n d i n g  of the patho p h y s i o l o g y  of a disease 
process is crucial to the development of treatment for that 
disease. Over the years there has been much d i s c ussion of 
the pa th op h y s i o l o g y  of portal h y p e rten si on and it is still 
in co mp letely  understood.
In 1826 Laennec described the app earance of the liver in 
chronic liver disease and coined the term "cirrhosis" (8). 
He stated that "its deve lo pment in the liver is one of the 
most co mm on  causes of ascites". The Russian surgeon Eck, who 
gave his name to the first expe r i m e n t a l  portacaval shunt 
operation, was also int rigued by the dev el opmen t of ascites 
in chronic liver disease and felt that this was due to an 
obst r u c t i o n  to flow w i t h i n  the liver (9). Interest in 
bleeding rather than ascites as a m a n i f e s t a t i o n  of portal 
h yp e r t e n s i o n  develope d over the en sui ng years so that 
Prebble was able to re view the world literature on bleeding 
varices in 1900 (10). By that time the presence and pos ition  
of varices, their role as shunts and their propensity to 
bleed had been establis hed.
Three cent ral questions regardi ng  the p a t h o p h y s i o l o g y  of 
portal h y p e r tensi on  have been posed over the years. Firstly, 
what is the cause of the chronic increase in portal 
pressure? Secondly, why do only some patients with portal 
h ypert en si on de velop oe so phageal varices? Third ly, why do 
o es op hageal varices bleed?
17
The cause of the chronic increase in portal pressure.
In terms of funda men tal u n ders ta nding of the disease 
process, the first is the most important question. Two 
opposing theories have developed. The first, perhaps more 
obvious theory, is the "o bs truct ion" or "backward flow" 
theory. O bstr uc tion was suggested as the cause of ascites in 
patients with portal h y p e r te ns ion by the early workers. 
Drummond and Mo rrison published a post -m ortem study of 
patients with cir rhosis in 1896 (11) and stated that the 
presence of shunts in cirrhosis cor relat ed with the absence 
of ascites which de vel ope d secondary to obstruction. Vidal 
also proposed in 1903 (12) that " co nsequ en t to scarring, the 
calibre of the int ra he patic ram ifi ca tions of the portal vein 
decreases, portal tension increases". The opposing theory, 
the "forward flow" theory, was suggested initially  by 
Banti's comments on his patients with congestive 
s p l e n omeg al y in 1894 (13). Studies by Herrick, published in 
1907 (14), supported the concept that an increased inflow
into the portal system was the cause of portal hypertension. 
He rri ck's expe ri ments d em onstrat ed  that portal pressure rose 
with increas ing arterial pressure and that this effect was 
more marked in the cirrhotic liver. During the first few 
decades of this century, therefore, the forward flow theory 
held sway but since then the backward flow theory has been 
more prominent. This swing was perhaps initiated by Mclndoe 
of the Mayo Clinic who reported a hist ologi cal study in 
1928, de sc rib ing hepatic cellular dest ruc tion, re gen era ting
18
nodules, sclerosis and the develo pment of col lateral venous 
channels (15). He thus emphasi sed the role of obstruction. 
Over the next 30 years the backward flow theory was 
supported by a number of workers who observed that the blood 
flow in the portal vein in portal h ypert en sion was not 
increased. The first proponent of the portacaval shunt in 
humans, Whipple, supported this theory because of Mclndoe's 
work on liver hist ol ogy and work of his own showing 
hist olo gical evidence of back pressure in the spleen in 
portal h yp ertens io n (16). In 1952 Bradley reported a 
decrease in blood flow in the portal vein in portal 
h y p e r t e n s i o n  (17) and this finding was confirmed in 
cirrh oti c patients by Mo ren o and co lleagues (18). They 
cal cu late d that increased resistance to splanchic blood flow 
must therefore be present. However in the past 30 years the 
forward flow theory has re-em erged. In 1959 Tisdale and 
c ol lea gue s reported the occurrence of portal hy per ten sion 
and bleeding o esopha ge al varices in the absence of 
o bstru ct io n (19) and around the same time Sherlock's group 
were e m p h a s i s i n g  the hyperdynamic c i r c u l a t i o n  in patients 
with liver disease (20). Witte and colleagues' exper iment s 
in dogs (21) su bs e q u e n t l y  supported the theory of increased 
splanchnic blood flow in portal hypertension , and with the 
advent of t h e r m o d i l u t i o n  techniques for the meas ur ement  of 
cardiac output (22) further c o n f i r m a t i o n  of the increased 
cardiac output and de creas ed systemic vascular res istan ce 
has been obtained (23). Two groups have cont ri buted very
19
sig nif ican tl y in the last five years. Gr oszmann's  group 
(24,25) have dev elo pe d an exp erimen ta l model of portal
h ypert en si on in the rat using partial portal vein ligation, 
and with the use of micro sph ere techniques have demonstrated 
the existence of a hyperdynamic c i r c ulati on  with an increase 
in the blood flow into the portal system, termed the portal 
venous inflow. Portal venous inflo w is made up of the
venous drainage of all splanchnic organs which is then
dist ri buted bet ween the por tasyste mic shunts and the portal 
vein. The use of radi oactive mic rosp he re techniques has 
meant that shunt blood flow, portal vein flow, total hepatic 
flow and portal venous inflow can all be measur ed and this 
has given a more comp re hensive  picture of haemodynamics in 
the portal hypertensive rat. Benoit's group (26) have used a 
similar model and methods but have added a m at hemati ca l
mode l to try to assess the relative co ntr i b u t i o n  of the 
'forward' and 'backward' flow components to the portal
hy pertension. Their pred ic tion is that the forward and
backward flow mec ha nisms account for 40% and 60% of the
increase in portal pressure respectively.
In clinic al terms the backward flow theory of portal
h y p e r te nsion has been correl ated with the hi sto logy of liver 
disease in that the height of portal venous pressure does 
seem to correlate with the degree of nodule forma tion in the 
liver (27). There is a poor c o r r e l a t i o n  with the apparent 
degree of cirrhosis and in particular of fibrosis (27). 
Theories about the cause of the increased portal venous
20
inflow proposed in the forward flow theory abound and at 
present the g a s tr oi ntesti na l hormone gl ucagon  seems the most 
likely candidate as the mediator of this process (28,29,30).
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The d i s t r i b u t i o n  of c o l l a t e r a l  flow.
The question of why only some patients with portal 
hy per te ns ion develop oe sophageal  varices has not been 
ad equately answered. The exis tence  of a collateral 
c ircul at io n in response to liver disease has been known 
since the last century (11) and v a r i a bilit y in the 
de ve lopm en t of co llaterals  in different areas of 
po rtasyst emic an ast omoses has also been known (31). Modern 
radiological techniques have shown that there is great
variation  in the degree of p o r t a system ic  shunting and in the 
di s t r i b u t i o n  of the shunts. Gr os zmann and colleag ues (32) 
used isotope studies and contrast rad iolog y to demonstrate 
that 16% of biopsy proven cirrh otics had no discer nable
por tas yste mi c shunting while 39% had complete shunting.
Bri tto n (33), in a study of 92 patients with portal 
hyperte nsi on, noted that two main patterns of distrib ut ion 
of collat erals  existed. Patients with a predominant 
coronary- azygous vein collateral pattern had a high 
incidence of sig ni fican t oesop hag eal varices associated with 
greater risk of bleeding and severity of bleeds. In the 
other patients the most common co llaterals  were in the 
regions of the inferior mes en te ric vein, the splenic and 
renal veins and the umb ilical veins. The cause of this 
vari ati on is unknown.
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The cause of v a r i c e a l  b l e e d i n g
P er h a p s  the m o s t  p r a c t i c a l  q u e s t i o n  w i t h  r e ga r d  to the 
p a t h o p h y s i o l o g y  of p o r t a l  h y p e r t e n s i o n  is w h y  do o e s o p h a g e a l  
v a r i c e s  bl e e d ?  Two t h e o r i e s  p r e d o m i n a t e ,  the t h e o r y  that
v a r i c e s  are e r o d e d  f ro m  w i t h o u t  due to acid from  the s t o m a c h  
and the the o r y that v a r i c e s  d i s r u p t  due to i nt e r n a l  fa ct ors .
In 1945 Baro no fsky and W a n g e n s t e e n  (34) published an animal 
experime nta l study in which they showed that o b s t ru ction of 
the splenic vein increased susce p t i b i l i t y  to peptic 
ul ceration  and erosions and they suggested that erosion by 
acid was a si gni ficant factor in the causa tion of variceal 
bleeding. W a n g e n k n e c h t  (35) studied 44 autopsy specimens 
some years after the patients' death from variceal bleeding 
and found evidence of oe sophageal inflammatio n and
u lc er ation in 19 cases. A similar study by Chiles et al (36) 
showed oesop hageal ul ce ra tion in 45 of 80 cases. However in 
1963 Orloff and Thomas (37) u n d e rt oo k a histologi cal study 
of oesophageal biopies in patients who had had surgery for
variceal bleeding withi n eight hours of admis sion to
hospital. They found little evidence of oesop hagitis and
concluded that the erosion theory was unlike ly  to be true. 
They felt that the previous studies (35,36) had the
dis advan ta ge  that they were performed  on tissue removed from
the body some time after the onset of bleeding and pointed 
out that varices do bleed in low acid states, since the 
m ajo rity of patients with cirrhosis have a very low gastric 
acid output (38). Since then a number of studies have been
published to support the view that e r o si on  of varices by 
acid is not a major factor causing bleeding. There is no 
increase in the incidence or length of reflux episodes in 
patients who have bled from varices compared to normals and 
lower oe sophageal  sphincter pressure does not differ
s ig ni ficant ly  from that in the normal patient (39,40). 
Several further histologica l studies have failed to show 
evid enc e of significant inf lamma ti on of the oesophagus in 
patients with bleeding from varices. (41,42). A controlled 
cli nic al trial has shown that the H2  receptor antagonist 
cimeti din e, which reduces gastric acid output, had no effect 
on the rate of recurre nce  of variceal bleeding (43) and this 
finding also helps to wea ken the e r o s i o n  theory. The theory 
that varices disrupt due to internal factors therefore seems 
more plaus i b l e .
It was noted some years ago that patients with large,
varices had a higher risk of bleeding than those with small 
varices (44). The law of Laplace states that the tension in 
the wall of a c y l i n d r i c a l  vessel is pro po rt ional to the 
radius and thus varices of greater diameter might be more 
likely to bleed because of increased wall tension. The 
a s s o c i a t i o n  of varicea l size with bleeding has been
confi rme d in recent years (45) but studies of portal 
pressure in cir rhotic patients have g e n e ral ly  failed to
associate the level of portal pressure with risk of bleeding 
(45,46). It seems that an increased portal pressure is 
ne cessary before varices develo p but that above this level
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the height of pressure is not related to bleeding. In 1951 
Butler reported studies of the anatomy of the veins of the 
oesopha gus  (47) and interest in this subject as part of the 
e x p l a n a t i o n  why varices bleed has revived in recent years. 
Four layers of veins have been identif ied and all channels 
are found to be s i g n i f i c a n t l y  dilated in patients with 
varices. It is felt that the deep intrinsic veins are those 
which form the varices seen at en doscopy  (48) and the red
wale marking s and cherr y-red spots reported as signifying
high risk of bleeding by Japanese workers (49,50) may
represent more superf icial channels. As long ago as 1900, 
Prebble (10) noticed that varices tended to bleed at the 
area of the g a s t r o - o e s o p h a g e a l  ju nc ti on and the few 
centimetr es above this rather than higher in the oesophagus. 
The work of Spence and col lea gu es (51,52) showing that in 
this r e g i o n  a large number of venous channels lie very near 
the mu cosal surface, may provide an e x p l a n a t i o n  for this 
observation. The presence of p er fo rating veins with
incompetent valves at the lower end of the oesophagus has
also been suggested by the use of endo scopic  ultrasound
(53). The turbulent flow in these areas may increase the
risk of rupture of varices at the lower end of the
o e s o p h a g u s .
In more general terms, poor liver function  increases the 
risk of bleeding from varices (54,55,56) and also increases 
the risk of gas t r o i n t e s t i n a l  bleeding from other sources 
such as gastritis (57). Liver fun ct ion has a strong
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influence on the prognosis in variceal bleedi ng (58,59). In 
1964 Child described a c l a s s i f i c a t i o n  system for patients 
with cirrh osi s which  depended on the sev erity  of jaundice, 
ascites and e n c e p h a l o p a t h y  along with serum albumin and 
nut ri ti onal state. This gave a good guide to prognosis. The 
c l a s s i f i c a t i o n  used in this thesis is a m o d i f i c a t i o n  of 
Child's grading by Pugh and colleagues (58) whi ch is based 
on the p r o t hrombi n time, serum albu min and biliru bi n and the 
presence of ascites and encep ha lopat hy. Patients with
cirr hos is are placed in grades A, B or C, with progressive 
w o r se ni ng  of liver function. Modifi ed Child's grade A
patients have a s i g n i fi ca ntly better prognosis than grade C 
patients after a variceal bleed. G a r d e n  and colleagues 
rep or ted that in a study of 81 bleeds from oes op hageal 
varices in 62 patients, three patients in modified Child's 
grade A on ad missi on  all survived, while 37% of 44 modified 
Child's C patients died during that admis si on (60). The 
un de r l y i n g  cause of the portal hype r t e n s i o n  also influences 
the prognosis. Patients with varices due to portal vein 
thrombo sis  have a higher risk of ble edi ng but a better
su rvi val prospect (61). It is gen er ally agreed that
co ntinued alcohol abuse carries a higher risk of re bleeding 
and mor t a l i t y  (62,63), tho ug h an accurate history of alcohol 
intake is diffi cult to obtain (64). The deve lopme nt  of a 
hepa toc ellular  ca r c i n o m a  as a c o m p l i c a t i o n  of cirrhosis 
carries a high risk of varicea l bleeding (63).
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T H E R A P Y  - T H E  A C U T E  B LE E D
T h e r a p y  for p o r t a l  h y p e r t e n s i o n  and o e s o p h a g e a l  v a r i c e s  
c a n  be d i v i d e d  i n to  the m a n a g e m e n t  of the acute  b le e d  and 
the p r e v e n t i o n  of r e b l e e d i n g .  Over the year s t he re has b een  
some o v e r l a p  b e t w e e n  th e s e  two a s p e c t s  be c a u s e  of the e r a  of 
e m e r g e n c y  shunt s u r g e r y  and the o p p o s i n g  a t t i t u d e  that 
t r e a t m e n t  for the ac ut e  bl ee d was s u f f i c i e n t  i n t e r v e n t i o n  in 
th es e  poor r i s k p a t i e n t s .
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Diagnosis and general measures 
The patient frequently presents with significant
hae mat emes is  or melaena from an unknown source. Clinical 
assessment and simple laborator y estimation s may be a guide 
to the amount of blood loss. Mailer and colleagues (65) 
reported that a 1200ml blood loss causes a tachycardia of 
more than 100 beats/ mi nute ac co mpanied by pallor and 
postural hypotension, and that a serum urea of more than 8.5 
mmol/1 in the presence of a normal creatin ine  in upper 
g a stro in te stina l bleeding probably indicates that at least
one litre of blood has been lost from the upper
gastroi n t e s t i n a l  tract (66).
With the advent of fib reopt ic endoscopy initial 
res us ci tation  can be followed by early diagnosis of the 
source of bleeding. Several studies (67,68,69) have
est ab li shed that up to 40% of patients with varices bleed 
from other lesions in the g a s t r o i n t e s t i n a l  tract, and 
accurate dia gnosis by means of endoscop y is therefore 
essential. Large varices with ov erlying inflamma ti on and red 
spots or weals on the mucosa are more likely to be the cause 
of bleeding than small pale varices (50). The problem of 
bleeding from gastric varices is not considered in detail in 
this thesis since this is much less common. Bleeding from 
gastric varices is diff ic ult to diagnose and most centres 
have managed such bleeding by means of u nderse wi ng of the 
varices at operation. A recent report des cribes the use of a 
combina ti on  of int rava ricea l and paravari ceal s c leroth er apy
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for the control of such bleeding (70).
Once the dia gnosis is established further res uscitation 
and measures to prevent com pli catio ns  are instituted. Since 
blood transfusion has been available this has been the sine 
qua non of the treatment of bleeding and large volumes of 
blood may be ne cessary (2). Bleeding from oesophageal 
varices is often associated  with significan t pre -existing 
co ag ul ati on defects due to chronic liver disease. These 
coagulati on defects may be due to thromb ocytop en ia secondary 
to h y p e r s p l e n i s m , depressed synthesis of the vitamin K 
dependent p rothrom bi n complex factors or a chronic, 
low-grade d issem in ated i n t r a v a s c u 1ar co agula tion (71). 
Pre-exi st ing clotting dis orders will be worsened by blood 
transfusion. Fresh frozen plasma is often given since any 
correct ion  of the co ag u l a t i o n  defect possible with vitamin K 
takes more than 24 hours. Platelet transfusions may be used 
if the platelet count is less than 8 0 , 0 0 0 X  10 /ml though the 
transfused platelets will be rapidly destroyed by the 
spleen. An tit h r o m b i n  III and fib rin olyti c inhibitors may 
reduce ongoing d i s s e mi nated i n t r a v a s c u 1ar coag ulation (71).
Hepatic e n c e p h a l o p a t h y  is a serious complicati on  of 
ga s t r o i ntesti na l bleeding in patients with liver disease and 
patients with this c omplic at ion have a poor prognosis (72). 
Bowel washouts may be performed to reduce the protein load 
in the gut. Neomycin has been used in the treatment and 
prevention of hepatic e n c e p h al op athy for 30 years (73) since 
it reduces the load of ammonia pro ducing bacteria in the
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gut. M e troni da zo le seems to have similar efficacy (74). 
Lact ulo se is broken down in the caecum to lactic and acetic 
acid and the resulting drop in faecal pH suppresses the 
g row th of ammonia forming bacteria. Lactu lose and neomycin 
were shown to be of equal efficacy by Conn's group (75) and 
the use of lactulose and neo mycin  together has been shown to 
be of benefit in one study (76). There is a significant 
incidence of bleeding from gastric erosions and stress 
ulcers in these severely ill patients and MacDougall and 
co lleagues have shown that an H 2 receptor blocker reduces 
this com plicati on  (77).
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C ont ro l of b l e e d i n g
25-40% of variceal bleeds stop spo ntaneo us ly (2,78), but 
when this does not occur measures to control the bleeding 
are n e e d e d •
i ) Oesophageal Tamponade 
The principles of balloon tamponade in the arrest of 
variceal ha emorr hage were descr ibed as far back as 1900 
(10). Sporadic reports of this method of treatment appeared 
thereafter but it became established with the developm ent of 
the Sengstake n Blakemore tube in the 1950's (79). This tube 
had three lumens - two leading to balloons which were 
inflated in the stomach and oesophagus respective ly  and one 
lumen which was used to aspirate the stomach. Shortly after 
this Linton and Ellis (80) described a tube with a single 
large gastric balloon and it has been suggested that the 
efficacy of either tube depends on occlu sio n of the veins by 
pressure at the g a s t r o - o e s o p h a g e a 1 junction. Despite the 
development of a four lumen tube to enable the asp iration  of 
both upper oes oph agus and stomach (81), the use of balloon 
tamponade has been criticised, p a r t i cu la rly in the United 
States. In 1967 Conn and Simpson (82) reported that 
tamponade with a three lumen tube achieved control of 
bleeding in only 56% of 40 patients and had a 35% incidence 
of major complications . Others argue that these reports are 
due to the use of balloon tamponade with a three lumen tube 
in less than ideal situations, where it is u ndou bt edly 
dan gerous (83,1). In 1971 Pitcher reported that bleeding was
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con tr olle d in 46 of 50 patients treated with oesophageal
tamponade with only two major and seven minor complic ations  
(83).
Despite its ef f i c a c y  in c o n t ro lling bleeding balloon 
tamponade has obvious disadvantages: it is unpleasant for
the patient and even in the best hands the risk of
a s p i ratio n and chest c o mplicat io ns cannot be com pl etely  
eliminated. In Pitcher's group of 50 patients the one
patient who died after o esopha ge al tamponade had evidence of 
asp ir at ion of blood into the trachea (83). The con trol of 
bleeding by less invasive means is therefore an attractive 
prospect and various drugs have been used for this purpose.
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ii) Drugs
a) Va so pressin
The first drug used for treatment of active variceal 
bleeding was vas o p r e s s i n  (84) and this has remained the drug 
in co mmon use. Studies by Shaldon and colleagues (85) 
establis hed that it causes a signif ica nt fall in portal 
pressure. Texter 's  studies in dogs showed that this effect 
is due to v a s o c o n s t r i c t i o n  which is most marked in the small 
vessels (86). However althou gh  its v a s o c o ns tr ictor effect is 
most pronoun ced in the skin, gut and skeletal muscle (87), 
v a s o p r e s s i n  is a gen era li sed v a soc on stricto r and it 
therefore causes a conc omitan t increase in systemic arterial 
pressure and decrea se in cardiac output. Several placebo 
cont ro lled trials of its ef f i c a c y  in active variceal 
bleeding have been performed. In 1962 M e r i g a n  and colleagues 
(88) achieved bleedi ng control on 16 of 29 occasions when 
patients with cl i n i c a l l y  bleeding varices were treated with 
20 units of v a s o p r e s s i n  over 20 minutes in c o m p a r i s o n  to 24 
occasions when patients were treated wit h placebo and all 
co nti nued to bleed. Un f o r t u n a t e l y  during this study 
en do sc opy was not available to c o n fi rm  the diagnosis and 
assessment of co ntinued bleeding was inadequate in some 
cases. Conn and c o l l e a g u e s (2) used intra -a rterial  
vaso p r e s s i n  infused into the superior mes enter ic  artery and 
gained co ntr ol of bleeding in 12 of 17 patients treated with 
v a s o pr es sin and con serv ative treatment in c o m p a r i s o n  to 4 of 
16 patients treated with conserv at ive treatment only. This
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study is dif ficult to assess because conservati ve  treatment 
included oesophageal tamponade in an u n d ef in ed number of 
patients. The most recent placebo con tro lled trial (89) 
failed to show a diff erence  in bleeding control rate between 
the v a s o p re ss in and placebo treated groups. None of these 
trials showed an impro vemen t in survival in patients treated 
with vasopressin.
Because of its mode of action, va so p r e s s i n  has significant 
s i d e - e f f e c t s . It has been shown in both animals (90) and man 
(91) that v a s o p r e s s i n  reduces cardiac output and myo cardi al  
in fa r c t i o n  as a c o m p l i c a t i o n  of v a s o p r e s s i n  therapy was 
first reporte d in 1951 (3). V a s o p ress in  also contracts the 
smooth muscle of the gut wall, causing abdominal colic, and 
ischaemic problems in the skin have been reported (92).
To try to reduce these problems and increase its 
ef f e c ti ve ness various means of a d mi nisteri ng  v a s o p res si n  
have been tried. In a study in 25 patients with bleeding 
varices by Jo hnson and colleag ues (93), infusion directly  
into the superior me se nteri c artery did not improve ef ficacy  
or reduce ge neral ised side-ef fe cts but increased local 
problems because of the more complex catheter insertion. On 
the other hand a study of 31 episodes of va ric eal bleeding 
by Sagar and coll eague s (94) where 16 patients received 20 
unit intravenous boluses of v a s o p r e s s i n  every 2-4 hours and 
15 patients received  peri pheral intravenous inf us ion at 0.4 
u n its/ mi nute showed a signif icant  advantage for continuou s 
infus io n since 13 patients in this group stopped bl eeding in
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c o m p a r i s o n  with two in the group given boluses. Continuous 
peripheral intravenous infusion  is now the most commo n means 
of ad m i n i s t r a t i o n  of vasopressin.
C o m b in at ion of vaso p r e s s i n  with other agents may reduce 
possible s i d e - e f f e e t s . Isoproterenol, a cardiac inotrope and 
pe ripheral va sodilato r, seems to be ef fec tive in red uc in g 
cardiac side-effe cts (95) but increases in portal pressure 
have been reported (95). The pe ri phera l vasodilators 
n itrop ru ss ide (96), n i t r o g l y c e r i n  (97) and isosorbide 
dinitrate (98) pr obably further reduce portal pressure. 
However al thoug h studies (96,97) have shown that
nitroprusside and n i t r o g l y c e r i n  reduce the systemic effects 
of v a s o p res si n Hallema ns and colleagues have failed to show 
any re d u c t i o n  in cardiac side-ef fe cts in stable cirrhotics 
by combini ng  isosorbide dinitrate and va sopres si n (99). The 
results of two co nt rol led trials co mp aring v a s o p r e s s i n  plus 
ni t r o g l y c e r i n  with  v a s o p r e s s i n  alone have been published 
(100,101). Al thoug h there were differ ences in the dose of 
vasopres sin , in the patient populations and in the route of 
a d m i n i s t r a t i o n  of n i t r o g l y c e r i n  (Gimson's group (100) gave 
intravenous ni tr oglycerin,  Tsai's group (101) gave
sub -l in gual nit rogl yc erin), both studies showed improvement 
in bleedin g co nt rol and r e d u c t i o n  in side-effe cts in the 
v a s o p r e s s i n  and ni tr og l y c e r i n  group. Despite this, no 
improvement in sur vival  was seen.
T r i g l y c y l  v a s o p r e s s i n  is a slow release f ormulat io n of
v a s o p re ssin whi ch can be given by in termittent  intravenous
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bolus rather than infusion. It was initial ly reported to 
have a selective action on the mese nteri c c i r c u lation  (102) 
but it has since been es tablish ed that changes in cardiac 
funct ion  and systemic blood pressure are similar to these 
with  v as op ressin  itself (103). The ma jo rity of reports 
(78,104) have been of a bleeding control rate similar to 
vas opressin, but one report demo nstrate d improved effic acy 
compared to vasopressin, giving rise to some doubt regarding  
the act ivity of the v a s o p r e s s i n  used (105). Similar cardiac 
sid e-e ffects have been reported (104).
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b) P r o p r a n o l o l
P ro pr ano lol has re cently been advocated for use in portal 
h y p e r tens io n because of the work of Lebrec and colleagues, 
who reported in 1980 (106) that it caused a significant drop 
in wedged hepatic vein pressure in cirrhotic patients. In 
1967, Price and colleagues (107) had demon strated that this 
effect was achieved by a re du ction in splanchnic blood flow 
in normal subjects. Further studies showed that the effect 
was lessened but not eliminate d when a car di oselective 
beta-blocker was given (108) and it can be concluded that 
the effect of pr opranol ol is achieved via both a redu ct ion 
in cardiac output and splanch nic v a s o c o n s t r i c t i o n  due to 
blockade of vaso- d i l a t o r y  splanch nic bet a-a drene rgic 
receptors. However, proprano lol has been used principally 
for preven ti on of r e b l eedin g because of its cardiac and 
vascular side -effe cts which could cause difficulti es in 
r e s u s c i t a t i o n  of the actively bleeding patient. Its use in 
the pre v e n t i o n  of r eble ed ing will be considered later.
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c) Other vasoactive agents 
Other adrenore ceptor blocking agents have been studied in 
stable cirrhotic patients but these have a lesser effect on 
portal pressure (109) and have not been used for actively 
bleedi ng patients. Nitrat es  as single agents have been 
studied for their effects on portal pressure but have not 
been used to cont rol variceal bleeding. Cimetidine is 
commonl y given to patients with active variceal bleeding. It 
has no effect on portal pressure (110) but has been shown to 
reduce the incidence of bleedi ng due to acute gastric 
erosions which are liable to deve lop in acutely ill patients 
(77).
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d) S om at ostati n
S o mato st at in was first isolated and desc ri bed by Brazeau 
and colleag ues  in 1973 (111) when it was identified as a
t e t r a d e capep ti de  with gr owth hormone release inhibitin g 
effects. It soon became apparent that s o m a t o s t a t i n  was 
widespr ead  in the body with p a r t icula rl y significant action 
in the gut. Bloom and colleagues described the red u c t i o n  of 
foo d-induced plasma ga strin rise by s o m a t o s t a t i n  in 1974 
(112) and further i n v e s t i g a t i o n  revealed Its effect in 
re ducin g spl anchnic blood flow in normal man in 1976 (113).
S o m a t osta ti n blocks in su lin and glu ca gon release, blocks the 
effects of c h o l e c y s t o k i n i n  and secretin, delays gastric 
e mp ty ing and has a potent effect on gastric acid secretion. 
The output of all other kn own ci rc u l a t i n g  g a s t r o i ntes ti na l 
hormones is blocked by s o m a t o s t a t i n  (114).
Initial animal work in dogs, using elec tr o m a g n e t i c  flow 
probes attempted to eluci date its mode of action in reduci ng 
splanc hni c flow (115,116). It appeared to reduce portal vein 
flow by means of pre -s planch ni c v a s o c o n s t r i c t i o n  and this 
effect appeared to be selective. Reports that s o m a t ost at in 
inf usi on was effec ti ve in co nt r o l l i n g  bleedi ng in peptic 
ulcer haemorrhage (117) and in activel y bleedin g oesophageal 
varices (118) began to appear. Further i n v e s t i g a t i o n  has 
confused the picture considerably . In normal man it has been 
de mo ns trated  that s o m a t o s t a t i n  causes a fall in portal vein 
flow (119) without systemic hae modynamlc effects (119,120) 
alt ho ugh this lack of systemic haemodyn amic effect is
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con tr ad icted in one report in ana est hetised man (121). In 
cirrhotic patients the picture is less clear. In 1981 Bosch 
and collea gues (91) reported that s o m a t o s t a t i n  caused a 
si gni ficant drop in wedged hepatic vein pressure in 
cirrhotics while other workers (120,122) have reported no 
effect. These workers could dem onstrat e no effect on 
systemic haemod ynami cs du ring s o m a t o s t a t i n  in fusion  although 
Naeije and associates reported on two occasions (123,124) 
that intravenous infusio n of s o m a t o s t a t i n  reduced the 
cardiac index as well as ca using a short lived red u c t i o n  in 
wedged hepatic venous pressure in patients with portal 
hypertension.
Attempts at e l u c i da ting these effects by means of animal 
expe ri me nts have also been con tra di ctory. No change in 
cardiac index has been d e m o n str at ed in animals but 
c o n t r a d i c t o r y  effects on reg ional blood flow have been 
reported. Becker and colleag ue s (123) could show only a 
r e d u c t i o n  in gastric and pan creatic blood flow with 
so mat o s t a t i n  whereas renal blood flow was increased, while
Price and co lleagues (126,127) showed a re d u c t i o n  in blood
flow in all areas of the splanchnic c i r c u l a t i o n  as well as 
in renal blood flow. Splanchnic effects seem to be mediated 
via the pr e- sp lan chnic arterioles rather than the portal 
vein since i n j e ct ion of s o m a to st atin into the portal vein 
produced no haem odynamic effect in rats (128).
Despite these co ntr ad ic tions , reports of the ef f i c a c y  of
s o m a t o s t a t i n  in upper g a s t r o i n t e s t i n a l  ble edi ng continue
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(129) and in two controlled  clinical trials it appears to be 
at least as effect ive as vas opressi n in the control of 
active variceal  bleeding (4,5). Clinica l e n t h u s i a s m  for its 
use seems to have been little affected by a recent report 
that the drug causes a signif icant red u c t i o n  in renal plasma 
flow in man (130).
One of the major d i s a d vanta ge s of so ma t o s t a t i n  is its 
e x t r emely  short plasma half-life of two to three minutes and 
this has stimulated the searc h for a lo ng- acting analogue 
wh ic h is also more stable in solution. SMS 201-995 is a 
synthetic octapeptide analogue of soma t o s t a t i n  with a plasma 
half-life of 45 minutes following the te rm i n a t i o n  of 
intravenous infus ion (6). It is si g n i f i c a n t l y  more potent 
than s o m a t o s t a t i n  itself and has a greater relati ve effect 
on growth  hormone release than on glucose and insulin 
m e t a b o l i s m  and gastric secretion. One report has shown a 
r e d u ction  in portal vein flow, measured by electr omagne ti c 
flow meter, and portal pressure in rats (131) with no effect 
on systemic h a e m o d y n a m i c s . It has also been reported, by the 
same group, to reduce portal vein flow and pressure in pigs 
(132) but systemic haemod ynamic effects were recorded in 
these animals. In rats, SMS 201-995 stimulates the 
r e t i c u l o e n d o t h e l i a l  system (133), red uces the effects of 
e n d o t o x a e m i a  (134) and prevents the developm ent of acute 
panc rea titis (135). Unlike som atos ta tin, it has been 
reported to increase urine flow in the dog (136). Burroughs 
and colleag ues  (137) could de mo nstrate no change in wedged
hepatic vein pressure in stable cirrhot ics  given various 
doses of SMS 201-995, but Wahren and Er ik sson were able to 
show a re ductio n in liver blood flow and wedged hepatic 
venous pressure after SMS 201-995 (138).
There is therefore muc h that is u n k n o w n  about som atos ta tin 
and, in particular, about its new lon g-acti ng  analogue. The 
effect of SMS 201-995 on systemic and portal haemodynamics 
in human cirrhot ics has not been confirmed. Its ef f i c a c y  in 
the treatment of active varicea l bleeding has not been 
in ves tigated, and in particular com p a r i s o n  of the effects of 
a s o m a t ostati n inf us ion with those of more invasive 
treatm ent s such as ba ll oon tamponade has not been 
und ertaken. Further in v e s t i g a t i o n  of the action of SMS 
201-995 on regional and systemic ha em odynamics may elucidate 
its potential benefits or side-effects in the cirrhotic 
pat ie n t .
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iii) I n j e c t i o n  s c l e r o t h e r a p y
The m e t h o d s  for c o n t r o l  of active v a r i c e a l  b l e e d i n g  w h i c h  
have be en  d i s c u s s e d  so far ex e rt  o n l y  a t e m p o r a r y  ef f e c t .  
P a r t l y  from a d e s ir e  to i n t e g r a t e  i m m e d i a t e  c o n t r o l  and 
d e f i n i t i v e  t r e a t m e n t  and p a r t l y  b e c a u s e  in some p a t i e n t s  
b l e e d i n g  is not c o n t r o l l e d  by the above m e t h o d s ,  other more 
d e f i n i t i v e  m e t h o d s  have b e e n  u s ed  over the years. T h e s e  w ill  
be d i s c u s s e d  in more d e t a i l  later.
The least aggressive of these methods is acute inj ection 
sclerotherapy. Injection sc le ro t h e r a p y  is obviously much 
more difficult t e c h n i c a l l y  in the presence of active 
bleeding but as expertise has developed it has been realised
that this might be a very effi cient method of stopping
variceal bleeding (55). Terbl an che in 1984 (139) reported 
the pr el iminary results of a trial assessing this method. 
82% of bleeds were cont rolled  by inj ec ti on sclerotherapy. In 
his hands, the use of the rigid en doscope under general 
anaesthetic was associated with a lower incidence of 
technical problems, bleeding and as pi ration  than the use of 
the flexible end oscope. A recent r e tr os pectiv e review  of 
injection s c l e r othera py  in the U n i v ers it y Department of 
Surgery, G l a s g o w  Royal Infirmary, has found that the rigid 
oesophagosc ope is asso ciated with a greater c o m p l i c a t i o n  
rate but confers no benefit in terms of reducing 
p o s t - i njectio n bleeding (140). Westaby and colleagues (141)
have compared em e r g e n c y  s c l e r othera py  with the use of
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v a s o p r e s s i n  and n i t r o g l y c e r i n  for c o n t r o l  of a cti ve v a r i c e a l  
b l e e d i n g .  A l t h o u g h  c o n t r o l  of b l e e d i n g  at tw e l v e  hours was 
s i g n i f i c a n t l y  be tt e r in the s c l e r o t h e r a p y  g r o u p  no
d i f f e r e n c e  in the a d m i s s i o n  m o r t a l i t y  or d e f i n i t i v e  c o n t r o l  
ra te c o u l d  be d e m o n s t r a t e d .  T h e r e  is c o n s i d e r a b l e  i n t e r e s t  
in this m e t h o d  of t r e a t m e n t  at p r e s e n t  and the r e s u l t s  of 
fu r t h e r  c l i n i c a l  t r i a l s  are aw a i t e d .
T r a n s h e p a t i c  sc l e r o t h e r a p y  was des cr ibed by L u n d e r q u i s t  and 
Vang in 1974 (142) but a l t ho ug h this method has been used in
the trea tme nt of act iv ely bleeding varices (143), the
radio l o g i c a l  expertise  requi re d means that this is not a 
practical  p r o p o s i t i o n  in the m a j o r i t y  of hospitals.
T r a n s h e p a t i c  s c l e r o t h e r a p y  may be c o n t r a - i n d i c a t e d  in many 
portal hyperten siv e patients with si gn ificant coag ulopathy,  
often worsen ed by blood t r a n s f u s i o n  after a var ic eal bleed.
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iv) Oesophageal tran se ction
Before the develo pment of the circular stapling  gun,
*
oesophage al  tr an section  for bleeding varices carried a very 
high morta li ty because of the need for thoracotomy. Pugh's 
report (58) of a 55% mor t a l i t y  even in 38 patients whose 
bleeding was con tro lled by other means for 24-36 hours so 
that they could be prepared for operation, is fairly 
typical. Howeve r, the advent of the automatic stapling gun 
caused a resurgence in e n t h u s i a s m  for oesophageal 
t r a n s e c t i o n  as an e m e r genc y treatment for bleedi ng varices. 
One of the chief advocates of o es op hageal  t r a n section  is 
Johns to n of Belfast and in 1982 he reported his results in 
80 patients, 41% of whom were alcoholics (144). The overall 
mor t a l i t y  in this series was 14% but in the 19 eme rg ency 
cases m o r t al ity was much  higher at 32% and Joh ns ton would 
now try to avoid oe sophageal t r a n s e c t i o n  as an em erg ency 
procedure, prefer ring sc lerotherapy. A report from the 
United States gives an even higher m o r t a l i t y  of 89% in 
emergen cy  operations (145) for u n c o n t r o l l e d  bleeding.
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v) P o r t a s y s t e m i c  sh un t s
The use of the portaca val shunt as an em e r g e n c y  treatment 
for active variceal bleeding was popular in the 1960's and
70's, parti cu la rly in the USA. Even in the hands of the most
expert enthusi ast the operative survival was only 58% in a 
series of all patients with variceal bleedi ng who had 
portacaval  shunts performed withi n 7-8 hours of ad mission to 
hospital (146). The five year survival rate was 38% and
en c e p h a l o p a t h y  occurred in nearly one third of the 
survivors. It is ge nerally agreed that the risks of
e m e r ge nc y port acaval shunt procedures ou tweigh the benefits 
of their eff icient cont rol  of haemorrhage.
Therefore the control of acute variceal bleeding is still a 
problem. It seems likely that the treatment of choice over 
the next few years will be temporary control with one of the 
more selective drugs while injecti on s c l e r o th er apy is being 
arranged as an em e r g e n c y  procedure.
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THERAPY - PRE VE NT ION OF REBLE EDING
The second aspect of the treatment of bleeding oesophageal 
varices is the pre ven tion of rebleeding. It has been stated
that 26% of patients who survive for two days after a
variceal bleed will rebleed, if untreated, within six weeks 
(147). Each episode of variceal bleeding carries a morta lity  
risk of between 25 and 50%. A study of the outcome in 
patients who had bled from oesophag eal varices and who had 
no further treatment to prevent rebleed ing  has shown that at 
12 months only 33% of patients survived (148). The
prevention  of reble eding is obvious ly an important part of
the treatment of these patients.
4 7
H i s t o r y
One of the first operati ons  used in portal hyperte ns ion was 
omentopexy. Report ed in 1898 by Talma and also described by 
Drummond and Mor ison (11) this became known as the
Ta l m a - M o r i s o n  procedure. The parietal peritoneu m was 
scarified and the omen tum  sutured to the raw surface in an 
attempt to stimulate the deve lo pment of collateral flow. It 
seems that around 50% of patients had further
g a s t r o in testi na l bleeding despite this procedure. An early 
al ter native to ome ntope xy  was splenectomy, origina lly 
advocated by Banti (13). These early operations formed the 
background to later development.
Two a p p r o a c h e s  to the p r e v e n t i o n  of r e b l e e d i n g  can be 
i d e n t i f i e d ,  the l o w e r i n g  of p o r t a l  p r e s s u r e  and d i r e c t  
a t t a c k  on the v a r i c e s  t h e m s e l v e s .  Over the ye ar s  these
a p p r o a c h e s  ha v e be e n used in a v a r i e t y  of ways.
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Portasys te mi c shunts
By redir ecting the flow of blood from the high pressure 
portal system to the low pressure systemic venous system, 
portacaval shunting will lower portal pressure effectively. 
In the early part of this century Vidal performed the first 
portocaval shunt in a human (12) and this technique was used 
sporadic al ly  over the next few decades. Vidal had a good 
understand in g of the pa th op h y s i o l o g y  of portal hypertension  
and described clearly the major problem of shunt surgery, 
encephalopathy. The first major report of the use of the 
portacaval shunt in a series of patients was by Whipple in 
1945 (16), who descri bed an en d-to- side portacaval shunt 
using Blakem ore 's vit al li um tube for the anastomosis. In 
subsequent decades, shunt surgery became established as a 
means of pr ev ent ing rebleeding from varices. Over the years 
it has become clear that it is an effective means of 
preventin g variceal bleeding but that it carries a high 
penalty. Operative mort ality  is significant, and is reported 
as between 7% (149) and 20% (150) for elective end -to-side 
portacaval anastomosis. The survivors have a 15-30% chance 
of de ve loping hepatic enc ep h a l o p a t h y  (151), the major 
lo ng-term c om pl icati on  of shunt surgery. A vari ety of 
operative techniques for portacaval shunting have been 
developed to try to improve the results.
The r e p o r t s  of the r e s u l t s  of shunt s u r g e r y  are o fte n 
d i f f i c u l t  to i n t e r p r e t .  M a n y  s t u d i e s  are r e t r o s p e c t i v e  and 
e ve n  those w h i c h  are p r o s p e c t i v e  c o n t r o l l e d  s t u d i e s  are o pen
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to criticism. The source of g a s t r o i ntestinal bleeding has 
not always been established, the cause of the cirrhosis has 
not been well documented, surgery has been performed at 
different times following an acute bleed and the results 
have been analysed in many ways. In one of the clearest 
reports Resnick and colleagues (152) looked prospectively at 
results of end-to-side portacaval shunt in alcoholic 
cirrhotics with upper g a s t r o i ntestinal bleeding in 
comparison with medical treatment of bleeds alone. There was 
no statistically significant difference in survival, the 
medically treated patients dying of bleeding while the 
surgically treated patients died of hepatic failure. The 
five year survival rate was appro x i m a t e l y  50% in a group of 
79 patients where 42% were allocated to Child's grade A.
A mesocaval shunt was proposed in 1948 by Linton (153) to 
overcome the diffi c u l t i e s  of portacaval shunting in children 
with portal vein thrombosis and in those adults who had had 
previous shunting. This was thought initially to function as 
a side-to-side shunt and was also recommended by Clatworthy 
and colleagues (154), p articularly in children. The benefit 
of a side-to-side shunt was said to be continued perfusion 
of the liver but the fact that the anastomosis is between 
the high pressure portal venous system and the low pressure 
caval system means that blood flow is still hepatofugal. 
Further, arteriovenous fistulas in the liver may shunt blood 
from the hepatic arterial system to the portal venous system 
and this will also flow away from the liver. These concepts
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were supported by a trial of end-to-side versus side-to-side 
portacaval shunts which demonstrated a higher incidence of 
post-shunt e n cephalopathy after side-to-side shunts (155).
A further attempt to design a shunt which maintains hepatic 
perfusion was the distal splenorenal shunt, described in 
1967 by Warren (156). This shunt aims to selectively drain 
blood from o e s o p h a g o - g a s t r i c  varices by anastomosing the 
distal splenic vein to the left renal vein, leaving the 
spleen in situ. This is technically more difficult than an 
end-to-side shunt but the promise of a lower incidence of 
e n c e p h alopathy has attracted many surgeons in recent years. 
A recent survey of the prospective randomised trials of 
distal splenorenal shunt and portacaval shunt has shown no 
difference in long-term survival in alcohol cirrhosis (151). 
However it is felt that patients with non-alcoholic 
cirrhosis who have stable liver disease might well benefit 
from distal splenorenal shunt in terms of increased survival 
(157), although this has not been demonstrated in a 
randomised trial. The effect of distal splenorenal shunt on 
the incidence of en c e p h a l o p a t h y  is disputed, some studies 
showing a lower incidence of enc e p h a l o p a t h y  while others 
have failed to show a difference from portacaval shunt 
(151). In patients with portal vein thrombosis a distal 
splenorenal shunt may be possible where a portacaval shunt 
is precluded. One of the most recent types of shunt is an 
alternative selective shunt, anastomosing the left gastric 
vein to the vena cava (158). This has not been assessed in
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W e s t e r n  p a t i e n t s  w i t h  their h i g h  i n c i d e n c e  of a l c o h o l i c  
c i r r h o s i s  •
Attempts to reduce the technical difficulty of shunt 
operations led to the use of a Dacron prosthesis (159). This 
resulted in the mesocaval interposition H graft which is 
technically easy but has a propensity for thrombosis (160). 
There has been a recent resurgence in interest in this 
technique (161), building on the idea that the fraction of 
the portal flow shunted will depend on the diameter of a 
synthetic graft used as the conduit for a* portacaval shunt. 
It therefore should be possible to divert sufficient blood 
from the portal vein to reduce portal pressure without 
completely depriving the liver of its portal flow.
After a period of dis i l l u s i o n m e n t  with shunt surgery 
because of the appearance of enceph a l o p a t h y  in so many 
patients there has been some increase in interest in the 
British literature (162). However the majority of doctors 
continue to reserve shunt surgery for the elective 
prevention of rebleeding in a very limited number of 
patients, in general, young patients with non-alcoholic 
liver disease and good p reservation of liver function. A 
recent report from India demonstrates that in extra-hepatic 
portal hypertension, if a distal splenorenal shunt is 
possible and remains patent, a good outcome can be expected 
(61 ).
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O e s o p h a g e a l  t r a n s e c t i o n
The a l t e r n a t i v e  a p p r o a c h  to p r e v e n t i o n  of r e b l e e d i n g  from 
v a r i c e s  is d i r e c t  a t t a c k  on the v a r i c e s  t h e m s e l v e s .
S u r g i c a l  l i g a t i o n  of the b l e e d i n g  v a r i c e s  was an o b v i o u s
s o l u t i o n  w h i c h  was s u g g e s t e d  by C r i l e  in 1950 (163). T his
was not e f f e c t i v e  in the p r e v e n t i o n  of r e b l e e d i n g  as all of 
his cas e s  r e b l e d  w i t h i n  two years. L i n t o n  (80) also 
r e c o m m e n d e d  t r a n s o e s o p h a g e a l  l i g a t i o n  of v a r i c e s  but saw 
this as an e m e r g e n c y  p r o c e d u r e  to g a i n  c o n t r o l  of b l e e d i n g  
and t h e r e a f t e r  p r e p a r e d  the p a t i e n t  for an e l e c t i v e  
p o r t a c a v a l  shunt.
The direct approach developed in two directions with some 
surgeons combining the two techniques. Tanner performed a 
sub-cardiac gastric transection on a series of patients who 
had bled from varices and reported that eight of his 32
patients had major rebleeding following this procedure
(164). T r a n s e c t i o n  of the oesophageal mucosa alone was
attempted (165) and some surgeons were even more aggressive 
and recommended total gast r e c t o m y  or oe s o p h a g o g a s t r e c t o m y 
(166). These major operations naturally had a high mortality 
rate. The most significant development in the field of 
t r a n s e c t i o n / r e s e c t i o n  for treatment of oesophageal varices 
was the development of the circular stapling gun and
Vankemmel of France was the first person to report its use
for oesophageal transection in portal h y pertension (167). In 
the United Kingdom Johnston from Belfast has been the main 
advocate of this method of treatment. He described his
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indications for operation and technique in 1978 (168) and 
first reported a major series of 80 patients in 1982. The 
operative mortality rate was 14% and only one death from 
variceal bleeding occurred in the follow-up period of three 
years (144). A more recent report (169) includes 100 
patients with a m o r t a l i t y  rate of 15%. Child's C patients 
had a high mor t a l i t y  rate of 27%. In a follow-up period of 
up to seven years, 26 patients had recurrent
gas t r o i n t e s t i n a l  bleeding but only 11 were bleeding from
varices and most bleeds were minor. Johnston carries out 
transection at the g a s t r o o e s o p h a g e a l  junction with 
meticulous d e v a s c u l a r i s a t i o n  of the lowest 5 cm of the 
oesophagus. The left gastric vein is ligated at the upper 
border of the pancreas and the p e r i o e s o p h a g e a 1 collaterals 
lying with the vagus nerves are also divided with any
branches. He only performs s plenectomy if the platelet count
is below 5 0 , 0 0 0 x  10 /l.
The d e v a s c u 1arisation of the o e s o p h a g o g a s t r i e  junction is 
much emphasised by J o h nston and this is the second direction 
of development of the direct approach to oesophageal
varices. It was advised at least as long ago as 1929 when 
workers from the Mayo Clinic described a case of coronary 
vein ligation (170). Tanner's sub-cardiac transection was 
accompanied by d e v a s c u 1arisation of the upper half of the 
stomach (164). In the Far East there is significant interest 
in the Suguira procedure, in which extensive
d e v a s c u l a r i s a t i o n  is performed through a thoraco-abdominal
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incision (171). Via the thoracotomy, transection of the 
thoracic oesophagus is performed and all dilated collateral 
venous vessels are divided. Further d e v a s c u l a r i s a t i o n  of the 
oesophagus, cardia and lesser curve is performed in the 
abdomen, including ligation of the left gastric vessels 
along with selective vagotomy and pyloroplasty. Splenectomy 
is routinely performed. Suguira and his colleagues (172) 
have reported the results of this procedure in 671 patients. 
The overall operative mortality was 4.9% and the incidence 
of recurrent variceal haemorrhage was 1.5% over a follow-up 
period of up to ten years. Only 52 of the 671 patients in 
this group had alcoholic cirrhosis and there is some doubt 
about the ability of the Western alcoholic patient to 
withstand such a major procedure.
Injection sclerotherapy 
The methods of prevention of variceal rebleeding discussed 
so far have all necessitated major surgery. This is 
obviously hazardous in many patients with portal
hypertension and less invasive methods of control are 
therefore attractive. In 1939 Crafoord and Frenckner (173)
described the injection of oesophageal varices with
sclerosant solution during o e s o p h a g o s c o p y . Little interest 
was shown in this method for some years other than MacBeth's 
report of 30 cases in 1955 (174). However, interest
increased rapidly following the report of Johnston and 
Rodgers in 1973 (175) of good control with few s i d e - e f f e c t s . 
Several prospective trials have confirmed that chronic
injection sclero t h e r a p y  reduced the incidence of rebleeding 
from varices when compared with conservative medical 
management (176,177). Long-term survival rates are probably 
improved when patients treated with regular injection 
sclerotherapy are compared with the group treated with drugs 
and blood transfusion a l o n e ( 1 76 , 1 78 ). Although Terblanche 
and colleagues (179) have reported that repeated injection 
sclerotherapy fails to improve survival, their study 
compared patients treated with repeated elective 
sclerotherapy to patients treated with sclerotherapy for 
variceal bleeds rather than only conservatively. Since there 
have been no other reports comparing these two treatments it 
is not clear whether regular s clerotherapy for o bliteration
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of varices confers a survival advantage over sclerotherapy 
only after variceal bleeds. Many other aspects of injection 
sclerotherapy, such as the optimal method, sclerosant and 
frequency of injection, are not well established.
When first described, sclerotherapy was performed using a 
rigid endoscope and this necessitated general anaesthesia. 
With the introduction of the fibreoptic endoscope it became 
possible to perform s c l e r otherapy under sedation. The use of 
the Williams sheath (180) around the flexible endoscope is a 
compromise between rigid and flexible endoscopy and a
general anaesthetic may not always be necessary while using 
this method. For the injection of actively bleeding varices 
Terblanche has reported that the rigid endoscope and a
general anaesthetic is preferable, causing fewer problems 
with bleeding and aspiration ( 139) . Westaby and colleagues 
have compared the use of the sheath and the free-hand
technique in varices injected soon after a bleed (181), and
found that there was an increased incidence of bleeding 
problems with the free-hand technique, but most patients 
find the use of the sheath intolerable without a general 
anaesthetic. The m a j ority of elective injection 
sclerotherapy is now performed under sedation with the 
flexible endoscope.
The type of i n j e c t i o n  has also b e e n  d e b a t e d  at length. 
V a r i c e s  m a y  be i n j e c t e d  i n t r a v a r i c e a l l y  or in the 
p a r a v a r i c e a l  reg i o n .  I n t r a v a r i c e a l  i n j e c t i o n  c a u s e s
o b l i t e r a t i o n  of the l u m e n  of the v a r i x  by s c l e r o s a n t  w h i l e
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paravariceal injection causes thickening of the tissue 
overlying the varix. Bleeding from the varix is thus 
prevented for different reasons. Sclerotherapy was first
described using the intravariceal technique but Paquet has 
been a strong exponent of the paravariceal technique in the 
last few years (182). It must be kept in mind that the 
division between the two techniques is at least partly 
artificial since Barsoum and colleagues (183) have shown 
that only 20% of intended intravariceal injections are 
totally i n t r a v a r i c e a l .
Little has been written about the large number of
sclerosants used for injection of varices. Different 
sclerosing agents tend to be used by those who favour 
paravariceal injection (usually polidocanol) and those who
use intravariceal injection (1.5% sodium tetradecyl
s u 1p h a t e (S T D ) , 5% sodium morrhuate and 5% e t h a n o l a m i n e ).
Sodium morrhuate is difficult to obtain in the UK while 
ethanoleamine cannot be used in the USA. In animal studies 
Reiner showed (184) that STD was more thrombogenic than 
morrhuate and Blenkinsopp (185) showed that STD was more 
thrombogenic than e t h a n o l a m i n e . However Jensen (186) has 
reported a study in dogs in which although STD was one of 
the most effective sclerosants, the performance of 
ethanolamine and morrhuate varied with the site of the veins 
injected. In man, Gibbert (187) found a higher incidence of 
oesophageal u lceration and increased m o r tality in a group of 
patients treated with morrhuate compared to a group treated
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with STD. Morrhuate has been associated with the development 
of adult respiratory distress syndrome in one report (188). 
5% ethanolamine oleate is probably the most common
sclerosant in the United Kingdom and a recent controlled 
trial found that injection with ethanolamine led to a lower 
rate of post injection bleeding and fewer oesophageal ulcers 
than injection with 2% STD (189).
The frequency of injection is another point of controversy. 
As discussed above, chronic injection sclerotherapy rather 
than s clerotherapy for acute bleeds only has been shown to 
reduce the number of rebleeds but improvement in survival 
has not been proven (179). During chronic injection 
sclerotherapy a trial from King's College Hospital has 
suggested that an increase in frequency of elective
injection from the more common three weekly schedule to
weekly has no effect on complication rate but reduces the 
bleeding rate (190).
The use of injection scler o t h e r a p y  is now well established. 
One report shows that of patients who survived an acute 
variceal bleed and were managed by chronic injection 
sclerotherapy, 67% survived for two years after their 
initial bleed (191). Bleeding was rare following variceal 
obliteration and a mean of 3.3 injections was needed to 
achieve obliteration.
Although the complications of s clerotherapy are usually 
minor in comparison with those of major surgery there are 
complications. Immediate problems with bleeding have been
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reported with a frequency of 4-14% depending on how recently 
the varices have bled (181). Chest infection is probably the 
commonest complication (192) and is particularly associated 
with injection soon after a variceal bleed (140). During 
injection using the rigid oesophagoscope perforation is the 
most serious c omplication and formed the major complication 
in the series of 264 patients treated over twenty five years 
by Spence and colleagues (193), the incidence of perforation 
being 2.2%. Perforations are extremely rare when the 
flexible endoscope is used for injection (176). Ulceration 
of the oesophagus is reported to a varying degree depending 
on the frequency of endoscopy. Soderlund and Ihre (194) 
found ulceration in 8 of 57 patients who had sclerotherapy 
at 24 hours, one week, 3 weeks, 6 weeks and three months 
after a variceal bleed. McDougall and colleagues (176) found 
ulcers in 15 of 51 patients who had sclerotherapy at three 
w eekly intervals till o b l i t eration of varices was achieved. 
They found the more advanced c o m p lication of oesophageal 
stricture in 9 patients. In a study of 55 patients, Westaby 
and colleagues (190) noted an 80% incidence of ulceration 
when sclerotherapy was performed at one weekly intervals but 
only a 30% incidence when the interval between s clerotherapy 
sessions was three weeks. Ulceration may cause bleeding and 
this may be confused with further variceal haemorrhage.
Not surprisingly, it has been noticed that oesophageal 
function is abnormal following chronic injection
sclerotherapy. Reilly and colleagues found abnormal
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peristalsis in 12 of 13 patients following sclerotherapy
(195). Although heartburn and retrosternal pain are common, 
minor complications immediately after sclerotherapy few 
patients complain of persistent oesophageal symptoms.
Despite the impression from uncontrolled reports that 
injection s clerotherapy is a much less hazardous treatment 
than the various surgical approaches to prevention of
rebleeding from varices, and should therefore be preferable 
in less fit patients, one controlled trial has shown no 
statistically significant difference in survival between
sclerotherapy and surgery. Cello and colleagues (196)
randomised 52 patients who were Child's grade C and who had 
had bleeding from varices, to either chronic injection
sclerotherapy or a portacaval shunt. 13 of 28 patients 
treated with scler o t h e r a p y  and 10 of 24 patients who had a 
portacaval shunt were discharged from hospital. Follow-up
was for a mean of 263 days and at the time of reporting,
nine patients in the s clerotherapy group and four patients 
in the shunt group were alive. K a p l a n-Meir plots failed to
show any significant difference in survival time. No
controlled trial has compared chronic injection
sclerotherapy with oesophageal transection.
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Transhepatic oblit e r a t i o n  of varices 
In 1974 Lunderquist and Vang described a method of
transhepatic o bliteration of varices by embolisation of the 
coronary vein which had been cannulated by the transhepatic 
route (142). This was initially appealing as a further 
relatively non-invasive method of treatment. It could also 
be performed at the same time as diagnostic radiology and 
pressure measurements in the portal system.Over the ensuing 
years it became clear that there are two main drawbacks of 
this technique: firstly the need for highly specialised
radiologists to perform it and secondly the complications 
associated with transhepatic cannulation of the portal vein. 
A comparison of transhepatic o b l i teration of varices with 
stapled oesophageal transection in uncontrolled bleeding 
from varices showed that both methods were equally effective
in stopping the bleeding and that hospital mortality was
similar (143). Despite this the need for specialised 
radiology has made transhepatic o bliteration of varices an 
uncommon procedure.
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The use of d r u g s  in the p r e v e n t i o n  of r e b l e e d i n g
The search for a drug which would lower portal pressure on 
a long term basis and thus prevent rebleeding from 
oesophageal varices has been widespread. In 1980 Lebrec and 
colleagues reported that propranolol caused a significant 
drop in portal pressure in sixteen cirrhotic patients who 
had had recent variceal bleeds (106) and propranolol was
suggested as a medical treatment for portal hypertension. A 
further report from this group in 1981 (197) stated that the
use of oral propranolol s i gnificantly reduced the number of 
bleeding episodes in patients with oesophageal varices. In 
1984 they reported again on this trial and were able to show 
an improvement in two year survival in the group of patients 
treated with propranolol compared to the placebo treated
group (198). However, initial e nthusiasm has been dampened 
by the results of two subsequent trials which could
d emonstrate no reduction in rebleeding rates or improvement 
in survival (199,54). One of the most recent double blind, 
controlled trials of propranolol versus placebo has 
demonstrated only a small d ifference in late rebleeding rate 
and long-term survival, suggesting that propranolol is
unlikely to be of value during the high risk period soon 
after a variceal bleed (200). The results of these trials 
are summarised in Table 1. It is generally felt that the 
excellent results obtained by Lebrec were due to a group of 
patients with s ignificantly less severe liver disease than
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most patients with varices and that propranolol has not been 
proven to be of use in the majority of patients. Lebrec's 
group have published work which confirms this reasoning, 
showing that the effect of propranolol on azygous blood flow 
is highly variable in Child's grade C patients (201). 
Lebrec's trial also included all causes of upper 
gastrointestinal haemorrhage in his varices patients, rather 
than only variceal bleeds and if recent reports of 
propranolol's efficacy in severe gastritis in portal 
hypertensive patients are confirmed (202), this may be 
another reason for Lebrec's good results.
Various other ad r e n o r e c e p t o r  blockers have been assessed 
e x p e r i mentally with regard to their portal pressure effects. 
Atenolol was found to reduce portal pressure less 
effectively than propranolol and prazozin had significant 
side-effects although portal pressure was reduced to the 
same extent as by propranolol (109). A new selective B2 
blocker (ICI 118,551) has been studied in animals (203) and 
is thought to hold some promise, since a significant fall in 
portal pressure was d emonstrated with no effect on heart
rate or systemic blood pressure.
Cimetidine has also been studied with regard to prevention 
of variceal bleeding. Burroughs and colleagues were unable 
to show any effect on portal pressure in cirrhosis with
cimetidine (110) and a controlled trial failed to show any
difference between patients on regular cimetidine and those 
on placebo in terms of rebleeding from their varices (43).
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T h e r e  is t h e r e f o r e  some d e b a t e  a b o u t  the pla c e  of l o n g - t e r m  
d r u g  t h e r a p y  in the p r e v e n t i o n  of v a r i c e a l  b l e e d i n g .
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Table 1 - Results from four trials of the use of propranolol 
in the prevention of variceal haemorrhage.
AUTHOR Lebrec Burroughs Villeneuve Garden
(198) (199) (54) (200)
n 56* 48 79 81
N U M B E R  REBLEEDING
PLACEBO 17/28 11/22 30/37 33/43
PROPRANOLOL 2/ 28 12/ 26 32/42 19/ 38
*0nly patients bleeding from varices are included here.
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PROPHYLAXIS
The ultimate in prevention of bleeding from varices must be 
to prevent the first bleed, which carries a mortality of 
25-50%. In the hey-day of shunt surgery in the United States 
prophylactic portocaval shunts were advised. However several 
controlled trials showed that survival was not improved and 
that morbidity due to e n c e p h a l o p a t h y  and hepatic failure was 
unacceptable (204,205). Prophylactic shunts have therefore 
fallen out of favour.
Prophylactic s c l e r otherapy has been supported by Paquet 
(206) whose study published in 1982 showed a r e d u ction in 
bleeding and m o r t a l i t y  rate in patients with large varices. 
Only patients thought to be at high risk. of bleeding were 
entered into this study and the bleeding rate in the control 
group was very high. Prophylactic scler o t h e r a p y  has not been 
widely accepted although it does seem much more likely to be 
a safe and useful u n d e r taking than prophylactic shunt 
surgery.
Two multicentre studies have looked at the use of 
propranolol on a prophylactic basis. A French study reported 
signi f i c a n t l y  fewer bleeds (3% versus 26%) and deaths (3% 
versus 37%) over a twelve month follow-up period in subjects 
taking propranolol compared with the placebo group (207). An 
Italian study also showed less bleeding on propranolol but 
only when those who stopped taking the drug because of 
side-effects were excluded (208). The compliance factor is
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obviously of great importance in studies of prophylaxis in a 
group of patients who are not always the best motivated.
The question of prophylaxis against the first variceal 
bleed therefore remains an open one. Further studies of both 
i njection s c lerotherapy and drug treatment are necessary.
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AIMS OF THESIS
1. To assess the previous results of oesophageal tamponade
as used in the U n i v ersity Department of Surgery, Glasgow 
Royal Infirmary, for acute variceal bleeding.
2. To study the acute effects of SMS 201-995 on systemic and 
portal haemodynamics in stable cirrhotic patients.
3. To examine the mode of action of SMS 201-995 using a
radioactive microsphere method to measure cardiac output, 
organ blood flow and portasystemic shunting in normal rats, 
rats with extrahepatic portal hypertension and cirrhotic 
rats.
4. To compare the efficacy of SMS 201-995 with that of
oesophageal tamponade in patients with active variceal 
bleed i n g •
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CHAPTER 2
OESOPHAGEAL T A M P O N A D E  IN THE MANAGEMENT OF VARICEAL 
H AEMORRHAGE
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INTRODUCTION
As discussed in Chapter 1, for some years the mainstays of 
treatment for active variceal bleeding have been vasopressin 
and oesophageal tamponade. In the University Department of 
Surgery, Glasgow Royal Infirmary, oesophageal tamponade 
using the 4-lumen Minnesota m odification of the
S e n g s t a k en-Blakemore tube has been the principal means of 
control of variceal bleeding for the past seven years. As a 
basis for future studies in control of variceal bleeding, 
the results of the use of oesophageal tamponade over this 
period have been reviewed, to assess not only the bleeding 
control rate, but also the problems associated with 
oesophageal tamponade.
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P A T I E N T S  AND M E T H O D S
One hundred and thirty eight patients presented on 223 
occasions to the University Department of Surgery, G l asgow 
Royal Infirmary from August 1979 until April 1986, with 
endosc o p i c a l l y  proven bleeding oesophageal varices. Only 
patients who had bled within 24 hours of p resentation are 
included in this review. Patients presenting with suspected 
variceal haemorrhage were initially resuscitated with a 
c o m b i n a t i o n  of crystalloid and colloid, and crossmatched 
blood where appropriate. At the time of admission, blood was 
taken for e s t i m a t i o n  of serum urea and electrolyte 
concentrations, full blood count and c o a g u l a t i o n  screen. Any 
c o a g u lopathy was corrected by the ad m i n i s t r a t i o n  of fresh 
frozen plasma and/or c r y o p r ecipitate as appropriate. Vitamin 
K1 ( 1 Omg daily) and cimetidine (400mg twice daily) were 
given p arenterally to all patients. No patients in this 
series r o u t inely received vaso p r e s s i n  or any other 
vaso-active agent to arrest their haemorrhage.
Early endoscopy was performed as part of the initial 
assessment of each patient. If active variceal haemorrhage 
was d emonstrated at endoscopy and deemed to be so severe 
that it was u n l ikely to cease without intervention, 
tamponade was instituted using the Min n e s o t a  four lumen 
m o d i f i c a t i o n  of the S e n g s t a k en-Blakemore tube (81) If such 
proven haemorrhage was minimal and thought likely to cease 
without intervention, tamponade was not instituted until it 
was clear that bleeding was continuing i.e. further overt
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haematemesis or occult haemorrhage reflected in a rising 
pulse rate and/or falling blood pressure. The tube was 
inserted by medical staff trained in its use. The initial 
practice was to pass the tube o r o g a s t r i c a l l y , but in the 
last two years the nasogastric route was preferred. 
Nasogastric i ntubation has been found to be easier than 
orogastric intubation and was more acceptable to most 
patients who had e xperienced previous orogastric intubation. 
The gastric balloon was inflated with 100ml of water and 
20ml of sodium meglumine iodamide (Uromiro 340 , Merck Ltd)'. 
The oesophageal balloon was inflated with air to a pressure 
of 40mmHg as measured by an aneroid barometer. The position 
of the tube was confirmed by abdominal radiography 
immediately after insertion and the patient was constantly  
supervised by trained nursing staff in the University 
Department of Surgery ward. Open drainage of the gastric and 
pharyngeal channels of the M i n n esota tube was supplemented 
by hourly syringe aspiration. Tube position was maintained 
simply by taping the tube to the side of the nose or to a 
spatula at the side of the mouth. Lactulose (15-30mls three 
times daily) was given ent e r a l l y  to minimise or avoid 
encephalopathy, and the rectum was irrigated through a 
rubber tube with up to eight litres of water or until a 
clear return was obtained. Sedatives and analgesics were 
avoided whenever possible.
The Minnesota tube was kept in position with both balloons 
inflated for 24 hours. The oesophageal balloon was then
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deflated and the tube left In place for up to twelve hours.
If bleeding did not recur then the tube was removed and
destroyed to prevent reusage. If bleeding recurred the
balloons were re-inflated. When the c o n dition of the patient
permitted, injection s c lerotherapy using a modified Negus 
rigid oesophagoscope (209) was undertaken.
Recurrent variceal haemoorhage during admission was defined 
as the development of shock ( p u l s e >1 00/min and/or systolic 
blood p r e s s u r e < 1O O m m H g ) requiring continued r e s u s c i t a t i o n  or 
the aspiration of fresh blood through the tube. Any such 
haemorrhage occurring after initial bleeding had ceased or 
been controlled with tamponade for 24 hours was deemed to be 
recurrent. Such recurrent bleeding was treated in a similar 
manner by tamponade.
The severity of the u n d e r l y i n g  liver disease was assessed 
in each patient using Pugh's m o d i f i c a t i o n  of Chlid's grading 
(58). In addition a prognostic score was calculated on 
a dmission for each patient using the derived e q u ation 
described by G a r d e n  et al (72). In that study three factors, 
namely p rothrombin ratio, serum creatinine and the presence 
of encephalopathy, were found to have independent 
s ignificance in the p rediction of outcome, which, when taken 
together, accurately predicted outcome in 90% of cases.
To try to e s t a b l i s h  the aetiology of the portal 
hypertension, a liver biopsy was performed on all patients 
during initial or subsequent admissions, unless 
c o ntraindicated by major coagulopathy.
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R E S U L T S
One hundred and thirty eight patients were admitted on 223 
occasions with e n d o s copically proven variceal haemorrhage* 
There were 93 males and 45 females with an average age of 
53.3 years (range 17-82 years). The aetiology of the portal 
hypertension in these patients is shown in Table 2. Figure 1 
illustrates the outcome of these 223 episodes of variceal 
h a e m o r r h a g e .
S p o n t a n e o u s  c e s s a t i o n  of h a e m o r r h a g e
In 92 bleeds (41%) haemorrhage ceased without passage of 
the Minnesota tube. In only two did bleeding recur during 
admission (both after sclerotherapy) and in both cases 
tamponade controlled haemorrhage. Eight of the patients in 
this group died after bleeding had settled; seven of 
progressive liver failure and one following a cardiac 
arrest; six of these patients had sclerotherapy.
Failed intubation
Five patients would not tolerate insertion of the Minnesota 
tube. One patient, having experienced oesophageal 
intubations on six previous occasions, would not allow the 
tube to be passed on a seventh occasion. V a s o pressin 
infusion failed to control haemorrhage and emergency 
sclerotherapy was required. Despite the eventual successful 
control of bleeding, the patient died of pneumonia three 
days later. In the youngest patient in our series, emergency 
oesophageal transection was required to arrest haemorrhage
w h e n  the tube was p u l l e d  up three times in q u i c k  s u c c e s s i o n  
b e f o r e  the b a l l o o n s  c o u l d  be i n f l a t e d .  In one of the
r e m a i n i n g  three p a t i e n t s  h a e m o r r h a g e  s e t t l e d ,  but he died of 
h e p a t i c  f a i l u r e .  In a f u r t h e r  p a t i e n t  h a e m o r r h a g e  i n i t i a l l y  
s e t t l e d  but r e c u r r e d  and was c o n t r o l l e d  by t a m p o n a d e ,  w h i c h
was t o l e r a t e d  on the s e c o n d  o c c a s i o n .  He s u b s e q u e n t l y
u n d e r w e n t  s c l e r o t h e r a p y  and this c o n t r o l l e d  b l e e d i n g .  
H a e m o r r h a g e  r e q u i r i n g  i n t u b a t i o n
Oesophageal tamponade was required for the remaining 126 
bleeds (57%) and haemorrhage was initially controlled on 123 
occasions (98%). Bleeding recurred on 44 occasions (35%)
during these 123 admissions: 25 on deflation of the balloons
and 19 following sclerotherapy. Oesophageal tamponade was 
required on all of the 47 occasions where bleeding recurred 
during admission (44 after tamponade, two where bleeding 
initially ceased and one where intubation was initially
refused). H a e m o rrhage was controlled on 41 of these
occasions (87%). A second epispde of recurrent haemorrhage 
occurred on 11 occasions (two after sclerotherapy),
tamponade was required on all 11 occasions and bleeding 
arrested on nine. Two patients rebled a third time (one 
after sclerotherapy) but in both patients haemorrhage was 
successfully controlled by tamponade. No patient rebled for 
a fourth time during one admission.
Overall, tamponade was successful in controlling variceal 
haemorrhage on 175 of the 186 occasions where its use was 
thought to be necessary (94%). It was more successful in
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controlling haemorrhage in patients at initial presentation 
and in patients with less severe liver dysfunction as judged 
by modified Child's grade (Table 3).
Failed control of haemorrhage 
The Minnesota tube failed to control variceal haemorrhage 
on ten occasions in nine modified C h i l d ' sCgrade patients and 
once in a modified Child's B grade patient. In the grade B 
patient haemorrhage was not controlled by re-intubation 
after the initial tube was pulled up by the patient. He 
subsequently required emergency oesophageal transection 
which controlled haemorrhage. Five of the modified Child's C 
grade patients died before any other life saving measure 
could be instituted and in two of these post-mortem 
examination revealed oesophageal tears thought to be caused 
by intubation. One further patient required emergency 
injection scler o t h e r a p y  which successfully controlled 
haemorrhage initially, but the patient rebled and died when 
intubation again failed to control haemorrhage. One patient 
pulled up the tube with balloons inflated before haemorrhage 
ceased and sustained a fatal car d i o p u l m o n a r y  arrest when the 
tube was repassed. In one patient repeat endoscopy 
demonstrated a bleeding gastric varix, which was 
successfully underrun at operation. The last of the nine 
modified Child's C patients bled after injection 
sclerotherapy and subsequent intubation failed to control 
bleeding. Haemorrhage gradually settled after it was decided 
that the patient was not fit for any active intervention,
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and he died three days la ter of a ches t i n f e c t i o n .  
C o m p l i c a t i o n s  of t a m p o n a d e
There were 28 com plic ation s attributed to oesophageal 
intubation in 186 episodes where tamponade was necessary 
(Table 4). Thirte en patients developed chest infections 
(defined as the deve lopment  of a pyrexia, in the presence of 
abnormal physical or radiolog ical signs in the chest and the 
absence of other obvious causes for the pyrexia, or the 
pro duction of purulent sputum) but nine of them had
undergone injection s c l e r oth er apy under general anaesthesi a 
following tamponade and prior to d e v e lo pi ng the infection. 
Seven of these patients died as a conse que nce of the
infection.
Eight patients pulled up the tube with the balloons fully 
inflated. Most of these patients com plained of transient 
dysphagia but one died from massive uncon tr ollable
haemorrhage from an oe sop hageal tear which was confirmed at 
post-mortem. Four patients sustained a c a r d i o - r e s p i r a t o r y  
arrest on passage of the Min ne sota tube: three were
successfully resus citated but one of these patients died 
(mentioned in the previous paragraph). There were no 
complications asso ciate d with the passage of the tube by the 
nasogast ric route. In one patient the tube could not be 
passed due to nasal septal dev ia tion but orogastric
intubation was successful.
Deaths
Table 5 shows details of the deaths which were attri buted
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to oesoph ageal tamponade in relat i o n s h i p  to whether 
sclerothe rapy was u n d e r t a k e n  during the final admis sion and 
in relat i o n  to the patient's calculated prognostic index 
(72). Four deaths were due to the failure of the tube to 
control haemorrhage. A further four deaths were defini tely  
associated with the use of oesop hageal tamponade. Seven 
deaths were due to chest infection. Four of these patients 
had s c l e r ot herapy  under general ana es th esia as well as 
oesopha gea l tamponade. One patient's dea th was complet el y 
un exp la in ed. She had a c a r d i o - r e s p i r a t o r y  arrest and could 
not be resuscit ated. Post m o rte m e x a m i n a t i o n  showed no 
ab normal ity to e x pl ain this.
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Table 2 - Aetio logy of portal hyperten si on in 138 patients
admitted with acute variceal haemorrhage and its
r el ationsh ip to Child's grade.
CHILD'S GRADE 
B C Total
Alco hol ic cirrhosis 4 21 73 98
Chronic active hepatitis 1 5 6 12
C ryp togenic  cirrhosis 0 8 1 9
Primary biliary cirrhosis - 2 4 6
Portal vein thrombosis 2 2 - 4
Primary scl erosing cholangitis 1 - 1 2
Idiopathic portal hyp er tensi on - 1 1 2
M et ast ati c breast carcinoma - - 1 1
Pancreatic car cinoma - 1 - 1
W ils on's disease - 1 - 1
Unknown 2 2
TOTAL 43 87 138
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Table 3 - Control of hae morrhage by tamponade and its
relation to modified Child's grade.
CHILD'S GRADE 
A B
I ni t i a l  bl e ed s  n=4 n=42
no of patients in whom 
initial bleed controlled 4(100%) 42(100%)
Rebleeds n= 2 n = 17
no of patients in whom 
rebleed controlled 2(100%) 16(94%)
C
n = 80
77(96%) 
n = 4 1
34(83%)
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Table 4 - Complicatio ns of oes ophageal tamponade. Figures in 
parenthesis denote deaths related to use of Minnesota  tube.
CHILD'S GRADE 
A B C
Aspirati on  + chest infection - - 4(3)
(no sclerotherapy)
As pi ration + chest inf ection - 4(1) 5(3)
(post-sclerot herapy)
Oesophageal tear on intubatio n - - 2(2)
Pulled up tube 1 2 5(1)
Cardiac arrest - 1 3(1)
Unexpl ain ed death - (1)
TOTAL 1 7(1) 20(11)
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Table 5 - Deaths thought to be associated with tamponade in 
relation to s c l e r o t h e r a p y  and prognostic index.
PATIENT AGE SEX CHILD ' S CAUSE OF SCLEROTHERAPY PROGNO!
GRADE DEATH INDEX
JMcG 61 M C failed control + 0.00
PMcG 55 M C chest in fection - 0. 00
PB 67 M C oesophage al tear - 0.01
JK 39 F C failed control
pulled up tube
& arrested - 0.03
HD 52 M C chest inf ec tion + 0.06
RW 54 M C c h e s t i n f e c t i o n + 0.08
AR 46 M C o es op hageal tear - 0.11
TMcL 47 M C failed control + 0.21
JD 56 M C failed control - 0.21
DJ 66 M B chest infec tio n - 0. 23
TA 68 M C failed control
&chest infection + 0. 35
AH 36 M C failed control + 0. 38
MG 61 F C pulled up tube + 0.66
MT 50 F C chest in fection - 0.84
HS 69 F C chest infecti on + 0.87
MP 68 F C une xp la ined death 0.91
Patients wi t h prognostic score >0.66 would have been expected
survive admission.
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223 bleeds
92 bleeds settled
2 rebleeds
126 bleeds required 
tamponade 
(98% controlled)
T
44 rebleeds
47 rebleeds 
all required tamponade
(87% controlled)
5 failed insertions
T
1 rebleed
11 rebleeds 
all required tamponade 
(82% controlled )
2 rebleeds 
all required tamponade 
(100% controlled)
Figure 1 - Outcome of 223 initial episodes of acute
haemorrhage in 138 patients.
variceal
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d i s c u s s i o n
The use of oe so phagea l tamponade in the management of 
bleeding o es op hageal  varices became accepted after 
Sengstaken and Blakemore (79) described their double 
ballooned tube. However the problem of r e gurgit at ion of 
gastric contents and asp ir ation of oesop hageal and gastric 
secretions was re porte d by several authors over the next few 
years (210,211). Because of this problem, Boyce (212) 
suggested the use of a plastic nasog astric tube taped to the 
3-lumen tube for as pi r a t i o n  of the oesophagus and this led 
to the de ve l o p m e n t  of the Min ne so ta tube wh ic h incorporates 
all four lumens w i t h i n  one tube (81). Mit che ll (213) has 
shown that this tube is less u n comf or table and associated 
with less r e s p i r a t o r y  c o m p l icatio ns  than the 3-lumen tube.
The present study confirms that many patients referred with 
variceal haemor rhage will settle without active in ter venti on  
to stop the bleeding. In this study 42% of all acute bleeds 
present ing  to hospital  settled without any active 
in tervent ion, al th o u g h  on three occasions (two where 
in tubat io n was not required and one where the patient 
refused intuba tion) further haemorrhage during admis sion 
required tamponade . This sub-gro up with spon tan eousl y 
settling bleeds had a similar d i s t r i b u t i o n  of modified 
Child's grade to the group req uir in g tamponade. Variceal 
size was not record ed  accurately enough  for co mp a r i s o n  
between the groups. En doscopy was u n d e r t a k e n  in all patients 
to exclude other pot ential sites of blood loss since it has
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been shown (67,69) that as many as 30% of patients known to 
have oes op ha geal varices are in fact bleeding from other 
sites. The o b s e r v a t i o n  that many patients with confirmed 
variceal ble eding  settle without intervention, may help to 
explain the variable results obtained in studies of control 
of varic eal haemorr ha ge, since there is considerable 
variat ion  in the entry cr iteria to these studies. Some 
authors are happy to include all patients with haematemesis 
or m e l ae na  in the 24 hours prior to admission  (214), while 
in other reports only patients who had been shocked (5), 
patients who had bled more than 1000ml (89) or patients who 
had failed to re sp ond  to c on servat iv e measures (168) are 
i n c l u d e d .
The 94% c o nt rol of variceal haemorrhage by tamponade seen 
in the present series is very similar to the 80-90% control
rate report ed  by some other authors (69,83,215). This high
control rate was achieved in a p r edomina te ly poor risk group 
co mp rising 63% mo dified  Child's C grade patients. Those 
patients in whom co ntrol of haemorrhage was not achieved all 
had poor prognostic scores (72), having advanced liver
disease with marked coag ulopathy.  Table 6 summarises the 
results obtained w ith oes ophageal tamponade by some other 
groups. Pitcher (83) performed a prospective study in 50 
patients usi ng the Boyce m o d i f i c a t i o n  of the 
Se ngsta ke n - B l a k e m o r e  tube and obtained an 88% bleeding 
control rate. Bauer (215) reported an 80% initial control
rate in 35 episodes of variceal bleeding in 25 patients.
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More rec ently, Panes (1) has achieved a 91.5% control rate 
in 108 patients with bleeding  oes ophageal varices using the 
Se ng stak en -B lakem or e tube. On the other hand, Conn (82) 
found only a 56% bleeding control rate in 40 patients. 
Further e x a m i n a t i o n  of his report reveals that endoscopy to 
confirm the site of blood loss was not always performed and 
the p o s s i bility  that a number of patients were bleeding from 
other lesions may help e x p l a i n  the poor control rate. 
Tamponade was also avoided until the patient had had a 
significant amount of blood transfused, presumably resul tin g 
in a d e t e r i o r a t i o n  in their c o a g u l a t i o n  status. In Conn's 
study, a 3- lumen tube was passed by house officers and was 
noted to be inco r r e c t l y  used in 26% of cases. This contrasts 
with other studies (83,1), where e xp er ienced  medical and 
nursing staff wo rk in g in intensive care or specialised units 
have been involved in patient care. This factor undo ub tedly 
contributed to the good control rate in the present study.
There is muc h c o n t r o v e r s y  rega rding the incidence of 
serious co m p l i c a t i o n s  associa ted with tamponade
(211,82,83,1). Conn and Simpson proposed that oesphageal 
tamponade should only be used as a last resort in 
cont ro lling v a r ic eal haemorrhage because of the high 
c o m p l i c a t i o n  rate seen in their centre, and that 
prophylactic t r a c h e o s t o m y  or e nd otrach ea l intu bation  prior 
to the use of the tube should be se rio usl y considered in an 
attempt to prevent these co mp lications (82). They found that 
14 of 40 patients (35%) admitted w i t h  acute variceal
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haemorrhage treated with oesophageal tamponade suffered 
major co mp lications; de ath was attributable to the use of 
the tube in 9 patients (22%). Pitcher (83), in contrast, 
reported a very low c o m p l i c a t i o n  rate. The majority of the 
other reports have shown a co mp l i c a t i o n  rate of between 10 
and 20% (Table 6) and this is con sistent with our 
co mp l i c a t i o n  rate per bleed of 15%. The mor ta lity per bleed 
attributed to tampo nade in the present series was 6.4% (not 
including patients with failed control). Patients with a 
prognostic score of 0.66 or greater would have been expected 
to survive a d m i s s i o n  (72). It is int erest in g to note that in 
only four of the deaths associated with tamponade was the 
prognostic score of the patient greater than 0.66. It could 
be argued that factors other than tamponade contributed 
signi f i c a n t l y  to the deaths of the twelve patients with poor 
prognostic scores, al th ough the pos si bility  that the two 
patients who suff ered oe so phageal tears on intubat ion might 
have survived had this event not occurred cannot be ignored.
A s p i ratio n of secreti ons  is the most c o mmon c o m p l i c a t i o n  of 
oeso pha geal ta mpo nade (82,215,217). The policy in the 
Un iversity  Depa rtment  of Surgery, G l a s g o w  Royal Infirmary 
has been to avoid sedat io n of patients when passing the tube 
to try to reduce the risk of asp ir ation  pneumonia. However, 
intubatio n in restless patients may also be hazardous. The 
10.3% in cid enc e of pneumonia  per in tu bat ion in the present 
series may reflect unfairl y on oesophageal tamponade given 
that many of these patients proceeded to s c l e r othera py  under
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general anaesthe sia . The use of a 4- lumen tube should reduce 
the risk of this c o m p l i c a t i o n  (213) and it may be that the 
use of e n d o t r a c h e a l  intu ba tion in the limited group of 
patients with severe e n c e p h a l o p a t h y  would reduce this risk 
in that gr oup ( 1).
Rupture of the oes ophagus  can occur from inflation of the 
gastric ball oon  in the oesophagus (217), from pe rforation  of 
the oesophagus by the tube itself (82) and following 
precipitous removal of the tube with balloons inflated (60). 
In the present series, the tube was removed by the patient 
with balloons inflated on eight occasions. Limited inflation 
of the gastric balloon may account for the fact that only 
one such patient sustained an oe sop hageal rupture.
The re fo re, in the present study, oesophag eal tamponade has 
been shown to provide good control of bleeding from 
oes ophageal varices. However there is a significant 
c om p l i c a t i o n  rate and four deaths were c e r ta inly associated 
with the use of tamponade while in eight other deaths 
tamponade may well have been c o n t r i b u t a r y . Patients 
ex perience marked disc omfor t due to oesoph ageal tamponade 
and this cannot be disregarded . In view of these findings, 
the search for an effective drug for the control of variceal 
haemorrhage is of con side ra ble importance.
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Table 6 - S u m m a r y  of some r e su l ts  p r e v i o u s l y  p u b l i s h e d
d e s c r i b i n g  the use of o e s o p h a g e a l  t a m p o n a d e  in v a r i c e a l  
b l e e d i n g .
AUTHOR CONTROL C OM PL ICATIO N MORTALITY
RATE RATE RATE
Read , 1960 84% - 74%
Conn , 19 6 7 56% 35% 22%
(due to t u b e )
Novis , 19 7 6 85% 30% 48%
Pitcher ,1971 88% 4% 36%
Bauer , 1974 80% 9%
Choj kier , 1980 40% 16% 90%
Sarin, 1984 87% 15% 0%
P a n e s , 198 8 92% 10% 33%
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THE ACUTE EFFECTS OF 
H A E M O DY NAMICS  IN STABLE
CH APT ER 3
SMS 201-995 ON PORTAL AND SYSTEMIC 
CIRRHOTIC PATIENTS.
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INTRODUCTION
Before SMS 201-995 can be considered for use in acute 
variceal bleed in g it is essential to e s t a b l i s h  its effect on 
portal pressure in stable portal hypertensive patients. 
There are two pub lica tions  on this subject in the 
literature. One is an abstract in which Burroughs and 
colleagues report that SMS 201-995 had no effect on portal 
pressure (137). However in this work a variety of doses 
given as in trave nous boluses or infusions was given to only 
six cirrhoti c patients and no controls were used. The second 
publicat ion is from W a h r e n  and Eri ks son in Scandinavia (138) 
and shows a r e d u c t i o n  in hepatic blood flow and wedged 
hepatic venous pressure in nine cirr hotics given a varying 
dose of SMS 201-995. Cardiac outputs were not measured in 
either of these studies. In the present study the effects of 
a 25yug/hr intr av enous inf us ion of SMS 201-995 on both 
systemic and portal ha emody namics have been studied in 
stable cir rh otic patients.
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p a t i e n t s  a n d  m e t h o d s
The study group com prised sixteen patients with 
hi stolo gi ca lly proven hepatic cirrhosis who had had an 
e n d o s c o p i c a l l y  prov en bleed from oe sophageal  varices. All 
patients were aged be tween 18 and 70 years and had been 
h a e m o d y na mi cally stable for at least seven days prior to the 
study. Patients wit h  a history of cardiac disease, diabetes 
mellitus or renal disease and those taking vasoactive drugs 
were exclu ded. All patients gave writte n informed consent 
and the study was approved by the Ethical Committee of 
Gla sgo w Royal Infirmary.
The patients were admitted to hospital on the day prior to 
the study and were assessed by full physical examination, 
urinaly sis  (M ultisti x, Ames) and measu rem ent of full blood 
count, c o a g u l a t i o n  screen  (p ro t h r o m b i n  time, ka olin  cephalin 
c o a g u la tion time, t h r om bin time and platelet count), serum
urea and e l e c t rolyte c o ncentr at ions, liver function tests
(bilirubin, alkaline phosphatase, alanine and asparate
tr ans amin as es) and serum pr otein and albumin, gamma
gl u t a m y l - t r a n s f e r a s e  and chol es terol levels. This enabled 
the a l l o c a t i o n  of each patient to a modifi ed Child's grade 
as desc ribed by Pugh (58). Height and weight were recorded. 
Body surface area was estimated using a nom og ram based on 
the formula 
body surface area =
0.007184 X weight0'42^  height?'72.5
Chest X-ray and 12 lead e l e c t r o c a r d i o g r a p h  were performed.
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Right heart c a t h e t e r i s a t i o n  was then performed under 
fluoroscopic control using a balIon-tipped thermodilutio n 
Swan-Ganz catheter  ( R M S ,93A - 1 3 1 - 7 F ) introduced via the right 
femoral vein by the Seldinger technique (218). The zero 
reference point was taken at the m i d- axilla ry  line. 
Measure men ts were made of right atrial, pulmonary arterial 
and pulm onary c a p i l l a r y  wedge pressure by attaching the
fluid filled ca theter to an ext er na l pressure transducer
(Statham st ra in  gauge and Gould transducer amplifier 
13-465-50). Left ventricular filling pressure was taken as 
pulmonary artery diastol ic pressure if this was withi n 2mm 
Hg of the pul monary c a p il la ry wedge pressure. Systemic blood 
pressure was me as ured with a cuff on the left arm using a 
standard m e r cu ry  s p h y g o m a n o m e t e r .
Cardiac output was estimated  by the the rm odilut io n method 
(22) using an A m e ric an  Edwards Lab orat ories  COM-1 cardiac 
output com puter. Im media tely following these systemic
haemodynamic m e a s u r e m e n t s  the catheter tip was manipulated 
into the hepatic vein where measu re ments of wedged hepatic 
vein pressure and free hepatic vein pressure were made. 
F lu or oscopy  was used to c o n firm the catheter position and a 
typical venous pressure wave was always obtained before 
m ea sur eme nts were performed. All pressure measur ements were 
transf err ed onto hard copy using an ink-jet recorder
(Siemens Min gogr af f) with a paper speed of 50mm/s.
These m e a s u r e m e n t s  were made at 0 minutes, 60 minutes, 120 
minutes and 180 minutes. Nine patients received an
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intravenous in fu sion of 25ug SMS 201-995 in 125ml of normal 
saline betw een zero and 60 minutes. Seven patients acted as 
controls and were given no SMS 201-995. In the patients 
given SMS 201-995 blood was sampled from the right atrium 
via the catheter  for e s t i m a t i o n  of drug levels at -15, 5,
15, 30, 45, 60, 90, 120, 150 and 180 minutes. The catheter
was removed after the final measuremen ts  and haemostasis 
ensured. At twe nty- fo ur  hours the pre-inv es tigatio n 
assessment was repeated.
H a e m o d y n a m i c  i n d i c e s  were c a l c u l a t e d  as follows:
1) Cardiac index (1/min/m^) = cardiac output/ body surface
are a
2) Systemic vascular res ist ance ( d y n e s / s / c m ^ ) =
(mean arteri al pressure - mean right atrial pressure) 
/cardiac output
3) T r a n s h e p a t i c  venous gradient (mmHg)=
wedged hepatic venous pressure - 
free hepatic venous pressure
SMS 201-995 levels in the patients rec ei ving the drug were 
assayed usi ng radio im munoass ay . RIA kits SMS 201-995 were 
supplied by Sandoz Horsforth. This r a d i o i m m u n o a s s a y  has been 
developed using a polyclonal antis erum from rabbit (219). At 
the 95% conf i d e n c e  level det ec tion is limited to 5pg/ml with
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a 0«lml aliquot of human blood plasma. Withi n assay and 
between assay vari a b i l i t y  at the 25pg/ml dose level has been 
found to be 5% and 10% r e s p e cti ve ly (219).
The data were analysed using repeated analysis of variance 
with the G r e e n h o u s e - G e i s s e r  cor rec ti on to the degrees of 
freedom. The time courses in the two groups were compared by 
testing for a time by treatment interaction. The level of 
significance was ch osen as the 5% level.
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r e s u l t s
The two groups of patients were comparable in terms of age, 
aetiology of liver disease, and Pugh's m o d i f icat io n of 
Child's grade (Table 7).
The results of the haemodynamic study are summarised in 
Table 8. The results for individual patients are shown in 
Appendices 1 and 2. Figures 2 and 3 show the changes in 
wedged hepatic venous pressure and transhepatic venous 
gradient with time in the two groups of patients.The groups 
differed with  respect to the changes in wedged hepatic 
venous pressure (p=0.036) and transhepatic venous gradient 
(p=0.032). In the SMS 201-995 group mean wedged hepatic 
venous pressure fell by 22% and mean transhepatic venous 
gradient fell by 30% at 60 minutes. By 120 minutes these 
pressures had re turne d to values not sig nifican tly different 
from those rec or ded prior to SMS 201-995 infusion. In the
control group there was no significant fall in wedged 
hepatic venous pressure and transhepatic venous gradient.
Figures 4 and 5 show the changes in cardiac index and
systemic vasc ular res istance with time for the two groups of 
patients. The re were no significant di ffe rences between the 
groups in terms of cardiac index and systemic vascular 
resistance, but in both groups there were significant
changes in these variables with time (p<0.01). Cardiac
index was reduced and systemic vascular resistance increased 
at 60 minutes despite there being no significant changes in 
heart rate or arte rial blood pressure during the study
per iod .
No sid e- ef fects were ex pe rienced by the patients who 
received SMS 201-995 and there were no complications of the 
cardiac cat he terisat i o n . Elec troca rd iograph s,  chest X-rays 
and lab ora to ry pa ra meter s were uncha nged following the 
pr o c e d u r e .
Mean plasma SMS 201-995 levels in eight of the nine 
patients given the drug are shown in Figure 6. Very low 
levels of SMS 201-995 were found in the samples from one 
patient. In v e s t i g a t i o n  revealed that there had been 
considerable delay in the p r e p ar at ion of the samples and 
this patient's results were therefore discarded.
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Table 7 - The ch arac t e r i s t i c s  of the stable cirrhotic
patients in the control and study groups
CONTROL SMS 201-995
GROUP GROUP
Number 7 9
Age 57+3.0 52+2.0
(mean +. standard error)
Pugh^s m o d i f i c a t i o n  of Child^s grade
A 4 4
B 2 3
C 1 2
Aetiology of liver disease
Alcoholic cir rhosi s 6 7
Primary bi lia ry cirr hos is 1 0
Chronic active hep at itis 0 1
Sclerosing c h o l angitis  0 1
99
Table 8 - Portal and sys te mic haemodynami c results In
control and study groups at 0, 60, 120 and 180 minutes from 
the start of a 60 m i nute i n f u s i o n  of saline or SMS 201-995 
Cardiac index (Cl) is s h o w n  in l/min/n.2 , systemic vascular 
resistance (SVR) in d y n e s / s / c m 5 , wedged hepatic venous 
pressure (WHVP) in mm Hg and t r a n s he pa tic venous gradient 
(THVG) in mm H g . Results are sho wn as m e a n  +  standard error
of the mean.
SMS 201-995 
GROUP
60 120 180
Cl
SVR
WHVP
THVG
CONTROL
GROUP
4.9+0.4 2 
8 20+8 3 
18.9+1.5 
14. 1 ± 1 . 7
0
4 . 3 ± 0 .4 2 
9 50+89 
14.7+1.3 
9.9+1.4
60
4 . 3+0.38 
89 2+8 7 
18.5±2.0 
14.7+2.0
120
4.4+0.4 
9 3 5± 10 3 
19.1+2.0 
14.5±2.0
180
Cl
SVR
WHVP
THVG
4. 5+0 .3 5 
88 5±4 2 
14.8+1.4 
8. 8±2. 1
3.6+0.2 2 
107 3±69 
1 4 . 6 ± 1 . 1 
7.8+1.3
3.9 ± 0 .33 
981+75 
1 5 . 6 ± 1 . 6 
8 .0+1.1
4.1+0.31 
959+81 
16.8±2.9 
8 .6+1.0
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Figure 2 - The change in wedged hepatic venous pressure with 
time in two groups of cirrhotic patients. One group of nine 
patients given 25/ig SMS 201-995 in 125ml normal saline as an 
intravenous infusion over 1 hour. Control group of seven 
patients given no drug.
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Figure 3 - The ch ange in t r a n s h e p a t i c  venou s gra di en t with
time in two groups of c i r r h o t i c  pati ents. One gro up of nine 
patie n t s  g i v e n  25jig SMS 201-995 in 125ml n o r m a l  saline as an 
i n t r a v e n o u s  i n f u s i o n  over 1 hour. C o n t r o l  g r ou p of s e ve n
4
patie n t s  g i v e n  no drug.
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Figure 4 - The change in cardiac index with time in two
groups of cirrhotic patients. One group of nine patients
given 25jig SMS 201-995 in 125ml normal saline as an
intravenous infusion over 1 hour. Control group of seven
patients given no drug.
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Figure 5 - The change in systemic vascular resistance with
t i me in two groups of cirrhotic patients. One group of nine
pat ie nt s given 25>ig SMS 201-995 in 125ml normal saline as an
intravenous infusion over 1 hour. Control group of seven
pat ie nt s given no drug.
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Figure 6 - Mean plasma levels of SMS 201-995 with time for
eight of nine patients given an intravenous infusion of 25 
M S SMS 201-995 in 125ml normal saline between 0 and 60
minutes.
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d i s c u s s i o n
This study has d e m o n s t r a t e d  that intravenous infusion of 
SMS 201-995 results in a sig nificant r e d u cti on  in portal 
pressure in patients with cirrh osis of the liver. One
previous study was unable to demonstrat e any effect on 
portal pressure in ci rrhotics but only six patients were 
studied and no con siste nt  dose of SMS 201-995 was used 
(137). Another study by Wahren's group (138) demonstrated a 
25-35% r e d u c t i o n  in hepatic blood flow as measured by
indocyanine green in nine cirrhotic patients as well as a
significant r e d u c t i o n  in wedged hepatic venous pressure from 
18+2 mmHg to 15±2 mmHg (me an+s t a n d a r d  error). However in 
neither of these studies were systemic haemodynamics 
examined in detail  and neither study used a control group of 
cirrhotic patients who did not receive SMS 201-995.
In the present study a 25;ug/hr infusion of SMS 201-995 was 
used since this was c on sidere d likely to have a haemodynamic 
effect eq u i v a l e n t  to that of a 250;ug/hr infusion of 
naturally o c c urring  somatostat in. An int ravenous infusion 
was used because it is likely to be the method used in the 
treatment of acute variceal bleeding if the drug is of 
clinical value. The drug levels achieved were consistent 
with a 45 minute half-life.
Tran she patic venous gradient was used as a mea su remen t of 
portal pressure in our largely alcoholic group of patients. 
In alcoholic liver disease it has been establ is hed that this 
measurement is comp ar able with direct meas ur ement of portal
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pressure usi ng a thin needle (220,221). Repeated 
measurements of t r a n s he patic venous gradient are possible, 
even in ascitic patients, whereas this is difficult and more 
dangerous using a thin needle to measure portal venous 
pressure directly.
Previous animal work (131) has suggested that SMS 201-995 
may act by r e d uc ing sp la nchni c blood flow by pre-splanehnic 
arteriolar v a s o c o n s t r i c t i o n .  Splanchnic blood flow, measures 
app rox imately  1.5 1/min in man and is a significant part of 
cardiac output. It might therefore be expected that 
splanchnic v a s o c o n s t r i c t i o n  would cause an increase in total 
systemic vascu la r resist ance. There are several potential 
reasons why we have not de mon s t r a t e d  this. Firstly, the 
increase in systemic vascular resistanc e may not be large 
enough to show  as a signif icant change in our patients with 
their fairly large range of systemic vascular resistance 
(514-1189 d y n e s / s / c m  ).Secondly, it is possible that SMS 
201-995 causes v a s o d i l a t a t i o n  in other vascular beds which 
compensates for splanch nic vasocon st riction . Thirdly, the 
animal work su gg esting  pr e- splanehnic va so c o n s t r i c t i o n  as a 
me cha ni sm of ac tio n for SMS 201-995 takes no account of the 
effect of por tasys te mic shunting of blood and the effects of 
SMS 201-995 on the percentage porta -system ic shunting in man 
is unknown.
Altho ugh  there are no sta tisti ca lly signi ficant changes in 
the wedged hepatic venous pressure and transhepa tic venous 
gradient in the control patients it will be noted that this
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group had lower portal pressures at time zero than the group 
receiving SMS 201-995. However, the con trol patients showed 
no drop in portal pressure throughout the study period in 
comparison to a r e d u c t i o n  of 30% in transhepatic venous 
gradient in the group rec eivin g SMS 201-995. All patients in 
the latter group sustained a fall in tra nshepatic venous 
gradient at 60 minutes.
Investigations of the systemic haemody namics demo nst rated a 
high mean rest ing cardiac index and a low mean systemic 
vascular res is tance . This haemodynamic profile is a common 
finding in patients with cirrhosis (222) and may be the 
result of several me chani sm s including arteriovenous
shunting of blood, inc reased c a techol ea mines (223) and a 
reduction in the d e g r a d a t i o n  of circ ulati ng  vasoactive 
metabolites (224).
During the study period there was an initial significant 
reduction in cardiac index and increase in systemic vascular 
resistance in both groups. The inclusion  of a control group 
with cirrho si s allowed us to separate the effects of the 
infusion from the effects of bed rest itself. The change in 
these hae mo dynami c indices was of similar magnitude in both 
groups and therefore not attributable to SMS 201-995.
Without a co ntr ol  group an erroneous as su mptio n of the
systemic ef fects of SMS 201-995 would have been made and 
therefore the results of studies without matched controls 
should be i n t e rpret ed  with caution. It remains to be
determined why the cardiac index should fall with bed rest
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in patients with  cirrhosis, ex actly the opposite from the 
response in severe heart failure (225). This phe nomenon  has 
been noted pre v i o u s l y  by Lebrec's group (226). It may be 
that bed rest t r a n s i e n t l y  reverses the haemodynamic
consequences of cirrhos is allowing the cardiac index to 
return towards normal.
In this study SMS 201-995 has been shown to have a
significant effect on portal hae modynamics with no
significant effect on systemic haemodynamics. No 
side-effects were ex perienced. The natural hormone,
somatostatin, has been used to control upper
gastroint es tinal bl eedin g (117) and bleeding from
oesophageal varices (118). In a randomised study in 63 
patients, Kravetz and col leagues  (A) reported that 53% of 
variceal bleeds were c o m p l e t e l y  controlled by somatostatin 
in c o m p a r i s o n  to 58% cont rolled by vas opressin. Jenkins and 
colleagues (5) found that s o m a t o s t a t i n  controlled ten of ten 
variceal bleeds In c o m p a r i s o n  with four of twelve variceal 
bleeds c o n t rolle d w i t h  va sopressin. These results were 
achieved with no major complica tions in patients receiving 
somatostatin. Ho wever the very short half-life of 
somatostatin limits its clinical use since any disturbance 
of the intrav enous infusion will rap idly reduce the effects 
of the drug. This may help ex pl ain the different results of 
the two c l i n i c a l  studies of s o m a t ostatin  in variceal
haemorrhage (4,5). With a half-life of 45 minutes in plasma, 
a proven effect on portal pressure and no major
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side-effects, SMS 201-995 could prove more useful in the 
practical m anage me nt of bleeding oesophage al varices.
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C H A PTER 4
RAT MODELS OF EXT RA HE PATIC AND INTRAHEPATIC 
HYPER TEN SION
PORTAL
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INTRODUCTION
In order to study the effects of SMS 201-995 in more 
detail, an animal model of portal hypertensi on  is necessary. 
Results of portal vein ligation exp er iments in both the dog 
(227) and the m o n k e y  (228) have been uns ati sfact or y as
collateral v e s sels rapidly develop which are sufficient to 
decompress the portal venous system. Fortun ately partial
portal vein lig at ion in the rat has proved a better model
and this has been used in the work for this thesis as a 
model of e x t r a h e p a t i c  portal hyp ertension.
However the m a j o r i t y  of patients suffer from portal 
hypertension se c o n d a r y  to chronic liver disease and not only 
have an in cre ased portal pressure but have abnormal liver 
function. A model of intrahep at ic portal hypertension would 
therefore be helpful in further assessing drug effects. The 
liver has an u n p r e d i c t a b l e  response to toxins and some 
difficulty has been exp er ienced in deve lop ing an adequate
animal model of cirrhosis. For instance, repeated doses of 
alcohol over four years in baboons resulted in cirrhosis in 
only two of thirte en animals studied (229). In recent years 
carbon te tr a c h l o r i d e  has been the most widely used 
hepatotoxin and in this thesis repeated doses of carbon 
tetrachloride have been used to produce cirrhosis in rats.
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a n i m a l s  a n d  m a i n t e n a n c e
Male Sprague Da wl ey rats ( B a n t i n  and Kin gman Limited, Hull) 
were used in all animal e xp erimen ts . The y „ere housed in 
stainless steel cages w i t h  a m a x i m u m  of six rats per cage. 
The animal house had an automated  twelve hour light/dark 
cycle and air c o n d i t i o n i n g  with a rel ative humidity of 
50±5% and a t e m p e r a t u r e  range of 21+1 C. Animals were fed on 
a standard rat diet (RN1(E) rat chow, Special diet services 
Ltd, Witham, Essex) with  water ad libitum.
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RAT m o d e l s
Partial portal vein ligatio n 
In 1979 H a l v o r s e n  and Myking (230) described and 
characterised a rat model of ex trahepatic portal 
hypertension, in which a cal ibr at ed stenosis of the portal 
vein was produc ed by partial portal vein ligation. They had 
previously reported  that a stenosis of 1.2mm diameter gave 
portal h y p e r t e n s i o n  with a mo r t a l i t y  of 25% (231). In the
present study a similar method has been used to produce a 
rat model of e x t r a - h e p a t i c  portal hypertension. The partial 
portal vein li gation  was per formed as follows. Rats were 
anaesthetised with halot ha ne  and a mixture of 2:1 nitrous 
oxide and oxygen. L a p a r o t o m y  was performed via an upper 
midline incision. In the rat the portal vein is formed by 
the confluence of the superior mese nt eric vein and the 
splenic vein and the py loric vein joins this vessel in the 
lesser om entum before the portal vein divides into left and 
right branches at the porta hepatis (Figure 7). A 21G needle 
(outer diameter 0.81 mm) was placed alo ngside the mobilised 
portal vein and a cali brated stenosis created by placing a 
3/0 silk tie around the needle and the portal vein, cranial 
to the pyloric vein. The needle was then removed, the 
abdomen closed wi t h  two layers of chromic catgut and the rat 
allowed to recover. There is a 25% morta li ty from this 
procedure, r e s u lt ing from tears to the portal vein, portal 
vein thrombosis and acc id en tal ligation of the hepatic 
artery. Figure 8 is a portogr am  illust rating the anatomy of
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this procedure, taken two hours after partial portal vein 
ligation had been performed.
Previous studies in this d e p a rt ment have cha racter is ed this 
model (7). Part ial po rtal vein li gation was performed as 
described above and portal pressure and %portasystemic 
shunting me a s u r e d  in groups of 6 portal vein ligated rats 
and 6 sham operated rats at days 1 to 10 and days 14, 21 and 
28. Portal pressure was mea su red by c a n n u l a t i o n  of the 
ileo-colic t r i b u t a r y  of the portal vein and %portasystemic 
shunting by the i n j e c t i o n  of radi o a c t i v e  microsp he res into 
this portal vein cannula. These methods will be described in 
full later. At three days po s t - l i g a t i o n  portal vein 
pressure was shown to be three times that in sham operated 
controls and po r t a s y s t e m i c  sh unting 37.4+17.2% (7). By
twenty-eight days p o s t - l i g a t i o n  portal vein pressure is 1.5 
times that in sham operat ed contro ls and portasystemic 
shunting was 50. 7+26. 7%  (7). Liver function tests and liver 
histology were normal throughout.  This therefore provides a 
model of e x t r a h e p a t i c  portal hypertension.
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AN ATO M Y
OF PO RTAL VENO US SY STE M  OF THE RAT
Liver
Spleen
Pyloric
Splenic
Middle colic
Intestinal
branches Right colic
Ileocolic
Figure 7 - The anatom y of the portal venous system in the 
rat. Partial portal vein ligation was performed by graded 
ligation of the portal vein  cranial to the entry of the 
pyloric vein. Cannulas to measure portal pressure were 
inserted into the ileo-colic vein and threaded cranially to 
a level just below the jun ct ion of the splenic and superior 
mesenteric veins.
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Figure 8 - Portogram showing the anatomy of partial portal 
vein ligation in the rat. Portogram performed two hours 
after portal vein ligation by injecting 5ml of Urograffin 90 
into a cannula just inserted into a tributary of the 
ileo-colic vein. X-ray exposure time 0.05 seconds, 
penetration 60kV, distance of 40cm from rat (Siemens image 
inte ns i fier ) .
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Carbon tetrachloride Induced cirrhosis.
The product ion of a small animal model of hepatic cirrhosis 
has been diff ic ult because of the un pr edictable 
hepatocellular reponse to toxins. Carbon tetrachlori de has 
been the most w i d e l y  used toxin in recent years but is not 
without problems. There is si gnifi cant variatio n in response 
between animals and a re ductio n in s ensitiv it y to carbon 
tetrachloride with age. Ho wever Procter and Chatamra (232) 
developed a method of p r o d uct io n of cirrhosis using weight 
loss as an index of the sens it ivity of each animal to carbon 
tetrachloride. This metho d has been used to induce cirrhosis 
in r a t s .
Animals weighi ng  a p p r o x i m a t e l y  150g were used. 
Phenobarbitone (BDH Che mica ls  Ltd, Poole) was added to their 
drinking water (5 0 m g / 1O O m l s ) to activate the enzyme 
cytochrome P450 whi ch has been shown to increase both liver 
size (233) and its s e n s i t i v i t y  to carbon tetrachloride 
(234). After ten days of ph e n o b a r b i t o n e  treatment, gavage 
with carbon t e t r a chlori de  was commenced. Carbon
tetrachloride (BDH Ch emi cals Ltd, Poole) was given by gavage 
via a speci ally d e s ig ne d Portex tube (5FG) which  allowed the 
toxin to be a d m i n i s t e r e d  with a tested accuracy of 0.04mls. 
Gavage was per fo rmed under general anaest hesia with 4% 
halothane in a 2:1 nitrous oxid e r o x y g e n  mixture which was 
delivered to a p e r spex box at high flow rates (nitrous oxide 
21/min and ox ygen 11/min) to enable rapid induction. The 
initial dose of carbo n tetrac hloride is impor tant as
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cirrhotic yield depends on the initial damage to the rat 
hepatocytes ( 232). This initial dose, defined as half the 
dose at whi ch deaths occur, had been e s t a b lis he d p r e v io usly 
as 0.15ml (7). Subsequ ent  weekly  doses of c a rbon
te tra chlorid e were d e t e rm in ed by using the percentage weight 
loss follo wing the pre ce di ng dose as an index of the degree 
of hep atocel lu lar injur y (232). Thus, if massive weight loss 
occurred a r e d u c t i o n  of 50% in the next dose was ne cessary 
while little weight loss, or pa rt i c u l a r l y  weight gain, 
ne ce ssitate d a doub l i n g  of the subsequ ent dose of carbon 
te tr ac hlo ride. Repeated damage to the liver suffici ent to 
cause ch e m i c a l  hepatitis without re s u l t i n g  in acute liver 
failure (233) was the refore achieved by titrating the 
percentage weight loss from the prece di ng dose of carbon 
t et ra chl oride against the next dose. The r e c o g n i t i o n  of the 
onset of ascites was important as a marked  r e d u c t i o n  in the 
amount of ca rbon t e t r a chlori de  given was nec es sary to avoid 
an increase in mort ality. From the fourth week of g a v a g e , 
each animal was held erect under a n a e st he sia before gavage 
and the presence of free fluid in the ab do men assessed by 
insp ec ti on and pal p a t i o n  of the lower abdomen. At the same 
time, splenic pa l p a t i o n  was performed. Early ascites was 
sometimes diff ic ult to detect on cli ni cal e x a m i n a t i o n  alone, 
and a more sensiti ve index of s u b c li ni cal ascites was a 
sudden rise in weight (20-30g) at day 3 or 4 after gavage in 
the presen ce of splenom egaly. Eight to ten doses of c a r b o n  
te trachlor ide were u s u a l l y  ne cessary to produce ascites and
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ex per iments were perfo rme d 14-21 days after the onset of 
ascites had been rec orded.
This cir rhotic model has been c h a r a ct er ised in this 
departm ent  (7). Rats treated with c a r b o n  tetra chloride as 
above for 8 to 10 weeks who had evidence of ascites and 
splen o m e g a l y  were studied. In one set of ex pe riments 6 such 
rats were com pa red to 6 rats treated only with 
p h e n o b a r b i t o n e . The portal venous pressure was measured  by 
ca nn u l a t i n g  the ile o-c olic tri butar y of the portal vein and 
%po rta sy stemic  sh untin g was measured  by injecting 
ra di oa cti ve m i c r o s p h e r e s  into the portal vein cannula. The 
cirrho tic  rats were found to have a portal venous pressure 
of 14.8+1.1 mmHg and portas ystemi c shuntin g of 25.4+4.7% 
(7). These animals had abnormal liver function and the 
results of liver f u n ct ion tests in the previous 
c h a r a c t e r i s a t i o n  studies are shown in Table 9. In a further 
series of ex pe r i m e n t s  r adio ac tive m i c r o s p h e r e s  were used to 
measure cardiac output and portal venous inflow in 6 
cirrhotic and 6 phenobar bit one treated rats. This method is 
also used in the current work and is des cr ib ed fully later. 
The c i r rhoti c rats had a hyperdynam ic  c i r c u l a t i o n  with a 
cardiac output of 172.5+45.4 m l / m i n  (controls 
116.7 + 2 0 . 9ml/min) and a portal venous in fl ow of 13.2+1.3 
ml/min (co ntro ls  9 . 2 +1.6 ml/min) (7).
Liver biops y and blood for liver function tests were taken 
from e a c h  c a r b o n  t e t r a ch loride  treated rat used in the 
current e x p e r im en ts. Figure 9 shows the hi stolog y of the
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liver in one rat treated with ca rb on  tetr ac hloride . The 
liver fun ct io n tests were abnorma l and are detailed later in 
this thesis (Table 20).
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Table 9- Liver fu nction tests in the pre vious ly  
ch ara ct er ised rat mod el  of cirrhosis (7). T en rats treated 
with c a r b o n  t e t r a chlor id e and phe nob arbit on e for eight to 
ten weeks until they had evidence of ascites and 
s p l e n omeg al y (cirr ho ti cs) were compared with ten rats given 
phe nobar bi to ne onl y(con tr ols) . ALT = alanine transaminas e. 
A S T=as pa rt ate t r ansamin as e. Values are m e a n + s t a n d a r d  error
and the results in the 
Whit ney  U tests. p<0.05
two groups were 
is taken to be
compare d using 
signi f i c a n t .
Mann
LIV ER FUN CTI ON TEST CIR RH OT ICS CONTRO LS P
Bilirubin(jimol/ 1) 20.2+2.3 10.3+1.2 0.01
Pr o t e l n ( g / 1) 4 2 . 3 ± 2 . 3 65.1+1.2 0. 001
A l b u m i n ( g / 1) 1 6 . 6 ± 1 .4 31.8+1.4 0.001
ALT(uni ts/ 1) 114.4+17.5 37.1+1.8 0. 001
AS T(u n i t s / 1) 24 5+39 .7 1 1 3 . 1±4 . 5 0.001
Alkaline Ph osphatase 438+58.9 9 3.8+9.8 0. 001
(u n i t s / 1)
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Figure 9 - Reticul.in stain of a section of the middle lobe 
of the liver in a rat treated with carbon tetrachloride for 
eight weeks, with ascites and splenomegaly.
CH A P T E R  5
METHODS USED IN ANIMAL H A E M O D Y N A M I C  STUDIES
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I NT R O D U C T  ION
As indicated  in Chapter 3, SMS 201-995 appears to be an
eff ective means of r e d u c i n g  portal pressure in human 
cirrhosis. However little is k n o w n  of its mode of action.
Some animal work has been u n d e r t a k e n  in an attempt to
clarify this. Shield's group have rep ort ed that SMS 201-995 
does decrease portal pressure in cirrhotic rats (131) and in 
normal pigs (132). In these studies, portal vein flow was 
measured using an e l e c t r o m a g n e t i c  flow meter around the 
portal vei n and portal pressure was measured via a cann ula 
in the il eo-colic vein. Portal venous resista nc e was
calculated by divid in g the portal pressure by portal venous 
flow and spl an ch nic vascula r resis ta nce was calcula ted by 
dividing the mea n arterial  pressure by the portal vein flow. 
By this means it was ca lc ulated  that SMS 201-995 inc reased 
splanchnic vascular r esistan ce  but had no effect on portal 
vein re si stance  and it was felt that its action  was probab ly  
to constri ct  pre-sp lanchn ic  arterioles. However this method 
makes no allowance for the effects of p or ta systemi c shuntin g 
and if this is sign ifica nt  portal venous inflow will be 
greater than portal vein flow and thus splanch nic vascular 
resistance will be overestimate d.
With the d e v e l o p m e n t  of ra dio active m i c r o s p h e r e s  for the 
measurem ent of blood flow in small animals (235, 23 6, 24), it 
is possible to measure blood flow th r o u g h  both the liver 
itself and th r o u g h  the po rt asystemic shunts. A better 
picture of systemic and portal hae mo dynami cs  can be built
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up. C a r d i a c  o u t p u t  is d e t e r m i n e d  by the i n j e c t i o n  of
micr osp heres into the left ve ntr icl e while a reference
sample is removed over a k n o w n  time from a large artery. The 
r a d i o ac tivity  in the re fer enc e sample is the n used to
calculate cardiac output by c o m p a r i s o n  with the total amount 
injected. This method also enables the c a l c u l a t i o n  of organ 
blood flows by m e a s u r e m e n t  of the organ activ it y in
c om p a r i s o n  with the referen ce sample. It is assumed that all 
the m i c r o s p h e r e s  are well mixed before becoming trapped on 
the first pass th ro ugh the per iph eral vessels, that they are 
di stribu ted in p r o p o r t i o n  to cardiac output and that they do 
not d i s t u r b  h a e m o d y n a m i c s . The method ena bles m ea su rement of 
organ flows without the problems of d i s t o r t i o n  inherent in 
the placement of an e l e c t r o m a g n e t i c  flow meter round a small 
vessel. It ca n be further applied to measure portasystemi c 
shunting by the i n j e ction of a second mic ro sp here into the 
portal vein and m e a s ur em ent of the activit y in the liver and 
the lungs. The se methods combined allow the study of drug 
effects on hepatic artery flow, portal vein flow, shunt 
blood flow and total hepatic blood flow.
This cha pter d i s c us ses the general me thods used in the 
conduct of the haemodynaraic studies performed  in animals and 
Chapter 6 reports the details of these studies and disc us ses  
their results.
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C O N D U C T  OF H A E M O D Y N A M I C  S T UD I E S.
F a s t i n g
All rats w e r e  f a s t e d  for at least  t w e l v e  h ou r s  p r i o r  to the 
e x p e r i m e n t s .  T h i s  was i n t e n d e d  to e l i m i n a t e  v a r i a t i o n  in 
portal v e n o u s  i n f l o w  due to i n c r e a s e d  s p l a n c h n i c  f l o w  
f o l l o w i n g  food i n t a k e  and also  m e a n t  that w a s h i n g  out the 
organ s b e f o r e  w e i g h i n g  was e a s i er .
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A n a e s t h e s i a
During some initial pilot work i n t r a - pe ri toneal
pen tobarbital was used as an ana es thetic  agent with the 
animal bre athing sponta ne ously,  but this gave an unr eli able 
depth of a n a e s t h e s i a  and large v a r i atio ns  in the animals" 
blood gases were seen. H a l o thane and a mix ture of 2:1 
nitrous oxide and oxygen was used for all the experime nts to 
be describe d in this thesis. In dogs, it has been 
established (237) that ha lot han e can reduce cardiac output, 
and therefore liver blood flow, in a dose dependent manner. 
A c o n c e n t r a t i o n  of 0.5% inspired hal othane was shown to 
cause no si gn ificant de p r e s s i o n  in cardiac output or total 
peripheral res is ta nc e though a si gni ficant reduction in both 
parameters occ urr ed at a co n c e n t r a t i o n  of 1.5%. However 
concentrations up to 2% did not alter portal venous pressure 
significantly. A standard c o n c e n t r a t i o n  of 0.5% halothane 
was used for m a i n t e n a n c e  of a n a e sthesi a in all of our 
experiments to avoid possible vari ations  due to the 
anae s the t i c .
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Blood g a s e s
Cooperman (238) has pointed out that changes in blood pCO 
causes changes in the splanchic ci rc ulation  with hype rcarbia  
causing v a s o c o n s t r i c t i o n ,  except during hal othane
anaesthesia, when v a s o d i l a t a t i o n  occurs. Th erefor e attempts 
were made to norm al ise blood gases as far as possible in 
order to avoid this source of error. This was achieved  by 
performing a t r a c h e o s t o m y  and v e n t il at ing the rat using a 
Harvard v e n t i l a t o r  (model 683) at a rate of 25 -35/min  with a 
tidal volume of 2 - 3 . 5ml. A Corning blood gas analyser (model 
165) was used to m o n it or  blood gases.
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Body t e m p e r a t u r e
Rectal t e m p e r a t u r e  was read at i n t e r v a l s  of five m i n u t e s
using a me rc ury ther mo meter through out  the expe ri ments and a
heating lamp was us ed to m a i n t a i n  the t e m p e r a t u r e  b e t w e e n  
o
36.5 and 37.5 C. A reduct io n in body temperat ure will cause 
mechanisms for heat p r e s e r v a t i o n  to come into play and thus 
change system ic h a e m o d y n a m i c s .
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Systemic blood pressur e 
Since h y p o t e n s i o n  will cause changes in blood d i st ributi on  
due to a u t o r e g u l a t o r y  m e c h an isms and this will affect 
splanchnic blood flow, animals with a mean arterial blood 
pressure of less than 7 5mraHg during the experi me nt were 
excluded from the analysis of the results.
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M E A S U R E M E N T  OF ME AN  A R T E R I A L  P R E S S U R E  AN D P O R T A L  V E N O U S  
PR ESS U R E.
Mean arteri al pressure was con s t a n t l y  mo nitored  du rin g all 
experiments. This was performed via a polyeth yl ene femoral 
artery ca n n u l a  (outer diameter 0.96mm) co nnect ed to a
Statham strain  gauge tr ansducer and a Gould transducer
amplifier (model 13-46 15-50) and recorder (8000S series).
This was c al ibrated  da ily  usi ng a m e r cu ry  manometer.  
Characte ri stic f l u c tuat io n of the recordin g from systolic to 
diastolic pressure was necessary to ensure a sati s f a c t o r y  
rec ord i n g .
Portal venous pressure was moni tored using a polye thylene 
cannula (outer diameter  0.96mm) inserted into the ileo-colic 
vein and fed upwa rds into the superior mes ent er ic vein below 
the ju n c t i o n  with the splenic vein (see Figure 6). This was 
connected via another Statham strain gauge transducer to the 
other c h a n n e l  of the Gould recorder.  C a l i b r a t i o n  for the 
portal venous pressure range (0-25 cm saline) was performed 
before e a c h  e x p e ri ment using a s p e c ia lly made manometer  
giving a pressure of 25cm of water. During each exp eriment  
it was en sur ed that r e s p i r a t o r y  f l u c t uatio n of the portal 
pressure was occur ring and that it was possible to w i t h d r a w  
blood from the portal vein via the cannula.
Systolic and dia st olic pressures were measure d by re ading 
ten values at twelve second int ervals from the r e c o r d i n g  
over the two minu tes at the end of the period for which 
measurement was to be made. Pulse pressure was obtained for
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each read ing by s u b t r a c t i n g  diastolic from systolic pressure 
and mea n arteria l pressure was c a l c u l a t e d  by adding one 
third of the pulse pressure value to the di astolic  value. 
Th ere after the m e a n  of the ten readings was calcula ted and 
taken as the mean systolic, d ia st olic, pulse or mean 
arterial pressure at the end of the period of measurement. 
Ten values for the m a x i m u m  and m i n i m u m  portal pressures were 
read in a similar manner and mean portal pressure for each 
reading t a ke n as the average of the m a x i m u m  and m i n i m u m 
readings. A mea n portal pressure at the end of eac h period 
of m e a s u r e m e n t  was c a l c ulat ed  as above.
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THE USE OF G A M M A - L A B E L L E D  M I C R O S P H E R E S  FOR HAEM OD YNAMIC  
MEASUREMENTS.
Microsp he res are sph eri ca l beads which are obtainable in
different sizes and can be labelled with a number of 
radio-activ e isotopes. The se isotopes emit radiation, 
including gamma rays, du ring the r adio- ac tive decay process. 
During these ex pe r i m e n t s  plastic m i c r o s p h e r e s  (New England 
Nuclear) with a diameter of 15+1 microns ( m a nufac tu rer's  
size) and labelled with Cobalt-57, G a d o l i n i u m - 153 or Ti n-11 3  
were used to meas ure blood flow.
Rat c a p i l l a r i e s  are k n ow n to have a m ea n diameter of
ap p r o xi mately 8 mic rons (239) and so m i c r o s p h e r e s  of a 
slightly greater diamet er  will lodge in the first capi llary 
ci r c u la tion ava ilable after inj e c t i o n  into the bloodstream. 
If s t r e a m l i n i n g  of the flow of m icros ph eres is present their 
d i s t r i b u t i o n  to target organs fol lowing i n j e c t i o n  will 
reflect the c a p i l l a r y  blood flow to that organ.
M ic ro sphere s injected into the left ve ntricle will be
distributed by the ar terial c i r c u l a t i o n  and give a measure 
of art erial  blood flow to any organ. If blood is w i t h draw n 
from the arterial  c i r c u l a t i o n  at a kn ow n rate, c o m p a r i s o n  of 
the r a d i o - a c t i v i t y  of the blood w i t h d r a w n  to that of a 
particular organ will give an absolute value for its blood 
flow. If a k n o w n  number of micr o s p h e r e s  is injected the 
cardiac output can also be calculated.
In normal rats with no portasyste mi c shunting, the hepatic 
sinusoids will trap all the m i c r o sp he res injected into the
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portal vein. Ho we ver  if po rt asy stemic shuntin g is present, 
some m i c r o s p h e r e s  will travel to the lungs via the shunts 
and be trapped in the lung capil la ri es. The ratio of 
microsp he res in the lungs to that in the liver and lungs 
gives a measure of portasy st emic shunting.
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Counting
Counting of r a d i o a c t i v i t y  in blood and tissue samples was 
performed using a gamma s c i n t i l l a t i o n  counter (Autogamma 
500, Packard Instr uments Ltd). Blood samples and the saline 
used to wash out the syringes were placed di rectl y into 
plastic counting vials. The hubs of the syringes used for 
the injecti on of m i c r o s p h e r e s  and blood sampling were also 
placed in vials for counting. Organs were washed free of 
food debris, we ighed (Sartorius scales, model 2254) and
chopped finely before the counting vials were filled half 
full of tissue. Count in g took place over five minu tes per 
sample using an open energy w i n d o w  (15-2000 k e V ) if only one 
radioactive isotope had been injected. An empty, clean vial 
was counted with each batch of e xp er iment al  samples, to
obtain the current bac kg ro und ra dio a c t i v i t y  count. This
value was subt ra cted from the value obtained for each
experimental vial.
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problems
Several p r o b l e m s  in the use of r a d i o - a c t i v e  m i c r o s p h e r e s  
for h a e m o d y n a m i c  m e a s u r e m e n t s  m u s t  be c o n s i d e r e d ,  
i) A g g r e g a t i o n
Microspheres adhere and clump together easily and this is a 
major pot ential source of error due to lack of uniform 
distribution. The presen ce of clumpi ng can be esta bl ished by 
examining a drop of mi cr o s p h e r e  solution under a light 
microscope. Clumpi ng occurs more often when mic ro s p h e r e s  are 
suspended in saline solut ions and it was therefore nec essar y 
to suspend the m i c r o s p h e r e s  in high mole cular weight 
solution (10% w/v dext r a n - 4 0  in 5% dextrose, R h e o m a c r o d e x , 
Pharmacia) to w h ic h 0.01% of the surfactant  'Tween-80' (BDH) 
had been added to minimise  clumping. Despite this, 
microsphere s uspensi on s aggre ga ted when left standing for 
prolonged periods and therefore the micr osphe re  solution was 
always v o r t e x - m i x e d  (Spinmix, Gallenka mp) for three minutes 
before injection.
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ii) L e a c h i n g
Le achin g is the s e p a r a t i o n  of the radio - i s o t o p e  from the 
mi crosphere s and this process increases with the age of the
microspheres. Al t h o u g h  the mi cr o s p h e r e s  will be trapped in
the c a p i l l a r i e s  of the target organs the r ad io-isot op e will 
continue to circu lat e and inaccurate results will be
obtained. A m o n t h l y  check was performed on each batch of
mic ros pheres, by c e n t r i f u g a t i o n  of the su s p e n s i o n  and 
me asuring the acti vi ty in the su pe rnata nt, to ensure that 
leaching was not present. The presence of less than 1% of 
total act iv ity in the superna tant was regarded ; as 
acceptable. .When m i c r o s p h e r e s  were only being injected into 
the portal c i r c u l a t i o n  a further check was possible with 
each e x p e ri ment by re m o v i n g  the kidneys and counting them in 
the gamma s c i n t i l l a t i o n  counter. Since all the m icrosp he res  
injected into the portal syst em  should have lodged in the
capillary c i r c u l a t i o n  of the liver or the lungs the kidney
counts in these e x p e r i m e n t s  should have been the same as the
background count. If the k i d n e y  counts were more than 50%
above the background count leaching was suspected and the 
results e x c lude d from analysis.
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iii) S t r e a m i n g
For accurate haem od ynamic  me as urement  the m i c r o sp heres must 
be e v e n l y  d i s t ribut ed  thro ug hout the c o lu mn  of blood in a 
given vessel. This is p a r t i c u l a r l y  impor tan t durin g the 
m e a s u re ment of cardiac output and organ blood flow using 
m ic ro sph eres. By checki ng  that the blood flow to eac h ki dney 
was equal to w i th in  10% of the total renal blood flow, and 
ex clu ding the expe r i m e n t s  where this was not the case, 
adequate mi xi ng  of m i c r o s p h e r e s  was ensured.
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iv) Spillover
In exp er im ents where two radio ac tive m i c r o s p h e r e s  were used 
the organs and blood removed for me as u r e m e n t  of 
r a d i o a c t i v i t y  required to be counted with regard to each 
microsph ere . Figure 10 shows the e n ergy  peaks of c o m m o n l y  
used r a d i o - i s o t o p e s  and the e n er gy  windows of the gamma 
s c i n t i l l a t i o n  cou nter were set a p p r o p r i a t e l y  for the 
micro sph ere used. Howeve r as spillover of r a d i o a c t i v i t y  from 
one peak to another occurs c o r r e c t i o n  for this was needed. 
This was achieved by c o u n t i n g  pure samples of the two 
m ic rospher es used and c a l c u l a t i n g  exp ec ted spillover counts 
for each of the organ samples counted. Spillover counts were 
then subt racted  from the total counts for each organ for 
each e n e r g y  w i n d o w  and co rr ected counts for each microsph ere 
obt a i n e d •
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Figure 10 - The energy peaks of gamma radiation from the
commonly used radioactive isotopes.
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d r u g  l e v e l s
Five ml blood samples were taken from all animals given a 
fixed drug dose. These were taken into lithium heparin 
bottles i mm ediat el y before sacrifice and the samples spun 
down immedia tely. The plasma was then stored at -20°C till 
analysis. SMS 201-995 levels were measur ed for each  sample 
using a r a d i o i m m u n o a s s a y  kit supplied by Sandoz Hor sforth.
This assay uses polyc lo nal a n t i serum  raised in the rabbit 
to SMS 201-995 coupled to bovine serum albumin (219). At the 
95% c o n f id en ce level d e t e c t i o n  is limited to about 5pg/ml 
with a 0.1ml aliquot of human blood plasma. With in assay and 
between assay v a r i a b i l i t y  at the 25pg/ml dose level has been 
found to be 5% and 10% r e s p e c t i v e l y  (219). Specificity has 
been tested with some available synthetic peptide 
derivatives wh ic h could possib ly originate from 
bi ot ra ns f o r m a t i o n  (219). One single met abo lite was available 
from work ongoing by Sandoz in metabolism . There was little 
interaction with the ant i s e r u m  using  the peptide fragments 
with the partial sequence of the unch an ged compound. 
However, a syntheti c product ( [Tyr] - a n a logue ) was of equal 
affinity to SMS 201-995.
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C H A PTER 6
THE EFFECTS OF SMS 201-995 IN NORMAL RATS AND TWO RAT MODELS 
OF PORTAL H Y P E R TE NSION
143
t h e EFFECT OF SMS 201-995 ON CARDIAC OUTPUT AND ORGAN BLOOD 
FLOWS IN NORMAL  RATS
I n t r o d u c t i o n
The aim of this e x p e r i m e n t  was to est ab lish whether SMS 
2 01“ 9 9 5 affected systemic h a e m o dyna mi cs in normal rats. 
Normal rats were giv en an intrave nous infusion of saline or 
SMS 201- 995  at three doses, the lowest a p p r o xi mating to 
three times the dose used in man. Arterial blood pressure 
was measure d before the infusion and after twenty minutes of 
infusion, and r a d i oac ti ve m i c r o s p h e r e s  were injected into 
the left ve nt ri cle to measure cardiac output and organ blood 
flows at the end of the infusi on period.
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Materials and methods
58 male S p r a g u e - D a w l e y  rats, ranging in weight from
280-410g, were used in these experiments. The results from
35 rats were excluded from analysis because of technical
problems dis cu ssed below and the results from three groups
of six and one group of five rats, were analysed. All
animals were fasted for at least 12 hours prior to the
study. An ae s t h e s i a  was induced in a perspex box using 2%
halothane and a mixture of 2:1 nit rous oxide and oxygen. A
tracheostomy was per formed and the rat was then ve ntilated
using 2:1 nitrous oxide and oxygen and 0.5% halothane. A
heating lamp was used to m a i nt ain rectal tempe ratur e between 
o
36.5 and 37.5 C. Both femoral arteries and one femoral vein 
were cannulate d using p o l y e thyl en e cannulae (OD 0.96mm). The 
right carotid arter y was cannulated  using a further length 
of pol ye th yl ene cannula and the cannula advanced into the
left ve nt ri cle under cont inuou s arterial pressure
monitoring. An abrupt change in the pressure tracing from an 
arterial to a left v e n t ricu la r form was seen when the
cannula passed through the aortic valve (Figure 11). The 
distance from the carotid artery at the level of the first 
tracheal ring to the left ven tr icle has been stated by 
previous workers (235) to be 4.2cm and it was found helpful 
to mark the cannula 4.2cm from its tip to show when the 
aortic valve was being approached. The rat was hep ari ni sed 
with 130 un it s / l O O g  body weight sodium heparin. One femoral 
artery can nula was used for m o n i to ring of arterial pressure,
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the other was used for wit h d r a w a l  of the refe rence sample 
and the femoral vein ca nnula for drug i n f us ion (Figure 12). 
0.3ml of arterial blood was then w i t h drawn from one of the 
femoral artery cannul as for blood gas esti ma tion. Th er e a f t e r 
the expe ri ment proce eded only if mean arterial pressure was 
greater than 75mmHg, pH was greater than 7.3, pC>2 was 
greater than lOOmmHg and pCC^ was betwee n 33 and 42mmHg. 
When these co nd ition s were achieved a 20 minute in fusio n of 
normal saline, or SMS 201-995 l^g/kg/hr, 2pg/kg/hr, or 
4;ig/kg/hr was co mme nced via the femoral vein cannula, using 
a Braun pump (type 871014). Each dose of SMS 201-995 or 
saline was given to one group of rats, 4jug/kg/hr being given 
to the group of five. The total volume infused was 1ml.
At the end of the 20 minute period a bolus of 0.2ml of 
radio-active m i c r o s p h e r e s  (Gd- 153 or Co-57) in 10% d e x t r a n  
was injected into the left ventricle over 20 seconds 
followed by a 0.2ml saline flush. The r a d i o - a c t i v i t y  in a 
0.5ml aliquot of these micro s p h e r e s  had al re ad y been 
measured in the gamma s c i n t i l l a t i o n  counter prior to the 
experiment. 0.2ml of m i c r o sphe re  s o l utio n from this aliquot 
was dr aw n up into a syringe imme d i a t e l y  before use and this 
sample vortexed for three minutes before injection. Ten 
seconds prior to in j e c t i o n  the wi th drawal  of a re ference 
sample of blood from the second femoral artery c a n n u l a  was 
commenced (Harvard pump model 1901A) and this con ti nu ed for 
70 seconds at a rate of a p p r o x i m a t e l y  lml/min. T wo  mi nut es 
after the i n j e c t i o n  of the m i c r o sphe re s 5ml of blood was
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removed from the first femoral artery c a n nu la for SMS
201-995 levels and then the animal was killed using an 
intravenous bolus of 0.5 ml saturated p o t a s s i u m  chloride 
solution. The pos it i o n  of the left v e n t r ic ular ca nnul a was 
checked. The brain, lungs, liver, spleen, stomach, small and 
large bowel, m e s e n t e r y  and kidneys were removed. The bowel 
was em pt ied of any resi d u a l  food particles by gentle washing 
in water and the organs weighed on a balance (Sartorius 
model 2254). The tissue samples were cut into small pieces 
and placed in vials for count in g in the gamma s c i n t i l l a t i o n  
c o u n t e r .
The residue of the 0.5ml aliquot of mi c r o s p h e r e s ,  the 
washout of the syrin ge (3 washes wit h water) used to inject 
the micro s p h e r e s ,  the syringe itself and the needle used for 
injection were also counted. The ref er ence sample syringe 
was weighed with the sample inside and the weight of the
sample obtained by s u b t r a c t i n g  its weight when empty.
The r e f er ence sample, three washes of its syringe with 
water and its syringe , needle and c a n nula  were placed in 
vials for coun ting. In this ex periment c o u n t i n g  took place 
over five mi nutes per vial and used an open en er g y  w i n d o w  
(lower limit 15keV: upper limit 2000keV). The total amount 
of a c t i v i t y  injected was c al culated  by su bt r a c t i n g  the
activity left in the syringe and needle used for injection,
the ac t i v i t y  of the washout from that syringe and the 
activity of the residue of the initial 0.5ml of 
microspheres. The refer en ce sample activity  was cal c u l a t e d
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by adding the act iv ity of the blood in the sample, the 
activity of the syringe washouts and the activity in the 
reference syringe, needle and cannula. The reference sample 
flow was calcu la ted by di vi ding the weight of the sample by 
blood de n s i t y  (l.lg/ml) and then div id in g by the time of 
withdrawal in minutes.
Mean arterial blood pressure before the inf us io n began and 
at twent y minutes ther eafter,  was ca lc ulated. Cardiac output 
and organ blood flows were then calculated.
Cardiac Output = (ref sample flow/ref sample activity)
X total amount of act iv ity injected.
Organ blood flow =
(ref sample flow/ref sample activity) x organ activit y
Portal venous i n flow was cal c u l a t e d  from the sum of the 
blood flows to the spla nch nic organs.
Both kidn eys were me as ur ed to check for adequate mixing of 
microspheres. Where the di fferen ce  betwee n the right and 
left k i d n e y  flows was greater than 10% of the total ki dney 
flow the e xp erime nt  was discarded . Since it is esse nt ial 
that the i n t r a v e n t r i c u l a r  i n j e ctio n of m i c r o s p h e r e s  does not 
disturb h a e m o d yn amics any e x p e r iments  where there was a fall 
in arterial blood pressure of greater than 10 mmHg du ring or 
after the inj e c t i o n  of micr o s p h e r e s  were excluded.
Mean arteri al  blood pressure in the four groups of rats at
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time zero were co mpared  usin g analysis of variance to ensure 
that the groups of rats were com parable  in this respect. 
Mean arteri al blood pressure after 20 mi nu tes  was compared 
between the groups by p erform in g W i l cox on  signed rank tests 
between zero and the change in blood pressure after 20 
minutes. The results of the cardiac index and portal venous 
inflow m e a s u r e m e n t s  in the four groups were com pa red using  
the Kruska l Wallis test. Results were taken to be 
significant if p<0.05.
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Figure 11 - The tracing from t he Gould recorder showing
arterial pressure duri ng insertion of the cannulas. Paper
speed 5mm/niin. Vertical scale 25mmHg/mm. This tracing was
taken during cannulati on of t he left ve ntricle for cardiac
output estimation and shows t he c hange in the pressure
waveform as the cannu la moved f r om the carotid artery
through the aortic valve into t he le f t ve nt r ic le .
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REFERENCE MICROSPHERE SAMPLE TECHNIQUE
Tracheostomy
Cannula to 
Right carotid
Reference
sample
Femoral
artery
Femoral artery
W ithdraw al
pump
Rectal probe
Fem ora l vein  
drug infusion
Figure 12 - The experimental lay-out for the measurement of 
cardiac output and organ blood flow in the rat.
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Result s
From a total of 58 rats used in these e x p e r i m e n t s ,  the 
results f r o m  35 rats w e r e  e x c l u d e d  for the f o l l o w i n g  
reasons. 13 r a t s  had e v i d e n c e  of d a m a g e  to the v e n t r i c u l a r  
septum w i t h  v e r y  h i g h  lung r a d i o a c t i v i t y .  In two rats 
arterial b l o o d  p r e s s u r e  d r o p p e d  by m o r e  than l O m m H g  d u r i n g  
the m i c r o s p h e r e  i n j e c t i o n .  In 10 rats the k i d n e y  c o u n t s  w e r e  
unequal by m o r e  t h a n  10% of r e n a l  b l o o d  flow. In four rats 
an a d e q u a t e  r e f e r e n c e  s a m p l e  was not o b t a i n e d  b e c a u s e  of 
kinking or c l o t t i n g  of the c a n n u l a  or m a l f u n c t i o n  of the 
pump. In six r ats the l eft v e n t r i c u l a r  c a n n u l a  was not in 
the v e n t r i c l e  at the end of the e x p e r i m e n t .
Tables 10, 11 and 12 are a summ ary of the results of this 
experiment in the 23 rats whose results were analysed. 
Appendix 3 shows the results for individual rats for mean 
arterial blood pressure, cardiac index and portal venous 
inflow. When mean art erial  blood pressure in the four groups 
of rats at time zero is considered, the F-ratio from the 
analysis of var ia nc e is no n - s i g n i f i c a n t  at the 0.05 
significance level. After the infusion of saline or SMS 
201-995 W i l c o x o n  signed rank tests on the diff erenc es  in 
mean arterial pr essure showed no signif icant  change (Table 
13). Cardiac index values are wi dely scattered (Figure 13). 
The test statis ti c from the Kruskal Wallis test comparing 
the cardiac index in the four groups was 3.6 and when 
referred to the C h i - squared  d i s t r i b u t i o n  with 3 degrees of 
freedom, proves to be non - s i g n i f i c a n t  at the nominal 0.05
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sign ifi ca nce level (p<0.4). When portal venous inflow as a 
percentage of cardiac output is exami ned there perhaps is a 
trend towards a r e d u c t i o n  in portal venous in flow with 
in creas in g doses of SMS 201-995 (Figure 14). However the 
test statistic from the Kruskal Wallis test was 0.35 and 
when re fe rred to the C hi-squa re d d i s t r i b u t i o n  wit h 3 degrees 
of freedom, proves to be n o n - s i gn ificant  at the nominal 0.05 
si gn ific an ce  level (p<0.97). With regard to the in di vidua l 
organ blood flows, no diff er ence between the groups can be 
s e e n .
Plasma levels of SMS 201-995 were less than lOOpg/ml in all 
the rats in the co ntr ol group. In the groups given SMS 
201-995 the me a n  pl asma level was 1 0 1 4 p g/ ml(sem  341) in the 
group given lpg/kg/hr, 19 20pg/ml( sem 329 ) in the group given 
2>ig/kg/ml and in the group given 4;ug/kg/ml two of the five 
rats had plasma levels of >2500 mg/ml , while the other three 
values were 1950, 2150 and 2150pg/ml.
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Table 10 - Weight and blood gases in the four groups of rats 
who had arterial blood pressure, cardiac index and organ 
blood flows mea su red after a 20 minute infusion of saline or 
l\ 2 or 4>ig/kg/hr SMS 201-995. Weight is shown in grams and 
pCOg Is shown in mmHg.
CONTROL ljig/kg/hr 2/ig/kg/hr 4;ug/kg/hr
GROUP
NUMBER 6
WEIGHT 348.2+18  . 2
( m e a n + s e m )
pH 7.4
median (7.33-7.58)
(range )
pCO 34.6+2.1
(mean+sem)
BASE
EXCESS -1.1 + 2.9 -1.6 + 2.4 -5.6 + 2.6 -3.7 + 1.9
(mean+sem)
6
3 1 9 . 8 ± 1 3 . 1 
7.35
(7.24-7.52) 
39. 1 + 0.5
6
3 3 4.5+13.5 
7.33
(7.27-7.46) 
3 5 . 2 + 2.3
5
3 2 5.4+13.8 
7 . 35
(7.26-7.4) 
3 6 . 4 ± 1 .5
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Table 11 - The effect of SMS 201-995 on mean arterial
pressure, cardiac output and portal venous inflow in normal 
rats. Dose of SMS 201-995 is shown in ug/kg/hr. Arterial 
pressure is shown in mmHg at 0 and 20 minutes. Cardiac 
index(CI) is shown in ml/kg/min. Portal venous inflow(PVI) 
is shown in ml /m in and as %cardi ac output(CO). All values 
are mean +, standard  error.
CONTROL
GROUP
lug/kg/hr
MEAN
ARTERIAL 0 104.2+7.4 94.2+6.2
PRESSURE
20 102.5+7.6 90.8+7.6
CARDIAC
INDEX
PORTAL
VENOUS
INFLOW
PVI AS 
I CO
20 5. 1+16 .2  259 .6 +3 5.6
10.4+1.1 11.3+1.0
14.6+0.3 14.2+1.3
2ug/kg/hr
93.3+4.0
85+7.2
11 .8+1 . 1
12.7+1.7
4ug/kg/hr
93 + 11 .8 
97+10.4
324.8+73.7 213.7+31.1
8.8+1 .3 
13.0+1.7
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Table 12 - The effect of SMS 201-995 on organ blood flow in 
normal rats. Dose of SMS 201-995 is shown in ;ig/kg/hr. Organ 
blood flow is shown in ml/kg organ weight /min.  All values 
are mean +, standa rd error.
C O N T R O L  
G R O U P .
l^g/kg/hr 2;ug/kg/hr 4/Ug/kg/1
b r a i n 0.9+0.08 1.4+0.3 1 . 6 + 0.4 0 . 8 + 0.1
l u n g 1.0+0.3 2.3+0.4 1.5+0.3 2.4+1.0
h e p a t i c
ARTERIAL 0.3+0.0 5 0. 3+0 .05 0.3+0.03 0.3+0.07
SPLEEN 1.1+0.1 0.9 + 0 . 1 0.9+0.06 1.2+0.3
STOMACH 0.3+0.05 0.5+0.06 0.4+0.08 0.4+0.03
SMALL
BOWEL 0.7+0.07 0.9+0.05 0.8 + 0.0 5 0.7+0.1
CAECUM 0.8 + 0. 1 0.8+0.07 0.9+0.1 0.7+0.1
COLON 0.5+0.04 0.5+0.03 0.5+0.06 0.4+0.0 7
MESENTERY 0.4+0.04 0.4+0.04 0.5+0.1 0.3±0.06
RENAL 5.2 + 0 . 4 4 . 8 + 0.2 6 . 4 + 0.8 4.5+0.2
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Table 13 - Results of W i l c o x o n  signed rank tests on
differences in mea n arteria l blood pressure after a 20 
minute intravenou s infus io n of saline 1, 2 or A >ig/kg/hr SMS 
201-995.
WS p
CONTROL 6.0 0.79
GROUP
ljug/ kg/ hr 4.5 1.0
2/ig/kg/hr 5.0 0.29
4/ig/kg/hr 3*0 0.37
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Figure 13 - Cardiac index in four groups of normal rats
following a 20 minute intravenous infusion of saline or 
ljug/kg/hr, 2/ig/kg/hr or 4;ug/kg/hr SMS 201-995. n= 6 for each 
group except the 4/ig/kg/hr group where n=5. Cardiac index 
shown in ml/min/kg.
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Figure 14 - Portal venous inflow calculated as
perce nt age of cardiac output in four gr ou ps of normal
following a 20 minute intravenous i nf us ion of sali
ljug/kg/ hr , 2>ig/kg/hr or 4>ig/kg/hr SMS 201-99 5. n= 6 in
group except the 4/jg/kg/hr group where n= 5.
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ne or 
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159
Discussion
In this exper im ent SMS 201-995 did not affect systemic 
arterial blood pressur e or cardiac output. This is in
keeping with previous reported results from Jenkins and 
colleagues in ci rrhotic rats (131) and from M o u n t okalak is  
and Levy in normal dogs (136). In another report Jenkins and 
colleagues showed a red uc tion in cardiac output in normal 
pigs after a 20 minut e intrav enous infusion of 250;ug/hr SMS 
201-995 (132). A s s um in g the weight of the pigs to be around
50kg this is a p p r o x i m a t e l y  ten times the dose nor ma lly used 
in man and this large dose may explain the effect seen. 
Three doses have been used in this study, the smallest of 
which is a p p r o x i m a t e l y  three times the dose used in man, but 
no si gn ificant effect on cardiac output in normal rats has 
been demonst rated.
Although there was a trend towards a reduction in portal
venous inflow after incr easing doses of SMS 201-995 this was 
not st ati s t i c a l l y  significant. Jenkins' previous work in 
cirrhotic rats showed a sign ifican t reduction in portal
venous flow and liver blood flow (131), but he took no
account of shunt blood flow and cirrh otic animals may well 
react d i f f e r e n t l y  from normals because of abnormal liver 
function and p o r t a s y s t e m i c  shunting.
SMS 201-995 levels in the 2 and 4;ig/kg/hr groups were 
higher than the SMS 201 -995 levels found in stable cir rhotic 
patients where the mean plasma level of SMS 201-995 at the 
end of 60 mi nut es infusion was 1 51 5+.2 8 0pg/ml when
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transhepatic venous gradient was s i g n i f i c a n t l y  reduced from 
baseline values.
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t h e EFFECT OF SMS 201-995 ON PORTAL PRESSURE IN NORMAL RATS.
Introduc tion
This e x p e ri me nt was performed to show whether SMS 201-995 
has an effect on portal pressure in normal rats. Portal and 
systemic arteria l pressure was mo nitored during the 
intravenous inf usion  of incr eas ing doses of SMS 201-995.
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Materials and methods
Twenty- thr ee male Spr a g u e - D a w l e y  rats, each we ighing 
between 280g and 420g, were used in these experiment s.
On the day of the expe ri ment the rats were fasted for at 
least twelve hours before a na esthes ia  was induced in a 
perspex box wit h 2 % ha lothane  and a mixt ure of 2 : 1  nitrous 
oxide and oxygen. A t r a c h eosto my  was performed and the rat 
was then v e n t ilate d using 2 : 1  nitrous oxide and oxygen and 
0.5% halothane. A heating lamp was used to m a i nt ain rectal 
temperature betw een  36.5 and 3 7 . 5 #C.
Laparotomy was per fo rmed via a lower midline incision  and 
the ileocolic t r i bu ta ry of the portal vein cannulated to 
record portal pressure. The abdomen was then closed in two
layers with chromic catgut. A minimal amount of he parinised
saline (500units in 500ml normal saline) was injected into 
the cannulae to prevent clotting. One femoral artery was 
cannulated for arteri al  pressure recording. One femoral vein 
was cann ula ted for the drug infusion. Arterial blood gas 
estimation was per fo rmed before the start of the infusion. 
Thereafter an infusion of saline at a rate of 0.0 5ml/ mi n was 
commenced via the femoral vein cannula. Continuous 
monitoring of portal and arterial pressure took place
throughout the study. T w enty minu tes of saline infusion was
followed in fourtee n normal rats by infusion of ljjg/kg/hr, 
2;ig/kg/hr and 4/ig/kg/hr SMS 201-995 using a Braun pump for 
twenty minute periods at each dose, main tainin g the inf usion  
volume at a con stant  rate (0.0 5 m l / m i n ). The other group of
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nine rats were given an ei ghty minute i n f usio n of normal 
saline ( 0 . 0 5 m l / m i n ). At the end of 80 minutes the rats were 
killed by a 1 ml intrav enous bolus of sat urated po t a s s i u m  
chlor i d e .
Arterial and portal pressures in the two groups were 
compared at the end of each in fusion  period using repeated 
analysis of variance ( BDMP Medi cal statisti cs package). 
Results were taken to be significan t if p<0.05.
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Result s
Three rats in the control group and eight rats in the study 
group suffered a rapid drop in arterial pressure and died 
during the experim ent. This was found to be due to blood 
loss into the peri to neal cavity following portal vein 
cannulation and these animals' results are not included in 
the analysis. The data from each rat are shown in Ap pend ix  4 
and the results are summarised in Table 14. Analys is of 
variance for repeated measur es de mon s t r a t e d  no sig nificant  
differences in arterial (p<0.67) or portal pressure (p<0.99) 
between the control and study groups. There were no 
significant changes in arterial or portal pressure with 
increasing doses of SMS 201-995.
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Table 14 - The effect of SMS 201-995 on portal and systemic 
pressure in normal rats. Arteria l pressures are shown in 
mmHg and portal pressures in cm water. Weight is shown in 
grams and the dose of SMS 201-995 given to the study group 
is shown in ^ig/kg/hr. All values except pH are mean ±, 
standard error.
CONTROL GROUP STUDY GROUP
NUMBER 6 6
WEIGHT 355. 5+21.5 305.2+7.4
pH(median) 7.35 7.33
(range) (7.27-7.46) (7.28-7.37)
pCO 36.1+1.2 33.3+1.8
BASE EXCESS -5.7+2.1 -7.5+1.5
MEAN A R T E R I A L  PRESSU RE
20 mi n / S a l i n e  96.9+7 .3 101.1+5.8
4 O m i n / 1 jli g 99. 3 + 4 .4 95. 4 + 5.5
60min/2jug 96.5±7 . 9 93 . 1 + 8 ,0
80min/4>ig 95. 1 + 1 . 6 84. 6 + 1 1 .1
MEAN PORTAL PRESSUR E
2 0 m i n /Sal in e 7.4+1.1 7.2±1.1
40min/ljuig 7 . 4.+ 0 . 9 7.9 + 0.7
60m in /2^g  8 . 4+.0 • 9 8 . 3 +0.4
80min/4/ig 7 . 8 .+ 0 . 8 7.7 + 0.5
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Discussion
This exp erime nt  could d e m o nstrate  no effect of SMS 201-995 
on portal pressure in normal rats. Al th ough there was a 
slight fall in mean arterial pressure in rats given SMS 
2 0 1 - 9 9 5 , this was not stat i s t i c a l l y  sign ificant and no 
significant d i f f e r e n c e  from the arterial pressures in the 
control group was demonstr at ed.
One previous group has reported similar work, on the 
effects of SMS 201-995 infusi on on portal pressure in sham 
operated rats (240) who served as controls for partial 
portal vein ligated and bile duct ligated groups. In Cerini 
and co lleagues e x p e r ime nt s the m e a s u r e m e n t s  were performed 
on u n a n a e s t h e t i s e d  animals and increas ing doses of SMS 
201-995 from 0.25 to 16>ig/kg/hr were infused for 10 minutes 
per dose. In sham operat ed rats no sign ificant diff er ence in 
portal pressu re was seen.
However in normal pigs a s i g n ifica nt  reduc tion in portal 
pressure after infusion of 250;ag/hr of SMS 201-995 for 20 
minutes has been re porte d (132). These d iffere nc es may be 
due to the species of animal used . The dose of SMS 201-995 
used by Jenkins and colle agues is also co ns i d e r a b l y  higher 
than the dose we have used.
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THE EFFECT OF SMS 201-995 ON PORTAL PRESSURE IN PORTAL
H Y P E RT EN SIVE RATS.
Introduction
This experi me nt  was performed  to show whether SMS 201-995 
has an effect on portal pressu re in portal hyper t e n s i v e  rats 
and to try to es t a b l i s h  a dose of the drug to be used in 
future experime nts. Portal and systemic arterial pressure 
were mo ni tored in rats who had e xt rahepat ic  portal 
h y p e r te nsion during the intrav enous infusion of incre asing 
doses of SMS 201-995.
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Materials and meth ods 
T we nt y-thre e male Sp r a g u e - D a w l e y  rats, each wei gh ing 
between 280g and 420g, were used in these exp eriments. These 
rats had undergone  partial portal vein ligation three days 
previously.
On the day of the ex perime nt  the rats were fasted for at 
least twelve hours before an ae s t h e s i a  was induced in a 
perspex box with  2 % halothane and a mixture of 2 : 1  nitrous 
oxide and oxygen. A trac h e o s t o m y  was performed and the rat 
was then v e n t il at ed using 2 : 1  nitrous oxide and oxygen and 
0.5% halothane. A he ating lamp was used to m a i nt ai n rectal 
temperature bet ween 36.5 and 37.5°C.
Laparotomy was perfor me d via a lower midline incision and 
the ileocolic tribu ta ry of the portal vein cannulated  to 
record portal pressure. The ab domen was then closed in two 
layers with chr omic catgut. A minimal amount of hep ari ni sed 
saline (500units in 500ml normal saline) was injected into 
the cannulae to prevent clotting. One femoral artery was 
cannulated for arterial pr essur e recording. One femoral vein 
was can nulated for the drug infusion. Arterial blood gas 
estimation was p e r forme d before the start of the infusion. 
Thereafter an inf usion  of saline at a rate of 0.05ral/min was 
commenced via the femoral vein cannula. Continu ous 
monitoring of portal and arterial pressure took place 
throughout the study. Tw ent y minutes of saline inf usion was 
followed in nine rats by infusion of ljug/kg/hr, 2 jug/kg/hr 
and 4jug/kg/hr SMS 201- 995  and in seven rats by inf us io n of
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8,16 and 32^ig/kg/hr SMS 201-995. Seven rats acted as 
controls and cont in ued to have saline infused. A Braun pump 
was used for int rave no us in fusion for twenty minute periods 
at eac h dose, m a i n t a i n i n g  the infusi on volume at a constant  
rate ( 0 . 0 5 m l / m i n ). At the end of 80 minutes the rats were 
killed by a 1 ml i nt ra venous  bolus of sa turated p o t a s s i u m  
c hlor ide .
Arteri al and portal pressu res in the two e x p e r i m e n t a l  
groups were com pared wit h  the values in the control group at 
the end of each i n f us ion period using repeat ed  analysis of 
v a r i a n c e ( BMDP Medica l Sta tis tics Package). Results were 
taken to be s ignif ic an t if p<0.05.
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Results
One rat in the control group, three rats in the l-4jig/kg/hr 
group and one rat in the 8 - 3 2/ig/kg/hr group sustained 
massive blood loss after portal vein c a n n ul ation and their 
results have been excluded from the analysis. The results 
are sum marised in Table 15 and the raw data for each rat are 
shown in A p p en di x 5. Figure 15 shows the change in portal 
pressure with time for each group of rats.
Arterial pressure  d e c re as ed s i g n i f i c a n t l y  with time in the 
control group (p<0.04) but this differ ence was not 
significantly di f f e r e n t  from the changes in arterial 
pressure with time in either the l-4yug /kg/hr group (p<0.11) 
or the 8-32jug/kg/hr group (0.07).
Portal pressure tended to fall with time, s i g n i f i c a n t l y  in 
the control (p<0.02) and l-4,ug/kg/hr groups (p<0.01). 
However there was no sign ifica nt  diff erence in the fall 
between the control and l-4;ug/kg/hr groups (p<0.09) and the 
fall in the control group was s i g n i fi cantly gre ater than 
that in the 8-32;ug/kg/hr group ( p < 0  . 004 ) .
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Table 15 - Weight, blood gases and mean ar terial pressure in 
three groups of portal hypertensive rats given intravenous 
infusions of either saline, 1-A^ig/kg/hr or 8 -3 2>ig/kg/hr SMS 
201-995. Saline was infused for the first twenty minutes, 
then either saline or d o u bling  doses of SMS 201-995 for 
twenty minutes at e ach dose. Arteri al pressures are shown in 
mmHg. Weight is shown in grams and the dose of SMS 201-995 
given to the study groups is shown in p g / k g / m i n .  All values 
are m e a n  + standard error. n= 6 for ea c h  group other than the 
8 - 3 2jug/ kg/ hr group where n=4.
CONTROL GR OUP l-4>ig/kg/hr 8 - 32>ig/kg/hr
WEIGHT 30 3±7 289+7.0 269+12
p H ( m e d i a n ) 7. 29 7. 29 7.31
( r a n g e ) (7.27-7.3) (7. 2-7.4) (7.23-7.45)
PCO 2 32+1 33±2 3 2 ± 3 .9
BASE EXCESS -9 + 2 -9 + 2 1 • 1+ 1— • 00
MEAN A R T ER IAL PRE SS URE
Saline 114+5 104 + 6 117±5
40min/ lpg/ 8 >ig 106±7 93±4 128 + 6
6 0 min/ 2jig/ 16/ig 9 6 ± 8 94±7 121+4
80min/ 4;ig/ 32>ig 9 8 ± 1 0 89 + 11 121+4
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Figure 15 - Change in mean portal pressure with time in
three groups of portal hypertensive rats given intravenous
infusions of either saline, l-4;ug/kg/hr or 8-32/ig/kg/hr SMS
201-995. Saline was infused for the first twenty minutes,
then either saline or doubling doses of SMS 201-995 for
twenty minutes at each dose. n=6 for each group other than
the 8- 3 2)i g/kg/hr group where n=4.
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Discuss ion
In portal h y p e r t e n s i v e  rats the results are less clear. 
Reductions in portal pressure were seen in both study and 
control groups, with lesser re du cti ons in mean arterial 
pressure. Any reduction  in portal pressure seemed to 
greatest in the l-4>ig/kg/hr group, although s t a t i st ic ally 
significant d i f f e r e n c e s  betw een the groups were not seen. 
For this ex pe r i m e n t  we used rats three days after portal 
vein ligation. This meant that a high portal pressu re was 
obtained but it was also noticed that these rats had a 
higher blood loss due to the ileo-colic vein c annulat io n  
than normal rats. Because of this blood loss, the rats were 
less stable, with a tendency to drop their arterial 
pressure, and aci d- ba se balance was less s atis fa ctory with a 
tendency towards m e t a boli c acidosis. These problems occurred 
in both study and control groups. Previous work in portal 
hypertensive rats has shown that portal pressure falls to a 
greater extent than mean arterial pressu re after ha emo rrhage 
(241) and that in a haeraorrhaged-transfused rat model of 
portal h y p e r t e n s i o n  there is reduced sen si ti vity to 
vasopressin (242). This may help to expl ain our results.
Since a 4>ig/kg/hr dose of SMS 201-995 has been used by 
other groups, did not appear to affect systemic 
h a e m o d y n a m i c s , but seemed pos sibly to have an effect on 
portal pressure  it was decided to use this dose in the 
succeeding exp er im ents. Plasma levels of SMS 201-995 had 
been shown to be s a t i s f a c t o r y  with a dose of 4^ig/kg/hr in
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the previous exp erime nt  and it was exp ec ted that these would 
be, if anything, higher in portal hypertens ive rats.
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t h e  e f f e c t  o f  r e p e a t e d  i n j e c t i o n  o f  m i c r o s p h e r e s  on
PORTASYSTEMIC SHUN TI NG M E A S U RE MENTS
Introduction
To es t a b l i s h  wh et he r SMS 201-995 affects the degree of 
portasystemic shunti ng  it was hoped to perfor m two 
measurements of % po r t a s y s t e m i c  shunting in a series of rats 
given an inf usion of SMS 201-995. Ho wever it is possible 
that the inje ct ion of m i c r o s p h e r e s  itself will alter the 
degree of p o r t a s y s t e m i c  sh unting by blocking the 
capillaries. T h e r efore two m e a s u r e m e n t s  of % p o r t a system ic  
shunting were perf ormed  in rapid succession  in a group of 
rats to ensure that success ive measu r e m e n t s  were comparable.
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Materials and methods
Five male S p r a g u e - D a w l e y  rats weighin g bet ween 250g and
300g and who had und er gone portal vein ligati on three days
earlier were used in this experiment. The rats were fasted 
for at least twelve hours prior to the experiment.
An aesthes ia was induced in a perspex box with 2% halothan e 
and a mixture of 2:1 nitrous oxide and oxygen. A
tracheostomy was performed and the rat was then ventilate d 
using a mi xt ure of 2 : 1  nitrous oxide and oxygen and 0 . 5 %
halothane. A hea ting lamp was used to ma in ta in rectal 
temperature be tween 36.5 and 37.5°C.
La parot om y was per fo rmed  using a lower midline incision and 
the ileocolic tr ibuta ry  of the portal vein was cannulated. 
The abdo men was closed in two layers with chromic catgut. 
One femoral arter y was cann ulated  for arterial pressure
recording. A mi ni mal amount of hep ar in ised saline (500 units 
heparin in 500ml of normal saline) was injected through the 
cannulae to prevent clotting.
Arterial blood gas e s t i mati on  was performed after these 
cannulae were inserted. Experi me nt pro ceeded if pH>7.3, p © 2  
M O O m m H g  and p C 0 2  was between 33 and 42mmHg.
A bolus of 0.1ml of Co-57 labelled m i c r o spheres  (1,000 
microspheres) was injected into the portal vein cannula 
followed by a 0.2ml saline flush. Prior to injection the
syringe co n t a i n i n g  the micro s p h e r e s  was vort exed for three 
minutes. Three mi nut es  later 0.1 ml of Sn-113 labelled 
microspheres ( 1 , 0 0 0  m ic ro sphere s)  was injected into the
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portal vein followed by a saline flush. Two minutes after 
the second inj ec tion of m i c r o spher es  the rat was killed by a 
lml i nt raveno us  bolus of saturated p o t a s s i u m  chlori de and 
the liver and lungs removed.
The lungs and liver were placed in vials for co u n t i n g  in 
the gamma s c i n t i l l a t i o n  counter. Counting took place over 
ten mi nutes  per sample and usi ng two e n e r g y  windows 
80 -15 0keV for Co-57 and 3 00-45 0k eV for Sn-113. The error in 
the meas u r e m e n t  of the r a d i o a c t i v i t y  introdu ced by the 
spillover of Co-57 en er g y  into the Sn-113 cha nne l and vice 
versa was cor rec te d by using Co-57 and Sn-113 standards.
% po rt a- s y s t e m i c  shu nting  was c alc ul ated for each  in jection  
by using the formula
% p o r t a - sy st em ic shun ting = counts in lung/co unts in liver 
and lung x 1 0 0 .
The results for the two injections in eac h rat were 
compared using the M ann Wh it ney U test.
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Results
The results are shown in Tables 16 and 17. The m a x im um  
difference betw een the two m e a s ureme nt s was 6 . 6 % and the 
mean diff er ence was 2.6%. A W i l co xon signed rank test 
demonstrated no s i g n ific an t d ifferen ce  between the two sets 
of me as u r e m e n t s  (p=0.26)
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Table 16 - The effect of intraportal injection of
microspheres on %shunt in g m e a s u rem en ts in portal 
hypertensive rats. We ight  is shown in grams, arterial 
pressure in mmHg and portal pressure in cm of water. n=5.
WEIGHT
pH-median(range) 
p C © 2
BASE EXCESS
MEAN A R T ERIA L 
PRESSURE
MEAN PORTAL 
PRESSURE
MEAN ± STANDARD ERROR 
2 6 7.8+10.4 
7.3 (7. 25-7 .4 )
3 5 . 5 ± 0 . 9 
-7.2+0.4
8 3 . 6 ± 6 . 7
15.8+1.6
% SHUNTING 
Co-57 - 1st I N J E CTIO N 
Sn-113- 2nd INJECTI ON
8 1 . 3 ± 3 .6 
83.4+3.3
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Table 17 - C o m p a r i s o n  of two successive % 
shunting m e a s u r e m e n t s  in 5 rats.
RAT NO. 1ST M E A S U R E M E N T  2ND M E A S UR EM ENT
1 78.8 83.3
2 75.3 81.9
3 73.3 73.0
4 92.7 93.2
5 8 6 . 6  85.7
MEAN 81.3 83.4
porta s y s t e m i c
DIFF E R E N C E
+ 4.5
+ 6.6
-0.3
+ 0.5
-0.9
+ 2 .6%
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Discussion
In this ex pe riment  there was very close agreement between 
the first and second m e a s u r e m e n t s  of %p o r t a s y s t e m i c  shunting 
in portal h y p e r t e n s i v e  rats. The re fore the in jection of a 
small dose of m i c r o s p h e r e s  into the portal system did not 
itself affect % portasysteraic shunting and this micr o s p h e r e  
method could be used to evaluate the effect of SMS 201 -995 
on p o r t a sy st emic shunting in the rat.
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t h e  EFFECT OF SMS 201-995 ON PORTAL PRESSU RE AND 
PORTASYSTEMIC S H U NTING  IN PORTAL H Y P E R T E N S I V E  RATS.
Introduction
The aim of this e x p e ri ment was to est ablish more clearly 
whether SMS 20 1- 99 5 causes a reduction  in portal pressure in 
portal h y p e r t e n s i v e  rats and w h e the r this is a cc ompanie d by 
a change in the degree of p o r t a s y s t e m i c  shunting in these 
animals. Portal vein ligated rats at three and twenty eight 
days p o s t - l i g a t i o n  were used since previous work  in this 
department has shown that %shu nt ing increases and portal 
hypertension d e c reas es  with time after portal vein ligati on 
and it was hoped that animals with a spectrum of values for 
shunting and portal pressure would be obtained. Following 
our previous e x p e r i m e n t s  with SMS 201-995 , 4;jg/kg/hr was 
chosen as the dose most likely to produce an effect.
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Materials and methods
Three groups of six and one group of seven male 
Sprague-Dawley rats, weighing between 250g and 440g were 
used in this experiment. Two groups of six had undergone 
portal vein ligation three days previously. The other 13 
rats had undergone partial portal vein ligation twenty-eight 
days previously. On the day of the experiment the rats were 
fasted for at least twelve hours before anaesthesia was 
induced in a perspex box with 2% halothane and a mixture of 
2:1 nitrous oxide and oxygen. A tracheostomy was performed 
and the rat was then ventilated using a mixture of 2:1 
nitrous oxide and oxygen and 0.5% halothane. A heating lamp 
was used to maintain rectal temperature between 36.5 and 
37 . 5°C.
Lap aro tomy was perfo rmed via a lower midline incision and 
the ileocolic trib utary of the portal vein cannulated. The 
abdomen was closed in two layers with chromic catgut and the 
portal vein cannula used to record portal pressure and for 
the in jection of mic rosp he res. One femoral artery was 
cannulated for arterial  pressure recording. One femoral vein 
was ca nnulated  for drug infusion. A minimal amount of 
heparinised saline (500 units sodium heparin in 500ml normal 
saline) was injected into the cannulae to prevent clotting.
Blood gas e s t i m a t i o n s  were perfo rme d before the infusion 
began and at 30 minute intervals thereafter. Infusio n 
commenced with normal  saline at 0.05 ml /m in for 30 minutes 
in all groups of rats. At the end of this time 0.1 ml Co-57
labelled m i c r o spher es  ( 1 0 0 0  m i c r o sphe re s) in 1 0 % d e x t r a n  was 
vortex-mixed for 3 minu tes  then injected into the portal 
vein cannu la  followed by a 0 . 2 ml saline flush.
Ther ea fter one group of six three day post portal vein 
ligation rats and one group of seven t went y- eight day post 
portal vein ligation  rats had 4>ig/kg/hr SMS 201-995 in 
saline infused at 0.05 m l / m i n  via the femoral vein. The 
other two groups co nt inued to have saline infused. After 30 
minutes of in fusion  0.1ml Sn-113 labelled m i c r o s p h e r e s  (1000 
microsp he res) were vor tex ed for three minutes and injected 
into the portal vein ca n n u l a  followed by a 0 . 2 ml saline 
flush.
In the t w e n t y-ei gh t day post portal vein ligation groups 
the ex pe r i m e n t  was ter mi nated two minutes after the second 
injection and the animal killed by in tr avenous inj ec ti on of 
lml saturated  p o t a s s i u m  chlor ide. In the three day post 
portal vein lig at ion groups the e xp eriment  was continued for 
a further thirty minutes  before sacrifice. Five ml blood 
samples for SMS 201-995 levels were take n from the femoral 
artery c a n n u l a  i m m e d i a t e l y  before sacrifi ce. After this the 
lungs and liver were removed and counted in a gamma 
s c i n t i l l a t i o n  counter as des cr ibed for the previous 
experiment. Coun ti ng took place over five minutes per sample 
using an 8 0 - 1 5 0 k e V  ene r g y  w i n d o w  for Co-57 and a 300 - 4 5 0 k e V  
win dow  for Sn-113. Counts were co rre cted for spillover using  
Co-57 and Sn-113 standards. Two values for percen tage 
portasyst emic shu nti ng were obtained for e ac h rat, at 30
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minutes and 60 min utes from the start of the exp eriment. 
Values for the systolic, dias tolic , pulse, mean arterial and 
mean portal pressures for 0, 30, 60, 90 mi nu tes were
obtained as pr eviou sl y described.
The resu lts were compar ed using Mann Whit ney U tests to 
compare the change in portal and mean art eri al pressures and 
change in % p o r t a systemi c shunting in the contro l and study 
groups for both the three day post portal vein ligation and 
the t w e n t y-eigh t day post portal vein ligation  rats. p<0.05 
was tak en  as the level of s t a t i stic al  si gni ficance.
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Results
The results for the three day post portal vein ligation 
rats are sum marised in Table 18. No results were excluded 
from analysis. App en di x 6 shows the raw data for each rat. 
No si gnifi cant di f f e r e n c e  in mean arterial pressure was seen 
between the control and study groups, throughout 60 minutes 
of infusio n of saline or SMS 201-995 (from 30 to 90 minutes 
of the e x p e r imental  period). In both groups there was a fall 
in portal pressure  but there was no difference  in this fall 
between the groups (p=0.29). As is seen in Figure 16 there 
was no co ns i s t e n t  change in %p o r t a s y s t e m i c  shunting in 
either control or study groups. There is no st a t i s t i c a l l y  
significant di f f e r e n c e  be tw ee n the groups (p=0.32). Both 
groups became in cr e a s i n g l y  acidot ic thr oughout the 
experiment •
The results for the twenty eight day post portal vein 
ligation rats are shown in Table 19. App endix 7 shows the 
raw data for each rat. The results from one rat given SMS 
201-995 were exc lud ed from the analysis because of a 
reduction of 40 mmHg in mean arterial pressure due to 
bleeding from the m e s e n t e r y  around the portal vein cannula. 
There were no sig n i f i c a n t  d i f f erences  in mean arterial 
pressure between the control and study groups. The control 
group sustained a larger drop in portal pressure than the 
study group but this dif feren ce  betwee n the control and 
study groups was not significan t (p=0.07). Changes in 
^portasystemic shunting were very variable in both groups.
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There is no statistically significant difference between the 
groups ( p=0. 31 ) .
When the results for both groups are c o n s i d e r e d  there was 
no c o r r e l a t i o n  betw een the drop in portal pressure with SMS 
201-995 and initial portal pressure (r=0.31; t=0.98; Figure
17), ini tial % p o r t a s y s t e m i c  shunti ng (r=0.26; t=0.81) or the 
change in % p o r t a s y s t e m i c  shu nti ng (r=0.123, t = 0 . 3 7 ; Figure
18). Neithe r was there any c o r r e l a t i o n  be tween the change in 
arterial pressure and change in portal pressure when all the 
groups were c o n s idered  (r=0.25; t=1.21; Figure 19).
Plasma levels of SMS 201-995 were found to be <100p g/m l in 
all co n t r o l  group animals and >2 50 0pg/ml in all study group 
animals .
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Table 18 - The effect of 4;jg/kg/hr SMS 201-995 on portal 
pressure and porta s y s t e m i c  shunting in 3 day post portal 
vein li ga ti on rats. Results shown were me asured at 30 and 60 
minutes (before d r u g / sa li ne and after 30min infusion). 
Arterial pressure is shown in m m H g , portal pressure in cm 
water and weight in grams. All values except pH are mean + 
standard error. n = 6  for eac h group.
CONTROL GRO UP  STUDY GROUP
WEIGHT 2 79 . 3±1 1 . 6 273 .0+11 . 3'
pH me d i an( r ange )
30 7.27(7 .2 3-7.3) 7.32(7.23-7 .34)
60 7. 22 (7 .15-7. 33 ) 7.27(7.2-7. 34)
pCO 30 36.4+1.3 3 4 . 7 ± 0 . 6
60 3 6 . 3 ± 1 .2 38.1+1.4
BASE EXCESS 30 - 9 . 7 ± 1 . 0 - 7.9 + 1 . 2
60 - 1 1 . 6 ± 1 .3 - 8 . 1 + 1 . 6
MEAN AR TERIA L 30 8 9 . 7 ± 7 .9 99.4+6.7
60 8 4 . 3 ± 6 .2 99.7+6.7
90 82 . 4 + 1 3 . 2 9 0 . 7±6.8
MEAN PORTAL 30 17.5+1.4 1 4 . 6 ± 1 .9
60 13.0+1.3 1 1 . 0 ± 2 . 2
90 1 0 .4 ± 1 .5 9.2+2.4
%SHUNTING 30 43.1+12.4 57.3+12.6
60 42.9 +1 2.7 51.1+13.8
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Figure 16 - %portasystemic shunting in twelve 3 days post
portal vein ligation rats. Measurement before and after a 30 
minute intravenous infusion of saline (6 rats) or 4^ig/kg/hr 
SMS 201-995 (6 rats).
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Table 19 - The effect of 4>ig/kg/hr SMS 201-995 on portal
pressure and p o rt asyste mi c shunting  in 28 day post portal 
vein ligatio n rats. Results shown were meas ured at 30 and 60 
minutes (before dru g / s a l i n e  and after 30min infusion). 
Arterial pressure is shown in m m H g , portal pressure in cm 
water and weight in grams. All values are mean + standard 
error. n = 6 for con trol group, 5 for study group.
CONTROL G R OU P STUDY GRO UP
WEIGHT 364. 5+20. 6 364.4+8.9
pH m e d i a n ( r a n g e )
30 7 . 28(7 .2 1-7.37) 7.26(7. 25-7.3)
60 7 . 2 2 ( 7 .15-7.3 1) 7 . 2 6 ( 7.25-7.3)
pco 30 36.9+2.2 33+2.2
60 37.4+1.9 35+3.3
BASE EXCESS 30 - 7 . 9 + 0 . 9 -8. 1 + 1 . 6
60 - 1 2 . 1 + 1 . 1 -9.9+1.1
MEAN ART ER IAL 30 105.0+2.6 1 0 4 . 5 ± 5 .0
60 99.1+5.2 1 1 0 . 2 ± 9 . 2
MEAN PORTAL 30 1 1 . 3 ± 0 .8 9.9+1.0
60 9 . 8 ± 1 .2 9.6+1.1
%SH UNTING 30 55.8+7.4 4 8 . 8+14.2
60 58.9+10.4 51.9+10.7
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Figure 17 - Plot of change in portal pressure against 
initial portal pressure in eleven portal vein ligated rats 
(six 3 days and five 28 days post portal vein ligation rats) 
given an intravenous infusion 4>ig/kg/hr SMS 201-995 for 30 
minutes. r=0.31. t=0.98. p<0.5.
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Figure 18 - Plot of change in portal pressure against change 
in %portasystemic shunting in portal vein ligated rats (six 
3 days and five 28 days post portal vein ligation) given an 
intravenous infusion of 4;ug/kg/hr SMS 201-995 for 30 
minutes. r=0.12. t=0.37. p>0.5.
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Figure 19 - Plot of change in portal pressure against change 
in mean arterial pressure in 23 rats in four groups - six 3 
days post portal vein ligation given saline; six 3 days post 
portal vein ligation given 4yg/kg/hr SMS 201-995; six 28 
days post portal vein ligation given saline; five 28 days 
post portal vein ligation given 4;ug/kg/hr SMS 201-995 . All 
infusions over 30 minutes. r=0.25. t=1.21. p<0.5.
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Discuss ion
In this expe ri ment no systemic hae mo dy namic changes were 
seen in either control or study groups. Portal pressure fell 
in all groups but no si gnifica nt effects of SMS 201-995 
could be shown. A wide variety of changes in shunti ng was 
seen.
In the part of this expe rimen t using 3 day post portal vein 
ligation rats a longer time scale was used than in previo us 
experiments. Because the problems due to blood loss and 
falling arteri al and portal press ures had been most apparent 
at the be gi nning  of the experiment s, it was felt that a 
longer period foll ow ing the insertion  of the cannulas might 
allow the animals to stabilise. The drug infusion was also 
given in the highest dose for a longer period to minimis e  
the chance that an effect was missed because of too short a 
period of observat ion. Ho wever during the course of these 
long ex pe r i m e n t s  portal pressures fell slowly in both 
control and study groups and this often occurred with little 
or no blood loss. The cal ibr at ion and base -line of the 
pressure tr ans ducers was checked re gularly to ensure that 
this was not the cause of the change. The con c l u s i o n  was 
that the slowly inc resin g me tabolic acidosis in the animals 
might be respons ib le for the change in portal pressure. This 
was dif fi cult to prevent although the changes were similar 
in the control and study groups.
In the 28 day post portal vein ligation rats similar 
negative results with SMS 201-995 were obtained, a l t ho ug h
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the drug infusion was not prolonged beyond thirty minutes.
As pre v i o u s l y  noted in this department (7), a wide range of 
% p orta sy st emic shu nti ng was produced by portal vein 
ligation. No co ns ist ent change in %p orta s y s t e m i c  shu nt ing 
was caused by the i n f us ion of SMS 201-995 in these animals. 
This is perhaps not sur pr is ing since a wide v a r iety of
anatomy and degree of shunting is found before drug 
treat men t. H a e m o d y n a m i c  changes must have been occurring  in 
the co nt rol rats with time, despite the unchan ge d systemic 
arterial blood pressure, since they also sustained chan ges 
in %p o r t a s y s t e m i c  shunting. Other influen ces such as
acid-base balance must have been more important than any
influence of SMS 201-995.
Th r o u g h o u t  this expe riment  con sidera bl e variet y in re spo nse 
was noted. In order to e s t a b l i s h  whether portal pressure
response to SMS 201-995 is influenced by initial portal
pressure, initial % p orta sy stemic shunting or change in 
%p orta s y s t e m i c  shunting, these variables were plotted for
each animal (Figures 17 and 18) and the c o r r e l a t i o n  
coeffic ie nt calc ul ated.  No evidence of c o r r e l a t i o n  b e t ween  
the change in portal pressure and the other vari ables was
found. Since any change in portal pressure might be si mp ly
due to a change in arterial pressure these two var ia bles 
were plotted (Figure 19). No simple c o r r e l a t i o n  was found.
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THE EFFEC T OF SMS 201-995 ON PORTAL PRESSURE AND 
PORTASYSTEMIC SHUNTI NG  IN CIRRHOTIC RATS.
Introduction
The aim of this exper im ent was to establ is h whether SMS 
201-995 affects portal pressure and % p o r t as ystemi c shunting 
in cirr hotic rats. Since these animals have abnormal liver 
function it was felt that they might react d i f f e r e n t l y  from 
animals with e x t r a h e p a t i c  portal hyp ert ension.
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Materials and methods 
Twent y male S p r a g u e - D a w l e y  rats, weighing between 295g and 
455g were used in this experiment. Each of these rats had 
been treated with carbon tet rachlorid e to produce cir rhosis 
as descri be d pr eviou sly, and had evidence of ascites on 
examination. All ex pe riments were performed betw een 7 and 14 
days after the onset of ascites.
On the day of the expe riment the rats were fasted for at 
least twelve hours before a naest he sia was induced in a 
perspex box with 2% halothane and a mixture of 2:1 nitrous 
oxide and oxygen. A tra ch eo stomy was performed and the rat 
was then ven t i l a t e d  using a mixture of 2:1 nitrous oxide and 
oxygen and 0.5% halothane. A heating lamp was used to 
maintain rectal temperatur e between 36.5 and 37.5°C.
Laparotom y was perfo rm ed via a lower midline incision and 
the ileocolic  tribu tary of the portal vein cannul ated to 
record portal pressure. The abdomen was closed in two layers 
with chr omic catgut. One femoral artery was ca nnulated for 
arterial pre ss ure recording. One femoral vein was ca nnulated 
for drug infusion. A minimal amount of h epar in ised saline 
(500 units sodiu m heparin in 500ral normal saline) was 
injected through the cannulae to prevent clotting. Blood gas 
estimations were performed before the infusion began. Then 
0.1 ml Co-57 labelle d m i c r o spher es  (1000 m i c r o spheres ) in 
10% de xtran  was vortex ed for 3 minutes then injected into 
the portal vein cann ula followed by a 0.2ml saline flush. 
Thereafter one group of eleven rats had 4;ug/kg/hr SMS
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201-995 in saline infused at 0.05 m l / m i n  via the femoral 
vein. The other group of nine rats had saline infused at the 
same rate. After 20 minutes of in fu si on 0.1ml G d - 1 5 3
labelled mi cro s p h e r e s  (1000 microsphe re s) were vortexed for 
three min utes and injected into the portal vein c a n n u l a  
followed by a 0.2ml saline flush. Blood gas e s t i m a t i o n  was 
then repeated.
The exp er im ent was t erm in ated two minutes after the second 
i n j ec ti on  and the animal killed by intravenous in j e c t i o n  of 
lml sat urated p o t a ssium chloride. Five ml blood samples were 
taken from the femoral artery cannula i m m e d i a t e l y  before 
sacrifice for SMS 201-995 levels and liver function tests. A 
small liver biopsy was taken for histology. After this the 
lungs and liver were removed and counted in the gamma
s c i n t i l l a t i o n  counter as des cr ib ed for the previ ou s  
exper ime nt. Counts were co rrected  for spillover using Co-57 
and G d -15 3 standards. Two values for per cen tage shu nt ing 
were obtain ed for e ac h rat, at time zero and twenty minu tes 
after the start of the experiment. Values for the systolic, 
diastol ic,  pulse, mea n arterial and mean portal pressure s
for 0, 30, 60, 90 minu tes  were obtained as p r e v i o u s l y
descr ibe d .
The results were co mpared using Mann  W h i tne y U tests to 
compare the change in portal pressure and change in
% p or tasyst em ic  shu nt ing between the study and control group. 
Results were cons idere d signific ant if p<0.05.
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Results
Two rats in the study group sustained a severe drop in 
arterial blood pressu re because of bleeding after portal 
vein can nulation. Their results are not included in the 
analysis. The liver fu nc ti on tests and his to lo gy of these 
rats are shown in Table 20. The results of the h a e m o d y n a m i c  
studies are shown in Table 21. Append ix 8 shows the data for 
each rat studied. The blood gas results are less co mparable 
in this ex pe riment  than the others, and the study group 
started with a lower pCO than the control group. The 
control group also became more acidotic during the 
experiment. There are no signifi cant diff er ences betw een  the 
groups wit h regard to change in portal pressure (p=0.33) or 
% po rt asystemic shunting  (p=0.39). Figure 20 d e m o n stra te s 
that a va ri et y of changes in %por ta s y s t e m i c  shuntin g was 
seen in both control and study groups.
SMS 201-995 levels at the end of the experime nt were found 
to be <100pg/ml in all control group animals and > 2 5 0 0pg/ ml  
in all study group animals.
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Table 2 0 - Liver funct ion tests in 18 cirrhotic rats used in 
the portal pressure and %p or t a s y s t e m i c  shunting experiment. 
ALT=Alanine tran sam inase , A S T = A spar ta te transaminase. All 
values are m e a n + s t a n d a r d  error. M a n n - W h i t n e y  U Tests show no 
significant di ff e r e n c e s  betwee n the groups.
LIVER FU NCTIO N TEST 
Number
Bilirubin(juraol/l)
Albumin(g/1)
ALT(units/1)
AST(uni ts/1 )
Alkaline Ph os p h a t a s e  
(uni t s /1 )
CONTROL GROUP STUDY GROUP p
9 9
5+1 8+2 0.07
21+3 19 ± 1 0.8
8 3 ± 1 9 15 5± 5 5 0.3
284+34 43 3+12 8 0.3
3 7 5±4 9 3 62±3 5 1.0
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Table 21 - The effect of 4^ig/kg/hr SMS 201-995 on portal 
pressure and portasys te mic shunti ng in cirrhotic rats. 
Results shown were me as ured at zero and 20 minutes (before 
and after 20rainutes of d ru g/ saline  infusion). Weight is 
shown in grams, arterial pressure in mmHg and portal 
pressure in cm water. All values are mean + standard error. 
n=9 for each group.
CONTROL GROUP STUDY GROUP
WEIGHT
pH m e d i a n ( r a n g e ) 
0
20
pCO 0 
20
BASE EXCESS 0 
20
MEAN AR TE RIAL 0 
20
MEAN PORTAL 0 
20
%SHUNTING 0 
20
357.3+23.7 
7. 34
(7.24-7.39)
7.23
(7.1-7.32) 
32.6+1.2 
31.8+1.5 
- 7 .9 + 1.0 
- 1 3 . 0 + 1 . 0  
89 . 2±4 .3  
7 8. 9 ± 3 .4 
12.5±1.8 
11.4+1.7 
1 8. 6 ± 4 .5 
21.6+5.6
386.4+15.5 
7.30
( 7 . 26- 7 . 42) 
7.3
(7 .2 3-7 .42 ) 
28 . 0 ± 2 •8 
31.1+2.2 
- 1 0.6± 1 .5 
-8 . 5 + 2 . 6  
90.8+4.9 
87.4+6.1 
1 2 . 3±0.9 
1 1.6±1 .1 
15. 0±4. 6 
20.5+6.3
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Figure 20 - %portasystemic shunting in ten cirrhotic rats 
measured before and after a 20 minute intravenous infusion 
of saline (9 rats) or 4/ig/kg/hr SMS 201-995 (9 rats).
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Discussion
The rats used in this experiment all had ascites, 
spl eno mega ly  and h i s t o logical  and bi ochemical  evidence  of 
hepatic cirrhosis. It was felt that the c o m b i n a t i o n  of 
abnormal liver fu nction and the a r t e r io ve nous and 
por tas yste mi c shunts known to exist in cirrhosis (243) might 
well cause a dif fe rent rea cti on to SMS 201 -995 than in 
animals with ext r a h e p a t i c  portal hypertension. A. shorter 
exp erimental and infusion time was chosen since p r o l on ging 
the previous e xp er im ents had been of no obvious benefit. 
Despite this shorter drug infusion, adequate levels of SMS 
201-995 were achieved.
This expe riment  showed no change in systemic blood pr essure 
or portal pre ssu re after SMS 201-995 infusion and no 
consistent change in %p o r t a s y s t e m i c  shunting after SMS 
201-995 infusion.
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DI SCUSSION
In con cl us ion, this series of e xperi me nts has shown that 
SMS 201-995 does not have significant  systemic h aemod yn amic 
effects in rats. It has not been possible to de mo n s t r a t e  a 
significant r e d u c t i o n  in portal pressure in normal rats, 
rats w it h e x tr ahepati c portal hyp er t e n s i o n  or ci rrh oti c 
rats.
There are several possible expla nations for the lack of 
effect of SMS 201-995 on portal pressure in these 
e xp eri men ts. Firstly, the change in portal pressure may be 
small and thus diffi cult to de mon strate with small numbers 
of animals. However not even a trend towards a fall in 
portal pressure was seen. Secondly, the method of m e a s u r i n g  
portal pressure may not be sensitive enough, but di ff e r e n c e s  
in portal pressure be tween normal, portal vein ligated and 
cirrho tic  rats have been shown whi ch are cons istent with  
previous work ( 7 , 1 3 1 , 2 0 3 , 2 3 0 , 2 4 4 , 2 4 5 )  and since the 
e x p e rimen ts  reported here, red uc tions in porta l venous 
pressure in cirrhotic rats given p roprano lo l have been 
d e m o n stra te d (un published  obser vat ions). Thi rd l y ,  the 
p os si bility  that the effect of SMS 201-995 is being reduce d 
because the prepa ration is ac tually  a
h a e m o r r h a g e d - t r a n s f u s e d  model (242) has arisen. This may be 
the case in the first 3 day post portal vein li g a t i o n  group 
but in the later exp er im ents there was little ev i d e n c e  of 
haemorrhage in the rats used either during c a n n u l a t i o n  or
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thereafter. Fi na lly  it may be that SMS 201-995 does not 
c o n s i s t e n t l y  cause a s ign ificant r e d u c t i o n  in portal
pressure in rats. Jenkins and colleag ues (131), in rats made 
cirrh oti c using d i m e t h y l n i t r o s a m i n e  and anaes t h e t i s e d  with  
p e ntob ar bi tal, d e m o n str at ed a red u c t i o n  in portal pressure 
after in travenous in fu sion of l-4;ug/kg/hr of SMS 201-995 for 
20 minutes. Cerini et al (240) showed no s i g n ific an t 
r e d u c t i o n  in portal pressure in normal rats but s ig nifican t 
effects at higher doses in portal hypertensive rats. In 3
week post partial portal vein ligated rats a s i g n if ic ant
re d u c t i o n  in portal pressure was shown with  doses of 
4jjg/kg/hr and above and in 4 week post bile duct ligated 
rats a signific ant red u c t i o n  was shown with doses of 2
>ig/kg/hr SMS 201-995. The m e a s u re me nts in Cerini and 
colleagues experim ents were performed in u n a n a e t h e t i s e d  
animals.
The di fferen ce s between these groups results and the 
results reported here may well be ex plain ed by d i f f e r e n c e s  
in the models of portal hy per t e n s i o n  used and by di ff e r e n c e s  
in an aes thesi a. Bile duct ligation is a model of s e c o n d a r y  
biliary cirr hosis and causes jaundice (246). The reduced
liver function  in these rats com par ed to our c a r b o n  
tet ra ch loride  treated rats, only two of which had a plasm a 
bilirubin greater than 30>imol/1 , may have caused red uced  
m e t a b o l i s m  of SMS 201-995 and thus increased any effect
(247). The D M N A  model of cirrhosis uses a k n o w n  c a r c i n o g e n  
as the agent causing hepatic damage and nodule format io n was
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not rep or te d in all rats treated in a study by Jenkins et al
(248), a l t houg h portal h y p e r t e n s i o n  d e v e l o p e d  with ascites. 
These d i f f e r e n c e s  in the models of c i r r h o s i s  may account for 
the d i f f e r i n g  results reported.
Pre vio us work has shown that p e n t o b a r b i t a l  a n a e s t h e s i a  
alters systemic and s p l a nchnic haem od y n a m i c s  in bile duct 
ligated rats(2 47 ). P e n t o b a r b i t a l  also re duces c i r c u l a t o r y  
re s p o n s e s  to hae morrha ge  (249) and to b e t a - b l o c k a d e  (250). 
H a e m o d y n a m i c  d i f f e r e n c e s  be tw ee n c o n s ciou s and hal othane 
a n a e s t h e t i s e d  rats have not been studied but it is possible 
that hal ot ha ne has altered the response to SMS 201-995. It 
is t h e refor e d i f f i c u l t  to com par e results of h a e m o d y n a m i c  
studies which have used di ff erent me th od s of a n a e s t h e s i a  and 
this may be another factor cau sing a p p a r e n t l y  c o n t r a d i c t o r y  
r e s u l t s .
In summary, no clear ev id ence of a r e d u c t i o n  in portal 
pressure or a l t e r a t i o n  in splanch nic h a e m o d y n a m i c s  due to 
SMS 201-995 has been d e m o n s t r a t e d  in our animal model. In 
view of this, further e l u c i d a t i o n  of the mode of a c t i o n  of 
SMS 201- 995 in this model is clearly im pr a c t i c a l .
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CH AP TE R 7
A COMPA RI SON OF THE E F F IC ACY OF SMS 201-995 AND OESO P H A G E A L  
T A M P O N A D E  IN THE CONTROL OF ACUTE VARICEAL HAEMORRHA GE .
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INTRODUCTION
Hav ing est ab lished  that SMS 201-995 causes a 30% r e d u c t i o n  
in portal pressure in a group of stable cir rhotic patients a 
co nt rolled cl inical  trial was commenced to assess its
e f f ic ac y in active va riceal bleeding. N a t u r a l l y  o c c u r r i n g  
s o m a t o s t a t i n  has been compared to v a s o p r e s s i n  for the 
control of variceal bleeding in two cl in ical trials (4,5) 
and was thought to be at least as ef fec tiv e as v a s o p r e s s i n  
but with less s i d e - e f f e c t s . Howe ver  because of its
i ns ta bil ity in solut io n and its very short half-life,
prac tic al problems arise during its ad minist ra tion. Rebound 
ph eno me na have also been observed at the end of intr av enous 
infusions of s o m a t o s t a t i n  (251). Since SMS 201-995 is a
lo ng-acti ng octape ptide  with a half-life of 45 minutes in
plasma it might well be a more useful drug. No rebo und
phe no mena  have been observed after SMS 201-995 in fusio n and 
its effect on insulin levels is small and s h o r t - l a s t i n g  in 
c o m p a r i s o n  to its other effects (6).
In this clinic al  trial the results of treatment wit h SMS 
201-995 have been compared with those of treatment with the 
M i n ne sota m o d i f i c a t i o n  of the Sengsta ke n Blakemore tube. In 
the Un iv e r s i t y  Department of Surgery, G l a s g o w  Royal
Infirmary, oesophagea l tamponade has been the standard means 
of co ntrol of active variceal bleeding for the past eight 
years. As reported in Chapter 2, a recent r e t r o s p e c t i v e
r evi ew of the results shows a 94% bleeding cont rol rate in 
126 bleeds from oesoph ageal varices with a 10% inc idence of
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chest i n f e ctio n as a complicati on. Al t h o u g h  c o n trol of 
bleeding with oes op hageal tamponade is good the incidence of 
co mp l i c a t i o n s  is signific ant and the tube causes 
con sider ab le  di sc omfort  to the patient. SMS 201-995 has not 
been ass oc ia ted with any sig nificant sid e- effects  in 
patients treated for acr ome ga ly (252) or carci noid syndrome 
(253). If cont rol of variceal bleeding with SMS 201-995 is 
co mp arable to that achieved with tamponade then this drug 
might achieve a signif ica nt improvement in the man a g e m e n t  of 
varic eal  bleeding.
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PATIENTS AND METHODS 
Forty patients were included in the study. At e n tr y all 
patients had en d o s c o p y  proven active bleedin g from 
o es op hageal  varices, of such a degree as to requ ire  blood 
transfu sio n. Portal hypertensive patients with ble edi ng from 
other sources were exclud ed as were patients who had had a 
m y o c a r d i a l  infarc ti on w i t h i n  the last six months, patient s 
with renal failure requ ir ing dialysis  and patients wit h 
insu lin  dep endent diabetes mellitus.
Fol lo wi ng adm ission to hospital with a suspected v a r i c e a l  
bleed, patients were resus cit ated with blood and plasma and 
fibreoptic en doscop y under sedation was performed w i thin two 
hours. Prior to e n d os co py  the trial was exp la ined and verbal 
consent obtained from either the patient or a rel ative. This 
study was approved by the Ethical Committee of the Royal 
Infirmary, Glasgow. H a v i n g  confirme d active bl ee ding from 
oesophag eal varices patients were ra nd omi sed to trea tm ent  
with SMS 201-995 or oesoph ageal tamponade using numbered 
sealed envelopes. The severi ty of the bleed was graded by 
the end o s c o p i s t  as mild, moderate or severe dep e n d i n g  on the 
endosco pi c findings and the patient's c l i nic al  state on 
admission. The amount of blood transfused prior to e n d o s c o p y  
and the time from the start of overt bleeding  was recor ded. 
Patients treated with SMS 201-995 were given an i n t r ave no us 
infusion of 25ug/hr SMS 201-995 in 120ml normal saline over 
48 hours via a syringe pump (Treonic IP4 , Vickers Medical). 
Patients rand omised  to oesophageal tampona de had the
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M i n n es ot a m o d i f i c a t i o n  of the Sengs ta ken Blakemore tube (4 
lumen) passed th ro ugh  the mouth or nose by an e x p e r i e n c e d 
member of me di cal  staff. The gastric ball oon  was inflated 
with 100ml of saline and 20ral of w a ter- so luble con trast 
medium. The oes ophag ea l balloon was inflated to 40mm  Hg as 
indic ate d by an anaeroid barometer and the tube gently taped 
in place. The tube position  was confi rm ed by chest X-r ay 
i mm ed iately  after i n s erti on  and the patient was c o n s t a n t l y  
sup erv ised by a trained nurse who aspirated the gastric and 
phar yng eal lumina of the tube hourly. Between a s p i r ation s 
the lumina remained on open drainage. The tube was left in 
place for 24 hours with both balloons inflated. At 24 hours 
the o e s o p hagea l balloon was deflated and the tube un taped so 
that the gastric balloon lay free in the stomach. If further 
bl eed in g occurred the oesophageal ball oon  was r e - i n f l a t e d  
and the tube taped as before. The tube was removed at 48 
hour s .
The standa rd general measures used to treat varice al  
bleedi ng were employed in all patients. Blood and plasma 
were used for volume and red cell rep la cement.  V i t a m i n  K, 
fresh frozen  plasma, platelets and/or c r y o p r e c i p i t a t e  were 
given as approp ria te if a c o a g ulatio n defect was found at 
the time of the bleed. Oral lactulose and regular bowel 
washou ts were used to try to prevent e n c eph al opathy.
All patients were c l o sely monitored with hourly blood 
pressure, pulse, urine volume and te mpera ture me a s u r e m e n t s . 
Patients in the SMS 201-995 arm had a n a s o - gas tr ic tube
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passed to monitor gastric aspirations hourly.
At the end of the trial period all patients und er we nt a 
further fibreoptic e n d o s c o p y  under se dat i o n  to assess 
control of bleeding and to per form inje ction  sclerotherapy .
All patients had clinic al  e x a m i n a t i o n  and the following 
i n vest ig at ions performed at 0 and 48 hours: full blood
count, c o a g u l a t i o n  screen, urea and elec tr olytes,  r a nd om  
glucose, liver fu nctio n tests, plasma proteins,
ga mma-glut  amyl transf erase, urate, chol e s t e r o l  and arteria l 
blood gases. An e l e c t r o c a r d i o g r a m  and chest X-ray were 
per formed at the begi nning  and end of the 48 hour period. 
Pugh's m o d i f i c a t i o n  of Child's grading was assessed at 0 and 
48 hours for eac h  patient. In addition, full blood count and 
serum glucose were rep ea ted 12 hourly and u re a and 
elec t r o l y t e s  and liver function tests rep ea ted at 24 hours. 
Two suc ces sive cr eatinine clearance m e a s u r e m e n t s  were also 
performed. Clinical exa minati on , chest X-ray and art er ia l 
blood gases were repeated at 72 hours and 7 days from 
ad missi on  to the trial. Fluid balance and re qu i r e m e n t s  for 
blood and blood products were recorded, along with pulse and 
blood pressure m e a s u r e m e n t s  at 12 hourly intervals.
C e s s a t i o n  of bleeding was recorded at the hour whe n less 
than 20ml of fresh blood was aspir ated from the st o m a c h 
provided there was no other evidence of bleeding. Rebl ee ding 
was deemed to have occurred if one or more of the following 
c r i t e r i a  were fulfilled:
a) overt haemorrhage or aspir ation of more than 100ml fresh
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blood .
b) passage of fresh blood per rectum
c) fall in h a e m o g l o b i n  c o n c e n t r a t i o n  of more than 4g/dl 
w i thin  48 hours
d) shock (pulse r a t e > l 0 0 : systolic blood p r e s s u r e < 100 ) in 
the presence of c o n t inuin g melaena.
If either treatment failed to cont rol the bleeding or if 
re bl e e d i n g  occurred during  the 48 hours of treatm en t the 
patient was crossed over to the other treatment. Co ntr ol of
bleeding was assessed during the first 4 hours of the trial
period (recorded as initial control) and for the whole 48 
hour period (complete control). The further progress of the 
patient during that ad mission  to hospital was recorded, with  
p ar tic ula r regard to survival and cause of death.
Sym ptomatic side- eff ects were assessed by enquiry from the 
patient and nursing staff. Evidence of chest i n f ection was 
looked for c a r ef ul ly by means of clinica l e x a m in ation,  
serial chest X-rays and blood gases and was deemed to be 
present if any of these parameters became abnormal,
co ns is tent with a chest infection. Other co m p l i c a t i o n s  were 
reco rd ed  as they arose.
Comp ar is ons of the two groups with regar d to age, 
p r e a d m i s s i o n  blood tra nsfusion, time to ble ed ing control, 
amount of blood transfused  and creatin ine  cle aranc e values 
were carried out using the student's t-test. C om parison s of 
the d i s t r i b u t i o n  of sex, aetiology, mo di fied Chil d's  
grading, number of patients who had p r e - a d m i s s i o n  blood
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transfus ion , number of first bleeds and cont rol rate at 48. 
hours were performed using Chi-squared tests.
Bleeding contro l rate at four hours, number of rebleeds, 
number of cr ossovers and survival were com pa re d us ing  
Fischer's exact test. p<0.05 was tak en as the level of 
s t a t is ti cal significance.
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RESULTS
The results of this trial are summarised in Ap pendice s 9 
and 10. 40 episodes of e n d o s c o p i c a l l y  proven active variceal  
b lee ding were included. Over the 23 months during w h i c h  the 
trial was ru nn ing  (1/7/86 - 31/5/88) 56 bleeds in 41
patients were excluded. On each of these occasions a patient 
was admitted withi n 48 hours of haematemesis or m e l a e n a  
wh ic h was thought to have been from o es ophage al  varices. The 
reasons for excl us io n from the trial are shown in Table 22. 
13 of these excluded bleeds proved fatal, either due to the 
bleed itself or its co mpl ications.
40 bleeds in 31 patients were included in the trial. 20 
bleeds were ran domis ed  to oes oph ag eal tampo nad e and 20
bleeds were rand omise d to treatment with SMS 201-995
infusion. These two groups were compar able with regard to 
sex ratio, age and ae ti ology of portal h y p e r t e n s i o n  (Table 
23), and though the oeso pha geal tamponade group had more 
modified Child's C grade patients than the SMS 201-995 
group, this differe nce  was not s t a t i s t i c a l l y
signifi ca nt(p<0. 3) .
The ch a r a c t e r i s t i c s  of the variceal bleeds included in this 
trial in terms of the number of first bleeds from varice s, 
the est im ated se verity  of the bleed, the time from its
initial m a n i f e s t a t i o n  and the amount of blood t r a n s f u s i o n  
given before a d m is si on to the trial were similar in the two 
groups, as shown in Table 24.
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Control of bleeding 
Bl eed ing was con trolled over the first four hours after 
admis si on to the trial in 19 of 20 patients treated with 
oesophageal tamponade and 18 of 20 patients treated with SMS 
201-995 infusion. This diff erence is not s t a t i s t i c a l l y
signif ica nt (p<1.0). The bleed not controlled by tamponade 
was crossed over to SMS 201-995 infusion at two hours but 
this also failed to control the bleeding. It was con tr olled 
by in jection scle r o t h e r a p y  but the patient died of 
he pat orenal failure at 40 hours from adm ission to the trial. 
This patient had a very poor prognosis on admission, having 
Grade III e n c e p h a l o p a t h y  and a prothr ombin time of 40 
seconds (72). The two bleeds not control led by SMS 201-995 
infusion during the first four hours were crossed over to 
oesophageal tamponade, whi ch controlled the bleeding.
In 15 bleeds oe so phageal tamponade con tro lled the bleedin g 
imm ed ia tely (Ap pendix 9) althoug h small amounts of fresh
blood were aspir ated from the sto mach for several hours in 
four bleeds. In 11 bleeds SMS 201-995 infusion  cont rolled 
the ble edi ng withi n the first hour with seven bleeds taking 
longer to settle (Appendix 10). This dif fe re nce in time to 
control of ble eding is not sta tistica ll y s i g n i fi ca nt 
(p<0.34 ) .
Over the 48 hour trial period, two patien ts in the
o eso phageal  tamponade group died, the patient me ntioned  
above whose bleedi ng was uncontrol le d by tampo nade and SMS 
201-995 infusion, and one other patient who died at 4.5
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hours from adm is si on due to hepatorenal failure. In 14 of 
the other 18 bleeds in the oe sopha geal tamponade group there 
was no rebleed ing over this time. In two bleeds rebleeding 
occurred during the first 24 hours when the o es ophagea l 
balloon should have been inflated, but in one case this had 
been a c c i d e n t a l l y  deflated and in the other the o esophag ea l 
balloon had burst, despite once only use. Two other rebleeds 
occurred during the second 24 hours when the o e s o ph ag eal 
balloon was deflated. All four of these rebleeds were ea sily 
controlled by either re -in flati on of the oesop hageal balloon 
or the inser tion of a new Mi nn esota tube in the case where 
the balloon had burst. Therefore no bleed required cr oss ove r 
to SMS 201-995 infusion because of rebleeding. In the SMS 
201-995 group there was no rebleeding in 10 bleeds. In eight
bleeds there was evidence of rebleedin g but in four cases
this settled withou t treatment. Four bleeds required
cro ssover to oesoph ageal tamponade and the bleeding was
controlled by this in each case. The dif fer ence in 48 hour 
bleeding control rate is not sta ti s t i c a l l y  signifi cant
( p < 0 . 1 ) .
The 20 bleeds in the oesoph age al tamponade group required a 
mean of 1680mls (sem 295mls) of blood tr an sfusion over the 
trial period while the 20 bleeds in the SMS 201-995 group 
required a mean of 1710mls (sem 252mls). There is no 
st atistic ally sig nifi ca nt diff ere nce between the groups 
(p = 0.4 ) •
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C o m p l i c a t i o n s
In the total of 21 bleeds treated with SMS 201-995
infusion, no patient complained of any s ym pt omatic
side -effects . One patient who was a ma tu r i t y  onset diabetic 
required an intravenou s infusion of soluble insulin 1-2
units/hour to mainta in  his plasma glucose at less than
15mmol/l but this control led  the plasma glucose level which 
remained stable when the SMS 201-995 infusion was stopped. 
No other patient required insulin infusion despite the fact 
that two other bleeds in the SMS 201-995 group occ urr ed in 
maturit y onset diabetics.
In 15 of the bleeds treated with oesophageal tamponade two 
cr eatinine clearance es timatio ns were made. The mean of the 
mean creatin ine  cle arance values for these patients was 106 
ml/m i n ( s e m  10). The mean creatinine clearance rate in 16 
patients treated with SMS 201-995 infusion was 84 m l / m i n ( s e m  
9). The values for the two groups are not s i g n i f i c a n t l y  
d i f f e r e n t ( p < 0 . 5 ) .
Chest infection developed after 17 of the 39 bleeds 
evaluable. The patient who died at 4.5 hours has not been 
included in this considation. The details of tr eatment and 
the inc idence of uncontro ll ed of recurrent bleeding in these 
cases are shown in Table 25. There is a s ig nifican t  
associa ti on  betw een chest infection and reblee di ng (p<0.05) 
but no a s s o ci at io n between chest infe ction and treatment 
with oes op ha geal tamponade (p<0.3). In the seven bleeds
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where chest infect io n only developed after the second 
endoscopy, four endo sc opies had been per formed with the 
rigid o e s o p h a g o s c o p e , giving an inc idence of four chest 
infections d e v e lo pi ng in seven p re viousl y n o n - i n f e c t e d  
patients compared to three chest infections d e v e l o p i n g  after 
21 fibr eo ptic second endoscop ie s in n o n - i nf ec ted patients. 
This differe nc e is sig ni ficant (p=0.043).
In the 26 bleeds treated at some time by oeso phage al  
tamponade, 22 patients co mp lai ned of disc omfor t caused by 
the M i n n es ot a tube. All of the other four patien ts had 
hepatic en ce phalo pathy.
Survival
None of thie 20 bleeds in the SMS 201-995 group proved 
fatal, in comp ar ison with five deaths from the 20 bleeds in 
the o es op hageal tamponade group. This d i f f erence just 
reaches stat is tical  si gni fican ce (p=0.047).
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T a b 1 o 7 2 -  The re.isnns for exc 1 us i.o n from the (; r i a ] of 5 6
o t h o r b 1 e e rl s t hmi g h t. to be f r o ri o e s o p h n g e a 1 varices.
N o  a c t i v e  b l e e d i n g  a f t e r  a d m i s s i o n  1 ]
Trans fer  from another hospital with 11
Mi nnesota tube in place
Danger of e x s a n g ui nation  - tamponade 5
instituted before endos copy possible
Moribu nd on admis si on and could not 2
be resusci tated
Wrong initial diagn os is of 1
M a 11 ory-W eiss tear
No active treatment - terminal disease 4
Em ergency inj ection scl erothe ra py 1
Excluded in error because 1
of age
Total 56
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Table 23 - Patient c h a r a c te ri stics for the two groups
treated with oeso phageal  tamponade or SMS 201 -995 infusion 
for active variceal bleeding.
Sex ratio 
(M: F)
Age
(me an± s era)
Ae tiology
Al co holi c cirrhosis 
Primary bili ary cirrhosis 
Chronic active He patiti s  
Cry ptoge ni c cirrhosis 
Sclerosin g cholan gitis 
Drug induced cirrhosis 
Cong en ital hepatic fibrosis
Pugh's m o d i f i c a t i o n
of Child's grade 
A 
B 
C
OESOPHAGE AL  SMS 201-995 p
TA M P ONADE IN FUSION
16:4 18:2 >0.5
51.6+3.3 4 9.9+3.5 <0.7
13 15
1 1
3 0
3 1 <0.5
0 1
0 1
0 1
1 2
4 8 <0.3
15 10
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Table 2 4 - Ch a r a c t e r i s t i c s  of the bleed for the two groups 
treated with oesop ha geal tam ponade or SMS 201-995 infusion 
for active va ricea l bleeding.
N u m b e r  of f i r s t  b l e e d s
Seve rity 
Mild
M o d e  rate 
S e v e r e
Hours from start of 
over t bleed ing 
(me an + s e m )
O ESOPH AG EAL
TA MPO NA DE
SMS 201-995 
I NFU SION
13
4
3
1 1 
7 
2
20.5+4.2 17.9+3.6
Number of patients 
tr ans fused before
ad mis sion to trial 11 9
Mis of blood transfu sed 
per patient tran sfuse d
before adm ission to study 1464+308 1867+291
(m e a n ± s e m )
P
<0.3
<0.6
< 0.6 
<0. 5 
<0.6
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Table 2 5 - Incidence of chest Infections in com pari so n with 
type of treatment and occurr ence of rebleeding.
CHEST TOTAL NUM B E R
INFECTION OF PATIENTS 
IN GROUP
SMS 201-995 i n f u s i on -t otal group 7 20
Oes ophageal ta mp onade-t otal group 10 19
SMS 201-995 infusi on alone 4 14
SMS 201-995 and tamponade 4 7
Oesophageal tam ponade alone 9 18
Unc ont roll ed  bleeding  or rebleeding 10 15
No furt her bleeding 7 24
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DISCUSSION
In this trial a 25>ig/hr intravenous infusion of SMS 201-995 
co nt r o l l e d  bleeding du ring the first four hours of tre atment 
in 18 of 20 patients with  active ly bleedi ng o e s o p h a g e a l  
varices. However the co ntrol rate had fallen to 50% by 48 
hours. Oes opha ge al  tamponade was able to control more bleeds 
without crossover, a l t ho ugh this di ff ere nce did not r e ach 
s t a t istic al  signi ficance.
The bleeds included in this trial formed 42% of all 
var ic eal bleeds treated in the unit while the study was 
ongoing. Since five patients with e x s a n g u i n a t i n g  ha emorrha ge 
were trea ted with tamponade in the Accident and Emergen cy  
Depart men t and two other patients with very severe bleeds 
could not be r e s u s c i t a t e d  on arrival in the ward, the 
patients with e x t r em el y severe bleeds may have been missed. 
On the other hand 31 patients who were admitted with a 
history of hae matemesis and/or melaena but who had no active 
bl eedin g at end os co py or recurrence of bleeding in hospit al  
were also excluded. These latter patients repre se nt the 
mildest var iceal bleeds.
Because of the e x c l u s i o n  of the seven patients wit h very 
severe bleeds, four patients in whom no active treatme nt was 
felt to be app ropriate and elev en patients t r a n s fe rr ed after 
initial tr eatment  el sew her e who might also form a higher 
risk group, the mo r t a l i t y  rate for the 40 bleeds include d 
was lower (12.5% of bleeds) than the overall m o r t a l i t y  rate 
of 18.7%. The fact that the most severe bleeds had a
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t en de ncy to exclude the mse lves from this trial is worth 
c o n s i d e r a t i o n  since it implies that alt ho ugh drug treatment 
for va ricea l bleeding may become the preferred means of 
initial treatment, a number of very severe bleeds may still 
require tamponade. This has implicat ions in terms of 
avai l a b i l i t y  of the skilled staff and the equipment  
ne c e s s a r y  for good results with oe sophagea l tamponade (83).
Two previous cont rolled  clinical trials have compared the 
n a r u ra ll y occurring te tr a d e c a p e p t i d e  s o m a t o s t a t i n  with 
v a s o p r e s s i n  in va riceal bleeding. Kravetz et al (4) 
randomi se d 61 cirrhotic patients with variceal bleed i n g  to 
48 hours of treatment with a varying dose of v a s o p r e s s i n  by 
intraven ou s infusio n (star ti ng at 0.4 u n i t s/m in ) or a bolus 
i n j e ct io n of 50>ig of s o m a t o s t a t i n  followed by an intrav enous 
in fu si on of 250;ug/hr, rising to 500>ig/hr if necessary. 
Patients who continue d to bleed were w i t h d r a w n  from the 
trial. 23 of 31 patients' bleeds were initi al ly co nt r o l l e d  
by v a s o p r e s s i n  but this had reduced to 18 of 31 at 48 hours. 
26 of 30 patients' bleeds were initi al ly c o n t r o l l e d  by 
so m a t o s t a t i n  but this had fallen to 16 of 30 bleeds by 48 
hours. Jenkins et al (5) entered 22 patients into their 
rand o m i s e d  cont rolled clinical trial com p a r i n g  re d u c i n g  
doses of v a s o p r e s s i n  by intravenous infusion or a 250/ig 
bolus inj e c t i o n  followed by an intr av enous in f u s i o n  of 
250>ig/hr of s o m a t o s t a t i n  over 24 hours. This st udy  was 
similar to that of Kravetz and coll eagues in that pati ents  
who c o n t inued  to bleed were wit hdrawn. Bleeding was
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con tr olle d over 24 hours in all 10 patients treated with
s o m a t o s t a t i n  but in only 4 of 12 patients treated with
vas opressin.
The results of the present study with regard to bl eeding
contr ol using SMS 201-995 are therefore similar to the
results of Kravetz et al(4), thoug h inferior to those of the
Li verpo ol  group (5). Since we have shown a d e t e r i o r a t i o n  in
cont rol  of bleeding with time, the difference in results may 
be due to the longer trial period in both Kravetz and 
colleagues' study and the present study. In Jenkins et al's
study s o m a t o s t a t i n  was only given to ten patients and the
small numbers in the various studies may give rise to
spurious dif ferences.
The pra ctical benefits of the longer acting analogue used 
in the present study lie in its greater sta b i l i t y  in
s ol ut ion and longer half-life, which reduce the di ffi c u l t i e s  
of int ra venou s infusion. From the study of the effects of
SMS 201-995 on portal pressure in stable cirrhot ics (Chapter
3) it is kno wn that after a 60 minute inf us ion of SMS 
201-995, tra nsh epati c venous gradient is s i g n i f i c a n t l y  
reduced. If this re d u c t i o n  is suff ici ent to be of cli ni cal 
importa nce  in st opping variceal haem orr hage, haem orrhage 
should cease wi thi n the first few hours of infusion. 11 of 
the 18 bleeds controlled by SMS 201-995 stopped w i t h i n  the 
first hour. The cause of the rec urrent bleeding du rin g SMS 
201-995 infusi on  might be ta chyphyl axis to the treatment. 
Ta c h y p h y l a x i s  has been described for v a s o p r e s s i n  (254) and
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an early synthetic analogue of vasopressi n,  o c t a p r e s s i n
(255) and it has been suggested (242) that it occurs because 
of d e s e n s i t i s a t i o n  of vas opr es sin recep tors induced by the 
e n d o genou s va so p r e s s i n  secreted in response to haemorrh age. 
Because of the changes which are seen in spl anc hnic
ha emo dy na mics after si gni ficant haemorrhage, it may be that 
t a ch yphyla xi s to s o m a t o s t a t i n  and its analogues also occurs. 
No re bo und  phenomena, such as rec urre nc e of va riceal  
haemor rha ge after stoppi ng so mat o s t a t i n  infusion, were 
observed in our patients, but it is possible that these
effects were di sguised by the effect of s c l e r o t h e r a p y  in 
c o n t r o l l i n g  bleeding. No di sturb ance of blood glucose levels 
was f ou n d .
A new treatment for any illness can be compar ed with either 
pl acebo or the current best means of treatment. It was felt 
that a c o m p a r i s o n  between SMS 201-995 and placebo was not 
j us tified on et hical grounds and a c o m p a r i s o n  wi t h  the 
previous best means of treatment in our dep a r t m e n t  has 
ther efo re been made. Previous controlle d trials in variceal  
ble edi ng have achieved variable cont rol rates with placebo - 
ra nging  from 25% at 24 hours (2), t h r ou gh 37% at 8 hours 
(77) to 45% at 24 hours (88). However strict c o m p a r i s o n  of 
trials is dif ficult because of diff er ences  in the s e v e r i t y  
of bleeds included, in the accuracy of diagnosis,  in the 
means of con serv ative  treatment, in the length of time of 
the trial period and in the me tho ds used to assess the 
results .
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In Chapter 2 it was shown that o e s o pha ge al tamponade 
achieved con trol of bleeding in 94% of patients treated in 
the Un iv ersity  Department of Surgery, G l a s g o w  Royal 
Infirmary. Stricter cr i t e r i a  of co ntrol were used in the 
current prospective trial in which the o es ophage al  b a ll oon 
was deflated during the second 24 hours of treatment in the 
tamponade group. This resulted in a lower con tro l rate of 
78% wit h tamponade at 48 hours, althou gh  control could be 
ea sily regain ed by r e i n f l a t i o n  of the o e s o phageal  balloon. 
The initial bleeding control rate with tamponade rema ins 
high, and it is matched by a high initial bleeding  c o n trol  
rate with  SMS 201-995 infusion.
A l t h o u g h  oes op ha geal tam ponade has proved an eff ectiv e 
means of con trol of variceal  bleeding in the past, it has 
se veral potential serious side-effects and a c o m p a r i s o n  of 
the incidence of si de-effects in the two groups in this 
trial is of consider ab le importance. Despite the fact that 
s o m a t o s t a t i n  plays a role in blo cking both ins ulin and 
g l u c a g o n  release at p h y s i ologi ca l levels (114) only one 
patient developed an abn orm al ity of glucose home os tasis  
d ur i n g  SMS 201-995 in fu sion and this was con tr ol led easily. 
Vora et al (130) has reported a r e d u ction in renal fu nc ti on 
due to som ato statin. In patients with portal h y p e r t e n s i o n  
and act iv el y bleeding varices many factors can influence a 
r e l a t i v e l y  simple meas uremen t of renal functio n such as 
c re at inine clearance but there was no d i f f er ence in 
c r e a tinin e clearance rates in the two groups of patients.
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Furth erm ore, no patient posed clinic al problems wit h renal 
fun cti on while re c e i v i n g  an infusion of SMS 201-995.
Previous reports r e g a rding the use of oeso phageal tamponade 
have e m p h asis ed  the risk of chest c ompli ca tions with  this 
treatment. Novis et al (69) noted eight chest inf ections in 
40 bleeds while Conn et al (82) rep or ted eight cases of 
a s p i r a t i o n  and one case of r e s p i r a t o r y  o b s t r u c t i o n  in 40 
bleeds. If this incidence of chest in fe ction was ass oc ia ted  
with tam ponade alone, a re d u c t i o n  in this c o m p l i c a t i o n  would 
have been expected in the group of patients treated with SMS 
201-995 infusion  only. This study has shown (Table 25) that 
chest infec ti on  was associa ted  s i g n i f i c a n t l y  with r e b l e e d i n g  
or c o n ti nued bleeding but not with tamponade. Furtherm or e, 
the use of the rigid oesoph agosco pe  for i n j e c t i o n 
s c l e r o t h e r a p y  appearred to increase the risk of the patient 
d e v e l o p i n g  a chest infection. The finding that o e s o p h a g e a l  
ta mpo nade was not ass ociated with an increased risk of chest 
i n f e c t i o n  is in itial ly surprising in view of the previous 
reports of this c o m p l i c a t i o n  (82,2 11 ,69,1 ). However in these 
se v ere ly  ill patients there are a number of factors whi ch 
might increase the risk of chest infection. Vomiting, 
end o s c o p i c  procedures, sed at ion and e n c e p h a l o p a t h y  might all 
be to blame and these are difficult to separate in a study 
with r e l a t i v e l y  few patients.
In the present study, discomf ort from the Min n e s o t a  tube 
was a major com plaint in 22 of the 26 patients treated with 
tamp on ade and this dislike of tamponade c o n t raste d m a r k e d l y
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with the lack of sympt omatic side-eff ec ts in patients 
treated only wit h SMS 201-995 infusion. It is also worth 
c o n s i d e r i n g  that the a d m i n i s t r a t i o n  of a drug in fus i o n  
requi res  less expertise on the part of the nursing and
medic al staff than oe so phageal tamponade. This may be a 
sign if ic ant advantage in hospitals where r e l a t i v e l y  few 
patients with bleeding varices are seen and an SMS 201-995 
inf u s i o n  may buy time for the pat ient's safe transfer to a 
specialis ed  centre.
The m a i n  aim of this trial was to assess the effect of SMS 
201-995 on bleeding from oe sophageal  varices and the finding 
of a higher survival rate in the SMS 201-995 treated group 
of patients was unexpe cted.  There was a higher number of
patients with poor liver function in the tamponade group and 
al t h o u g h  this difference in the modified Child's grading was 
not s t a t i s t i c a l l y  si gnifica nt both the non - s i g n i f i c a n c e  of 
the differ en ce in Child's grade and the signifi ca nce of the 
differe nc e in survival may be art efactua l due to the small 
numbers. However this area merits further i n v e s t i g a t i o n  
since liver function is well e s t a b l i s h e d  as the m a i n  
influence of survival (148) after varic ea l bleeds and SMS 
201-995 has been reported to improve the function of various 
organs in animals. It has been rep orted that nat u r a l l y  
occurri ng  s o m a t os ta tin may have c y t o p r o t e c t i v e  pro per ti es 
and prevent the d evelop me nt of hepatic and gastric lesions 
in rats (256). It was reported also to stim ulate  the
r e t i c u l o - e n d o t h e l i a l  system in rats (257). Work from
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L iv erpool has shown that SMS 201-995 also stimula tes the 
re t i c u l o e n d o t h e l i a l  sy st e m  in rats (133) and reduce s the 
effects of e n d o t o x a e m i a  in rats (134). Work on the human 
r e t i c u l o - e n d o t h e l i a l  sys te m with s o m a t o s t a t i n  or its 
analogue has not been published. However there is a 
po ss i b i l i t y  that such an effect on the r e t i c u l o - e n d o t h e l i a l  
s yst em might lead to improved survival since it is k n o w n  
that the r e t i c u l o - e n d o t h e l i a l  syste m is abnormal in liver 
dise ase  ( 258 ) .
In concl usi on, inf usion of SMS 201-995 would appear to have 
c e r t a i n  adv antages over oes ophag ea l tamponade for the 
immed iat e control of bleeding oe so phageal varices, wi t h  any 
r e d u c t i o n  in bleedi ng cont rol being offset by its better 
t o l e r a b i l i t y . However, control det eriorat es  with time and it 
is possible that its future role may be in the t e m por ar y  
co nt rol of bleeding while the patient is resu s c i t a t e d  before 
acute i n j ect io n scl er o t h e r a p y  is undertaken .
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CH AP TE R 8
CONCLUSI ONS
2 3 3
An episode of ble edi ng from o e s o p hag ea l varices has a 
mo r t a l i t y  rate of between 25 and 50% (69,60). Patients die 
not only because of in ability to co nt rol ble ed in g but 
because of compli c a t i o n s  of the bleed or its treatment. 
Hepatic failure is a major cause of death and is the most 
difficult  c o m p l i c a t i o n  to deal with. It is wor th noting, 
th er efore, that cont rol  of variceal bleeding  is only part of 
the m a n a ge ment of patients with portal hypertension.
The methods of con trol of varice al ble ed in g c u r r e n t l y  in 
use vary in their ef f i c a c y  and in their side-e ffects. No 
metho d is ideal.
R e view  of the literature reveals that it is possib le to 
cont rol  over 90% of varice al bleeds using o es ophage al  
tamponade (1) but this cont rol is temporary. Some worker s 
have found a high incidence of co mpl i c a t i o n s  (82), and this 
is thought to occur parti c u l a r l y  when tamponade is used by 
the in exp e r i e n c e d  (83). Alt ho ugh v a s o p r e s s i n  is wi dely used 
its major cardi ov as cular  side-effec ts are well kn own (3) and 
doubts about its e f f icacy have been raised (89). The 
c o m b i n a t i o n  of va so p r e s s i n  and v as od ilators  to try to reduce 
s i d e - effe ct s is not yet well es ta b l i s h e d  in cl i n i c a l  
practice, and the lon g-actin g triglycl v a s o p r e s s i n  has 
similar cardiac side-eff ec ts to the original analogue (105). 
Despite the fact that natural ly oc curring s o m a t o s t a t i n  has 
been shown to be at least as effecti ve as v a s o p r e s s i n  in 
co ntr ol of variceal bleeding (4,5) its short plas m a  
half-life and ins tabil it y in s o l ution  lead to pr a c t i c a l
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problems during the treatment of patients. Acute injection 
s c l e r o t h e r a p y  has the advantage of prov iding defi ni tive 
treatment and control rates of more than 80% have been 
reported by T e r b lanc he  (139). Howe ver s c l e r o t h e r a p y  is 
t ec hn ically di ffi cult in the presence of active bleeding.
This thesis the refore set out to examine oes opha ge al 
tamponade as one of the current means of control and then to 
assess the l ong-a ct ing so mat o s t a t i n  analogue SMS 201- 995 
with regard to its use in portal hypertension.
A r et rospec ti ve  review esta blished  that in the Uni v e r s i t y  
Dep ar tm ent of Surgery, Gl as go w Royal Infirmary, 92% of 
variceal bleeds can be initi ally controlled by o esop ha geal  
tamponade. Alt ho u g h  it was found that c o m p l i cat io ns were 
strongly ass oc iated with poor liver function, a si gn ificant  
incidence of serious c o m p l icati on s was recorded and the need 
for a better method of managing  acute varice al bleedin g was 
conf i r m e d .
In stable cirrh otic patients, an intravenous infusi on  of 
25ug/hr SMS 201 -995 has been shown to cause a 30% re du ction  
in tran shepa ti c venous gradient with no effect on systemic 
ha e m o d y n a m i c s  and no significant side-effects. These results 
led on to the study of the effects of SMS 201-995 in animal 
models of portal h y p e r t e n s i o n  and also formed the basis of 
the su bs equ ent studies in actively bleeding patients.
The results of the animal work using SMS 201-995 were 
di sappointi ng. No convinci ng re duction in portal pressure 
due to SMS 201- 995  could be d e m o n st ra ted in normal rats,
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rats wit h e x t r a he patic portal h y p e r t e n s i o n  or cirrhotic
rats. Since dif fe rence s in portal pressure be tw een normal
rats and the rat models have been dem o n s t r a t e d  and drug
effects have been shown using other com pounds,  it is
con cl uded  that in these animal models, anaesthe ti sed with
halothane , any effect of SMS 201-995 on portal pressure is 
m i n i m a l .
In the c ontrol le d trial c o m p ar ing SMS 201-995 with 
o e s o p h a g e a l  tamponade in active var ic eal ble eding, an 
in itial cont rol rate of 90% with SMS 201-995 was found in 
c o m p a r i s o n  to 95% with  oesopha geal tamponade. This c o n trol 
rate fell off to 70% at 24 hours and 50% at 48 hours
com pa red to 84% at 24 hours and 77% at 48 hours wi t h
oe sopha ge al  tamponade. All the bleeds which were 
u n c o n t r o l l e d  or where reb l e e d i n g  occurred with SMS 201-995 
were c ontrol le d by oesopha ge al tamponade. SMS 201-995 
t he refore probably gives a better bleedi ng cont rol rate than
might be expected wit h placebo (30% at 6 hou rs-F ogel,
1982(89); 3 7 % - F r e e m a n ,1986 ( 78)) and there is no 
s t a t i s t i c a l l y  signi ficant differe nce in the bleeding co nt rol 
rate b e t we en  the groups treated with SMS 201-995 and 
o esoph ag ea l tamponade. The main advantage of SMS 201-995 
tr eatme nt  in c o m p a r i s o n  with o e s o p ha geal tam po nade in 
a c t i v e l y  bleeding varices was its t o l e r a b i l i t y  to the 
patient. All conscious patients found that oeso p h a g e a l 
tampo nad e produced cons iderabl e disc omfort  while no symptoms
were rep or ted by the patients treated with SMS 201-995
236
infusion. Chest c o m p l i ca ti ons were more st rongly  rel ated to 
r e b l e e d i n g  ep isodes than to the means of treatment. This 
trial shows that SMS 201-995 may be usefu l in achievi ng  
initial cont rol of bleeding, ena bl ing r e s u s c i t a t i o n  of the 
patient before i n j e ct io n s c l e r ot he rapy is perf ormed  as an 
urgent procedure. If ble eding can be controlled wit h  SMS 
201-995 infus io n in je ction s c l e r othe ra py will be tech n i c a l l y  
easier and this should provide more defin it ive co ntr ol  of 
bl eed ing than is possible with  drug in fusion  or oeso pha geal 
tamp ona de a l o n e .
This work has sug gested several further lines of 
i n vest ig at ion. The treatme nt of acute varice al bleeds with 
SMS 201-995 inf us ion followed by urgent scler o t h e r a p y  needs 
as se ssme nt  in c o m p a r i s o n  with acute s c l e r o t h e r a p y  alone or 
t am ponade followed by acute scler oth erapy . Further 
i n v e s t i g a t i o n  of the mode of actio n of SMS 201-995 is 
appr opr iate. Since animal work has not been helpful, 
possib le methods for studying this in man should be 
exam ine d. Control of ble eding  varices is likely to be more 
c l o se ly  related to the pressure in or flow t h r o u g h  the 
varices themsel ves rather than to indirect mea s u r e m e n t s  such 
as tra nsh epat ic  venous gradient. Since the direct 
m e a s u r e m e n t  of i nt ra va ricea l pressure is now possibl e 
(2 59,2 6 0 , 2 6 1 )  and en dosco pi c Doppler flow probes have also 
been de ve lo ped to measure variceal flow n o n - i n v a s i v e l y  
(262,5 3) it would be useful to k n o w  the effect of SMS 
201-995 inf us ion on variceal  pressure and flow. The
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meas u r e m e n t  of azygos vein blood flow might also be a more 
releva nt m e a s u reme nt  than tr anshepatic venous gradient, 
since this will give a measure of the flow in at least some 
of the porta systemic shunts. This m e a s u r e m e n t  is now 
possible usi ng t h e r m o d i l u t i o n  techniques and sp ecially 
shaped catheters (263).
The d ev el op ment of an oral analogue of SMS 201-995 is 
u n d er way and once this is available further areas of use may 
be opened up. If it can be shown that l o n g -t er m oral SMS 
201-995 causes a r e d u c t i o n  in either portal pressure or one 
of the more specific shunt blood flow parameters dis c u s s e d 
above then a contro lled trial of its e f f i c a c y  in p r e v e n t i o n  
of re b l e e d i n g  from o es ophagea l varices will be worthwhile.
Our finding of an increased survival rate in patients with  
acute var iceal bleeding treated with SMS 201-995 deserves 
further in vestigati on. It has been su ggested  that SMS 
201-995 stimulates the r e t i c u l o e n d o t h e l i a l  syste m (133) and 
affords pro te ct ion from the effects of e n d o t o x a e m i a  (134). 
Patients with d e c o m p e n s a t e d  cirrhosis  are k n ow n to have an 
inc re ased  risk of bacterial infections because of re duced  
r e t i c u l o e n d o t h e l i a l  functio n (258) and low serum f i b r o n e c t i n  
levels have been shown to be a ss ociated  with a poor 
prognosis in cirrhotic patients (264). Thus SMS 201-995 may 
benefit the portal hypertensive patient in other ways than 
simply the red u c t i o n  of portal or va ri ce al pressure.
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A P P E N D I X  1
In dividual  patient data  for wedged hepatic venous pressure 
and tra nshe patic venous gradient with and without an 
i n t r aveno us  infusio n of 25(pg SMS 201-995 from 0 to 60 
minutes . Pressures shown in mmHg.
CO NTROL G R O U P
Wedged hepatic venous pressure T r a n s h e p a t i c  venous gradient
Patient 0 60 120 180 0 60 1 20 18 Omins
JB 15 15 16 17 9 9 8 9
JT 13 13 14 13 11 11 11 10
WR 1 1 12 13 15 4 4 4 5
RM 13 14 15 14 8 8 9 8
PL 14 16 14 17 8 10 8 9
DO 18 18 22 25 4 6 8 11
TM 20 * * * 18 * * *
MEAN 14 .8 14 .6 15. 6 16.8 8 .8 7. 8 8. 0 8.6
SEM 1 . 4 1. 1 1. 6 2.9 2. 1 1. 3 1. 1 1.0
SMS 201-995 GROUP
Wedged hepatic venous pressure T r a n s h e p a t i c  venous gradien t
Pat ie nt 0 60 120 180 0 60 120 18 Omi ns
RS 14 12 12 14 9 8 8 9
AG 20 18 * * 13 1 0 * *
FW 16 14 14 16 12 1 0 12 13
JL 24 18 19 19 16 1 2 13 12
AA 19 10 18 19 19 10 15 17
AS 13 14 * * 7 6 * *
BB 24 20 24 28 21 18 22 23
AF 21 12 24 19 16 5 18 13
TM 19 15 18 19 14 10 15 14
MEAN 18.9 14. 7 18. 5 19. 1 14 . 1 9. 9 14. 7 14.5
SEM 1 . 5 1. 3 2. 0 2. 0 1 . 7 1. 4 2. 0 2.0
* m i s s i n g  value due to te ch nical problems wi t h  equi pment.
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AP P E N D I X  2
Indi vidua l patient data for cardiac index and systemic 
vascula r res istance with and without an intravenous 
i n f u s i o n  of 25ug SMS 201-995 from 0 to 60 minutes. Cardiac 
index sho wn in l/min/m^ , systemic vas cular  res is tance  shown 
in dynes/s /cm^.
CONT ROL G ROUP .
Cardiac index Systemic vascul ar resist an ce
Patient 0 60 120 180 0 60 120 180
JB 4 . 3 3. 2 3.6 3.9 949 1 186 943 893
JT 5.4 3.8 3.6 3.6 994 1391 1 336 1360
WR 4.4 3. 3 3.4 3.5 759 951 917 940
RM 5.9 4.6 5.2 5.5 715 9 08 808 835
PL 4.8 4. 1 4. 7 4.4 867 997 896 872
DO 3.4 3. 2 3. 1 3.7 919 905 987 857
T M 3.5 3. 0 * * 992 1174 * *
MEAN 4.5 3. 6 3.9 4 . 1 885 1073 981 959
SEM 0. 35 0. 22 0. 33 0.31 4 2 69 75 81
SMS 201-995 G R O U P
Cardiac index Systemic vascular resi s t a n c e
Pat ie nt 0 60 120 180 0 60 120 180
RS 3.4 2.4 3.0 2.9 953 1 357 1025 1236
AG 5.0 4.0 3.9 4.5 731 900 829 786
FW 5. 1 4.9 4. 1 4.0 9 28 918 1084 1150
JL 4.5 3. 6 3. 6 3. 7 813 1028 1017 964
AA 3.3 3. 5 3.2 3.4 1189 1152 1 244 1226
AS 3.9 3. 2 3.4 3. 3 1119 1229 108 3 1292
BB 7.0 6.3 6. 1 6. 1 514 629 588 542
AF 6. 3 5. 1 5.8 6.4 473 574 490 508
TM 5.5 5.6 5.2 5. 1 664 774 667 711
MEAN 4.9 4.3 4.3 4.4 820 950 892 935
SEM 0.42 0.42 0. 38 0.41 83 89 87 103
*m issin g value due to t e c hn ical problems w i t h  equ ipme nt .
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A P P E N D I X  3
In dividual  data from four groups of rats who had cardiac 
index and portal venous inflow measur ed after a 20 minute 
in f u s i o n  of saline or 1, 2 or 4/ig/kg/hr SMS 201-995. Mean
ar teria l blood pressure is shown in mmHg , card iac index in 
m l / m i n / k g  and portal venous inflow as % of cardiac output 
for e a c h  rat.
RAT N U M B E R
1 2 3 4 5 6 MEAN SEM
MEAN A R T ER IA L BLOOD PR ESS URE
Contr ols
Omin 130 1 10 100 110 100 75 104. 2 7.4
20 120 100 105 125 90 75 102. 5 7.6
ljig/kg/ hr SMS 201-995
0 120 85 80 105 85 90 94. 2 6. 2
20 100 60 80 105 90 110 90.8 7 . 6
2>ig/kg/ hr SMS 201-995
0 100 90 85 105 80 100 93.3 4.0
20 75 75 60 100 95 105 85.0 7. 2
4/jg / kg/ hr SMS 201-995
0 65 100 100 130 70 93.0 11.8
20 80 100 105 130 70 97.0 10.4
CARDIAC INDEX
Co ntr ols 153 214 216 24 7 24 0 161 205. 1 16.2
l;jg/kg/ hr 210 225 240 174 287 421 260. 6 35.6
2/ig/kg/hr 322 176 188 244 354 664 324. 8 73.7
4jug/kg/hr 165 14 0 206 239 318 213. 7 31.1
PORTAL VENOUS INFLOW
Control s 15. 3 13.9 13.8 15.3 15.6 13.9 14. 6 0.3
1/ig/kg/ hr 12. 8 17.1 16.9 15.6 14 . 1 8.9 14. 2 1 . 3
2/ig/ kg/ hr 10. 9 15.8 15.6 14 . 6 14. 1 5. 2 12. 7 1. 7
4/ig/ k g / hr 17. 7 9.3 13. 1 15.7 9.0 1 3. 0 1. 0
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APPENDIX 4
Individual data for mean arterial and mean portal pressure 
in two groups of six normal rats given intravenous infusion 
of saline for 80 minutes or saline followed by dou bling 
doses of 1 , 2  and 4 ^ g / k g / h r  SMS 201-995 for 20 minutes at 
each dose. Mean arterial pressure is shown in mmHg , mean 
portal pressure is shown in cm water.
RAT NUMBER
1 2  3 4 5 6 MEAN SEM
MEAN ART ER IA L PRESSU RE 
CONT ROL  GROUP
2 0m i n 105 119 68 109 91 90 96.9 7.3
4 Omin 91 106 81 106 1 04 108 99.3 4.4
60min 61 120 100 103 94 102 96.5 7.9
8 Omin 89 96 94 100 95 97 95.1 1 .6
SMS 201-995 GROUP
saline 89 108 119 109 100 81 101.1 5.8
l^g/kg/hr 84 104 108 99 103 74 95.4 5.5
2;ig/kg/hr 94 96 126 90 89 64 93 . 1 8.0
4;ug/kg/hr 85 90 133 81 66 53 84.6 11.1
MEAN PORTAL PRESSURE
CO NTROL GROUP
2 0m in 11.4
o•00 4.2 9.5 4.4 7 . 1 7.4 1 . 1
4 0m i n 9.6 8.9 4.9 9.3 4.4 7 . 5 7.4 0.9
6 Omi n 12.1 9.1 7.0 9.1 5.6 7 . 6 8.4 0.9
8 Omin 10.5 7.3 7.8 00 . 4.7 8.0 7.8 0.8
SMS 201-995 GROUP
saline 8.3 5.7 3.4 9.6 10.4 6.0 4 . 2 1 . 1
ljJg/kg/hr 8.8 7.3 5.4 9.3 9.7 6.7 7 . 9 0.7
2jug/ kg /hr 9.2 9.1 8.1 8.6 8.8 6.3 8 . 3 0.4
4/ig/kg/hr 8.7 7.5 8.4 8.7 7 . 5 5.2 7 . 7 0.5
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APPENDIX 5
Individual data for mean arterial and mean portal pressure 
in three groups of three day post portal vein ligation rats 
given intravenous infusion of saline for 80 minutes, saline 
followed by doublin g doses of 1 , 2  and 4 jug/kg/hr SMS 
201-995 for 20 minutes at each dose or saline followed by 
doubl in g doses of 8, 16 and 32 ^ g / k g / h r  SMS 201-995 at each 
dose. Mean arterial pressure is shown in mmHg , mean portal 
pressure is shown in cm water.
RAT NUMBE R
1 2 3 4 5 6 MEAN SEM
ME AN  ARTERIA L PRESSURE
CONTROL GROUP
20min 110 136 105 108 117 106 113.6 4 . 8
4 Omin 98 135 111 90 97 104 105.7 6.6
60rain 100 125 97 93 66 97 96 . 1 7.7
80min 102 140 75 95 67 105 97.5 10.5
SMS 201-995 GROUP ONE- 1-4 ^ig/kg/hr
saline 129 99 95 98 110 90 103.5 5.8
l^g /kg/hr 94 86 105 98 86 90 93.3 3.7
2>ig/kg/hr 125 100 87 90 83 79 94.1 6.9
4/ig/kg/hr 134 74 66 109 84 65 88.6 11.2
SMS 201-995 GROUP TWO- 8-32 /ig/kg/h r
saline 104 123 125 115 116.6 4.7
8;ng/kg/hr 113 .142 127 130 128.1 6.0
16>ug/kg/hrll3 120 1 30 122 121.3 3.5
3 2/ug/kg/hrl 11 118 130 123 120.5 4.0
(continued overleaf)
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APPENDIX 5 continued
RAT NUMBER
1 2  3 4 5 6 MEAN SEM
MEAN PORTAL PRESSURE 
CONTROL GROUP
2 Om i n 12.9 15.8 12.3 17.3 11.3 17.5 14.5 1.1
4 Omin 12.0 15.0 7.3 17.4 11.3 17.5 14.6 1.3
60min 11.4 14.1 10.7 16.5 8.4 14.6 12.6 1.2
80min 10.5 12.0 8.1 16.2 8.4 15.0 11.7 1.4
SMS 201-995 GROUP ONE - 1-4 jug/kg/hr
saline 17.5 16.8 14.8 18.5 15.9 15.4 16.5 0.6
1/ig/kg/hr 14.3 14.5 13.0 18.2 12.9 13.3 14.4 1.0
2jug / kg / hr 16.6 11.7 9.8 16.6 13.4 10.1 13.0 1.2
4jug/ kg/ hr 15 .4 7 . 8 7 . 6 1 7 .2 1 2 . 9 7 . 9 1 1 . 5 1 .7
SMS 201-995 GROUP TWO - 8-32 jig/kg/hr
saline 22.4 22.3 18.5 19.5 20.7 1.0
8jug/k g /hr 22 .3 20.4 18. 0 1 7 . 7 19 . 6 1 .1
16ju g/kg/hr22 .4 21 . 5 20.0 17 .7 20.4 1 .0
3 2/Ug/kg/hr22.8 24 . 5 20. 3 1 6. 5 21 .0 1 .7
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APPENDIX 6
Individual data for mean portal pressure and %p o r t a s y s t e m i c  
shunting in two groups of six three day post portal vein 
ligation rats given a 30 minute intravenous infusion of 
either saline or 4;jg/kg/hr SMS 201-995. Mean portal pressure 
is shown in cm water. Portal pressure and %p or ta s y s t e m i c  
shunting mea sured in each rat before and after the infusion 
period.
RAT NUMBER
1 2  3 4 5 6 MEAN  SEM
MEAN PORTAL PRE SSURE
CONTROL GROUP
Before 19.1 21.1 21.0 16.3 13.7 14.1 17.5 1.4
After 13.8 14.2 18.5 9.7 9.7 12.4 13.0 1.3
SMS 201-995 GROUP
Before 8.6 10.9 14.6 18.3 14.2 21.1 14.6 1.9
After 4.2 9.4 10.2 14.0 8.1 19.9 11.0 2.2
% P 0 R T A S Y S T E M I C  SHUNTING 
CO NT ROL GROUP
Before 50.7 1.0 89.5 57.9 26.4 32.9 43.1 12.4
After 48.2 15.4 94.4 55.9 35.2 8.1 42.9 12.7
SMS 201-995 GROUP
Before 35.0 5.1 74.3 84.6 76.1 68.7 57.3 12.6
After 15.3 6.1 52.7 87.0 63.0 82.5 51.1 13.8
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APPENDIX 7
Individual data for mean portal pressure and %p or ta s y s t e m i c  
shuntin g in two groups of twenty-eig ht day post portal vein 
ligation rats given a 30 minute intravenous infusion of 
either saline or A/ig/kg/hr SMS 201-995. Mean portal pressure 
is shown in cm water. Portal pressure and % p o r t asyst em ic 
shuntin g mea sur ed in each rat before and after the infusion 
period.
RAT NUMBER
1 2  3 4 5 6 MEAN SEM
MEAN PORTAL PR ESSUR E 
CONTROL GROUP
Before 10.1 13.8 9.1 11.4 13.8 9.7 11.3 0.8
After 6.8 11.9 6.8 9.6 14.6 9.0 9.8 1.2
SMS 201-995 GROUP
Before 10.4 9.9 12.6 10.5 6.3 9.9 1.0
After 11.3 8.8 12.3 10.1 5.8 9.6 1.1
% P 0 R T A S Y S T E M I C  SHUNTING 
CO NTROL GROUP
Before 65.3 61.6 51.2 30.6 43.7 82.4 55.8 7.4
After 74.7 56.3 56.3 25.6 41.7 98.8 58.9 10.4
SMS 201-995 GROUP
Before 91.0 58.5 6.4 32.4 55.3 48.8 14.2
After 71.0 52.3 10.4 61.8 63.3 51.9 10.7
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APPEND IX 8
Ind ividual data for liver function tests, mean portal 
pressu re and % po rta s y s t e m i c  shunting in two groups of nine 
ci rrhotic rats given a 20 minute intravenous infusion of 
either saline or 4;ug/kg/hr SMS 201-995. B i 1 i r ub in ( B i 1 i ) is 
shown in ^imol/1, al bumin(Alb)  in g/1, alanine
t r a n s a m i n a s e (A L T ) in units/1, aspa rtate t r a n s a m i n a s e (A S T ) in 
units/1 and alkaline p h o s p h a t a s e (AP) in units/1. Mean portal 
pressure is shown in cm water. Portal pressure and 
% p o r t a s y s t e m i c  shunting measured in each rat before and 
after the infus ion period.
RAT NUMBER
1 2 3 4 5 6 7 8 9 MEAN SE1
LIVER FU NC TION TESTS
CONTROL GROUP
Bili 10 5 6 3 3 3 3 10 2 5 1
Alb 1 4 9 26 44 25 18 10 25 18 21 3
ALT 29 12 145 125 53 67 63 1 90 67 83 19
AST 225 285 355 475 225 195 235 395 170 284 34
AP 670 205 425 435 235 300 370 475 260 375 49
SMS 201 -995 GROUP
Bili 5 13 21 7 5 7 8 5 5 8 2
Alb 21 20 15 16 20 16 17 24 22 19 1
ALT 57 420 470 68 40 68 83 93 97 155 55
AST 370 1410 530 190 150 420 250 260 320 433 128
AP 300 380 335 340 225 495 555 280 350 362 35
(continued overleaf)
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APPENDIX 8 continued
RAT NUMBER 
1 2 MEAN
MEAN PORTAL PRESSURE
CONTROL GROUP
Before 18.5 
Af te r 17.1
5.4 13.0 16.4 16.3 10.3 5.4 19.1 8.3 12.5
6.8 12.4 14.0 14.7 6.9 3.8 18.7 7.9 11.4
SMS 201-995 GROUP
Before 14.8 11.8 10.4 9.8 9.5 17.9 
After 15.6 13.0 9.1 7.7 8.3 17.3
14.5 11.8 10.2 12.3
12.0  11.0  11.0 11.6
%P O R T A S Y S T E M I C  SHUNTING 
CONTROL GROUP
Before 8.7 4.7 14.0 10.7 13.6 44.1 33.0 9.3 29.1 18.6
After 4.7 2.7 13.3 15.9 9.3 34.3 52.1 38.4 24.1 21.6
SMS 201-995 GROUP
Before 11.9 8.2 
After 29.9 2.7
1.9 5.7 35.5 37.0 8.0 25.1 2.1 15.0
2.6 26.7 61.2 29.2 6.7 18.2 7.2 20.5
SEM
1 . 8  
1 . 7
0.9 
1 . 1
4.5
5.6
4.6
6.3
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APPENDIX 9a
Individual patient data for the 20 variceal bleeds treated 
wit h oes op hag eal  tamponade. Charac t e r i s t i c s  of the patients 
and the details of the bleed prior to adm is sion to the 
study. Times .are shown in hours.
PT
NO
AGE AE TIO LOGY BLEED
NO
ADM
CHILD'S
PREADM 
BLOOD 
TRANS 
(mis)
TIME
FROM
OVERT
BLEED
SEVERITY
1 34 alcohol 1 C 1 500 38 mod e ra te
4 65 alcohol 4 A - 1 mild
7 67 pbc 1 C - 24 mild
8 63 a l c o h o 1 1 C 2400 43 mild
10 44 alcohol 2 C 3200 22 severe
1 1 38 alcohol 1 C 800 72 mild
15 58 alcohol 7 C - 4 mild
16 61 c ah 2 B 1200 29 mild
1 7 29 alcohol 2 C - 5 mod e ra te
18 61 cah 3 C - 3 mild
21 56 cah 6 C - 8 moderate
23 30 alcohol 3 C 800 30 mild
25 70 crypt 1 C 400 6 mild
26 32 alcohol 3 B 1200 16 severe
30 30 alcohol 1 C 3200 25 severe
32 67 alcohol 3 C - 2 mild
35 66 crypt 3 C 400 7 mild
36 50 crypt 2 C - 48 mild
37 64 alcohol 2 B 1000 9 moderat e
38 46 alcohol 5 B - 1 7 mild
pbc =prim ar y biliary cirrhosis 
cah =chro ni c active hepatitis 
c r y p t = c r y p t o g e n i c  cir rhosis
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APPENDI X 9b
Individual patient data for the 20 varice al bleeds treated 
with oeso phageal tamponade. Details of treatment and its 
results during the study period and outcome of that
admission  to hospital. Times are shown in hours.
PT INITIAL TIME COMPLETE TIME X-OVER BLOOD OUTCOME
NO CONTROL OF
CONTROL
CONTROL OF
REBLEED
TIME TRANS
(mis)
1 y 0 y _ _ 1000 alive
4 y 0 y - - 800 alive
7 y 1 y - - 1800 alive
8 y 0 y - - 800 alive
10 y 0 — — 2000 died at 
5 hrs
1 1 y 1 y — — 800 died at 
9 days
1 5 y 0 y - - 1200 alive
16 y 0 n 33 - 2000 alive
1 7 y 0 y - - 1600 alive
18 y 0 n 16 — 4000 died at 
4 days
2 1 y 1 y - - 1200 al ive
23 y 0 y - - 800 alive
25 y 0 n 47 1600 died at 
9 days
26 y 2 n 10 2400 alive
30 n — — — 2 5600 died at 
4 0 hrs
32 y 0 y - - 2000 alive
35 y 0 y - - 1 600 alive
36 y 0 y - - 800 alive
37 y 0 y - - 1400 alive
38 y 0 y - - 1200 alive
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APPENDI X 10a
Individual patient data for the 20 variceal  bleeds treated with 
SMS 201-995 infusion. Charac t e r i s t i c s  of the patients and the 
details of the bleed prior to adm issi on  to the study. Times are 
shown in hours.
PT AGE
SEVERITY
NO
AETIOLO GY
NO
BLEED 
CHILD'S
ADM
BLOOD 
TRANS 
(ml s )
PREADM
FROM
OVERT
BLEED
TIME
2 64 alcohol 2 C _ 24 mild
3 68 alcohol 1 C 2800 36 moderate
5 75 alcohol 1 C - 1 severe
6 28 chf 1 B 1600 24 mild
9 75 alcohol 2 C - 3 moderate
12 44 alcoho 1 1 A - 7 modera te
13 49 alcohol 1 B 3600 71 mild
14 29 alcohol 1 C - 25 mod era te
1 9 45 alcohol 2 C - 7 mode rate
20 32 alcohol 1 B 800 22 mild
22 74 crypt 2 B 1200 29 mild
24 32 alcohol 2 A - 7 mild
2 7 65 drug 5 C - 3 mild
28 49 pbc 2 C 2000 19 severe
29 46 alcohol 4 B 1200 18 moder ate
31 43 s cl ch 1 B 2000 24 mild
33 50 alcohol 2 C - 5 mild
34 50 alcohol 1 C 1600 9 mode rate
39 33 alcohol 3 B - 6 mild
40 46 alcohol 6 B - 18 mild
c h f=co ng en ital hepatic fibrosis 
p bc =p rimary  bil iary cirrhosis 
s c l c h = s c l e r o s i n g  cholangitis  
d r u g = m e t h o t r e x a t e  induced cirrhosis 
c r y p t = c r y p t o g e n i c  cirrhosis
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APP EN DIX 10b
Individu al patient data for the 20 variceal bleeds treated with 
SMS 201-995 infusion. Details of treatment and its results 
during the study period and outcome of that admission  to 
hospital. Times are shown in hours.
PT I N I T I A L T I M E C O M P L E T E T I M E X - O V E R B L O O D OU TCO P
NO C O N T R O L OF
C O N T R O L
C O N T R O L OF
R E B L E E D
T I M E T R A N S
(mis)
2 y 0 y — _ 1 600 alive
3 y 1 n 24 24 5600 alive
5 n — — - 4 2000 alive
6 y 0 y - - 1200 alive
9 y 1 n 45 - 800 alive
12 n - - - 1 2400 alive
13 y 4 y - - 1200 alive
14 y 0 y - - 2000 al i ve
1 9 y 1 n 9 9 2400 alive
20 y 2 y - - 800 alive
22 y 0 y - - 800 alive
24 y 0 y - - 1200 alive
27 y 0 n 22 22 2200 alive
28 y 2 n 22 - 2400 alive
29 y 1 n 16 - 2000 al i ve
31 y 0 y - - 800 alive
33 y 0 y - - 800 alive
34 y 0 n 24 24 2400 alive
39 y 0 y - - 800 alive
40 y 0 n 44 - 800 alive
